The = Relationship among Hypoxia, Proliferation, and Outcome in Patients with = De Novo Glioblastoma: A Pilot Study

Introduction

Glioblastoma (GB) is one = of the=20 deadliest of human cancers, characterized by a 12- to 14-month = median=20 survival in patients treated with surgery, radiation, and = temozolomide [1]. There is extensive ongoing research on the = mechanism(s)=20 of this dismal prognosis, including the role of signaling = molecules,=20 cytokines, and drug-modifying enzymes [2]. Several of these factors are modulated by = hypoxia,=20 leading to substantial clinical and experimental interest in this = subject=20 [3]. Hypoxia is present in many tumor sites = including cervix,=20 head and neck, prostate, bladder, pancreas, and soft tissue = sarcomas (for=20 review, see Evans and Koch [4]). Hypoxia has also been shown to affect the = efficacy of=20 chemotherapy [5]. In some tumor types (cervical cancer, = sarcomas), it is=20 associated with tumor aggression, for example, hypoxic tumors are = more=20 likely to invade and/or metastasize [6,7] as a result of upregulation of proteins = such as=20 matrix metalloproteinase, vascular endothelial growth factor, and = BCL-XL=20 [6=E2=80=938]. We have previously reported on = the presence and=20 level of hypoxia in a series of brain tumors of varying histologic = diagnosis, demonstrating that the level of hypoxia increases with = tumor=20 aggressiveness [9]. However, tissue PO₂ has never been=20 demonstrated to be a predictive factor in the outcome of patients = with GB.=20 Proliferation, another well-studied physiologic process in tumors, = remains=20 controversial as to its prognostic significance in GBs [10=E2=80=9312].

EF5 is a 2-nitroimidazole = drug that=20 is administered intravenously to patients approximately 24 hours = preceding=20 surgery. It covalently binds to hypoxic cells at a rate that is = inversely=20 proportional to tissue PO₂ [13,14]. Analytical methods using highly = specific,=20 fluorescent monoclonal antibodies against EF5 adducts have been = developed,=20 calibrated to in vitro controls, and validated, allowing = the=20 quantification of tissue oxygen levels and the production of = tissue oxygen=20 maps [15]. Immunohistochemical (IHC) studies have = generally=20 reported an inverse spatial relationship between hypoxic and = proliferating=20 cells [16,17], but we noticed that proliferating=20 (Ki-67-positive [Ki-67+]) cells could be found in regions of high = EF5=20 binding in many human GB tissue sections (<= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 1

).=20 This has been previously observed in liver metastases [18]. On the basis of our observation of = colocalization of=20 hypoxic and proliferating cells, we developed quantitative methods = using=20 frozen tissue sections to analyze the cellular PO₂ from = tissue=20 sections in the region immediately surrounding any defined = anatomic=20 structure (e.g., blood vessels [19] or individual cells [present studies]). = Herein, we=20 describe the development and application of such algorithms to=20 quantitatively assess EF5 binding in the region of Ki-67+ cells. = We=20 hypothesized that tumors with many proliferating hypoxic cells = would be=20 more biologically aggressive, perhaps due to the up-regulation of = invasion=20 and metastasis-causing cytokines. In this pilot study, we provide = data=20 supporting that the EF5 binding level surrounding proliferating = cells,=20 expressed as a ratio=20 [EF5/Ki-67_binding]/[Tumor_binding], is a = significant=20 predictor of patient outcome. We also showed that this ratio = variable can=20 independently predict these end points beyond the recursive = partitioning=20 analysis (RPA) classification [20]. (The RPA classification is based on both = pretreatment=20 patient and tumor characteristics and treatment-related variables, = and it=20 has been shown to be associated with survival duration.) = Measurement of=20 the relationship between hypoxia and proliferation in GBs is not = likely to=20 be directly applicable to clinical practice using the complex = methods=20 described herein. However, these techniques should inform the = biology and=20 pathophysiology of GBs for future investigations as well as aid = the=20 development of molecular and imaging theragnostics.

Materials and Methods

The Institutional = Review Board=20 of the University of Pennsylvania Clinical Trials and Scientific=20 Monitoring Committee (Abramson Cancer Center) and the Cancer = Therapeutics=20 Evaluation Program of the National Cancer Institute approved this=20 prospective trial of EF5. All patients signed a consent form for = both the=20 study and for privacy (Health Insurance Portability Accountability = Act).=20 Patients of all ethnic and sex groups were included. Eligible = patients=20 were those undergoing resection of a brain mass assessed as likely = be a=20 neoplasm based on imaging appearance. Exclusion criteria included = patients=20 with a history of grade 3 or 4 peripheral neuropathy [21], pregnant or nursing patients, and patients = younger than=20 18 years.

EF5 Administration

The National Cancer = Institute,=20 Division of Cancer Treatment, supplied EF5 in 100-ml vials = containing an=20 aqueous solution of 3 mg/ml EF5 plus 5% dextrose and 2.4% ethanol. = EF5 was=20 administered through a peripheral intravenous catheter = approximately 24=20 hours before surgery at a rate no greater than 350 ml/h and to a = total=20 dose of 21 mg/kg. Blood samples for drug levels were obtained = before=20 (control), 1 hour after drug administration, and at the time of = surgery.=20 Calculation of the drug concentration integrated with respect to = time=20 (area under the curve, AUC) was used to correct the absolute EF5 = tissue=20 binding level (IHC) for variations in drug dose and drug exposure = time=20 between patients [22].

Tissue Acquisition, Processing = for EF5=20 Binding, and Analysis of EF5 Images

On the day after EF5 = administration,=20 tumors were surgically resected and placed in sterile, iced EXCELL = 610=20 medium (JRH Biosciences, Lenexa, KS). In collaboration with the=20 pathologist, tissue samples deemed unnecessary for clinical = diagnosis were=20 taken to the laboratory for processing and analysis.

IHC staining methods and = quantitative=20 fluorescence microscopy of EF5 in in situ tumor sections = (<= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 1

)=20 and EF3 in tissue cubes for cube reference binding (CRB) were = performed as=20 reported previously [23]. CRB determination is an in vitro = technique=20 where millimetersized tissue cubes taken from an individual = patient's=20 tumors were incubated at 600 =C2=B5M/h in EF3, a sister drug of = EF5, under=20 controlled hypoxic conditions. The goal of this procedure was to = determine=20 the maximum level of EF3 binding possible for each patient's = tumor. This=20 technique allowed normalization of the in situ EF5 = binding to=20 each tumor's maximum binding value after correction for the AUC = [22,23]. In addition to staining for EF5 alone, = adjacent=20 tissue sections were 1) costained for EF5 and Ki-67 (called = EF5/Ki-67), as=20 previously reported [24] (<= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 1

),=20 and 2) stained with =E2=80=9CCompeted Stain=E2=80=9D (antibody = mixed with 0.5 mM authentic=20 EF5) to account for fluorescence due to nonspecific staining (data = not=20 shown). The latter value was subtracted from the calculated value = of=20 in situ EF5 binding.

Images were analyzed using = routines written in=20 MatLab (The MathWorks, Inc, Natick, MA), whereby EF5-dependent=20 fluorescence intensity values were sampled within an image (or = part=20 thereof ) based on intact (viable) nuclei identified by a Hoechst = 33342=20 mask [19] (<= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 2

).=20 Hoechst 33342 was applied to the slide immediately preceding = imaging to=20 stain the nuclei. The final EF5 intensity values were corrected = for lamp=20 intensity, individual patient AUC, and the competed stain value. = The=20 result of these corrections provided an EF5 binding value for each = pixel,=20 expressed as a percent of CRB (%CRB) [8,23]. We have converted %CRB into tissue = PO₂=20 ranges using extensive data from in vitro studies [9,13,23,25].

<= STRONG>Figure=20 1

Examples = of EF5,=20 Ki-67 (proliferation), and Hoechst 33342 (viable cells) = binding in=20 GBs. Color codes: hypoxia (EF5 binding, red), viable cells = (Hoechst=20 33342, blue) and proliferation (Ki-67, green). Left panel: = patient=20 39; right panel: patient 55. Both = (more ...)

To further characterize = the image,=20 cumulative frequency histograms of the %CRB of all the pixels in = the image=20 were calculated. Using this terminology, the median binding would = be=20 CF₅₀. To emphasize the most hypoxic cells, we used the=20 CF₉₅ value, wherein 95% of the cells have lower values = and 5%=20 have higher values. Thus, CF₉₅ =3D 20% would mean that = 95% of the=20 EF5 values in the image were at or below 20% of maximum EF5=20 binding.

Proliferation Analysis

All images were loaded,=20 preprocessed, and analyzed based on Hoechst 33342 and EF5/Ki-67 = images for=20 each tissue section (<= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 2

).=20 To correct for small misalignments due to wavelength shifts, the = EF5/Ki-67=20 images were each aligned to the Hoechst 33342 image.

The Hoechst 33342 image was masked = to reduce=20 background noise using the Imtophat method (MatLab; The MathWorks, = Inc). A=20 threshold was applied to eliminate all pixels with an intensity = value=20 below 0.005, yielding a black-and-white image mask. The resulting = image=20 was repeatedly (up to 1000 times) morphed with a majority = transformation=20 that turns any black pixel surrounded by five or more white pixels = to=20 white. This step filled in small areas that may have been missed = by the=20 previous threshold. The masks were reviewed individually at the = end of the=20 process to ascertain that the process was successful in capturing = the=20 features of the Hoechst 33342 image (<= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 2

A counting algorithm was then = applied to the=20 EF5/Ki-67 and Hoechst 33342 images to identify each cell and to = determine=20 accurate counts of the number of total cells and of proliferating = cells.=20 To eliminate background values, the Imtophat filter was applied to = both=20 images. Each cell was identified in an iterative process. Each = iteration=20 included identification, centralization, and hole-punching steps = (<= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 2

).=20 Identification was achieved by applying a threshold to the image = that was=20 at first highly discriminating and was gradually reduced in a = quadratic=20 fashion to a preset minimum value determined through repeated=20 experimentation. Each of the identified objects was then = =E2=80=9Cshrunk=E2=80=9D to a=20 point using a centralization process resulting in the replacement = of the=20 cell with a single pixel located at its centroid (center of mass). = The=20 hole punch completed the iteration, whereby the original image had = a=20 cell-sized (15 =C2=B5m) disk centered on each centralized = identified point=20 removed from future iterative steps. This process resulted in a = highly=20 accurate cell count, as determined by hand counting in small areas = (data=20 not shown). The procedure used 30 iterations, with an initial = threshold=20 value of 1.00 decreasing to 0.03 in a quadratic fashion. These = steps=20 resulted in two new images termed point maps, one for = Hoechst=20 33342 and one for the Ki-67 aspect of the EF5/Ki-67 images (<= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 2

After the Hoechst 33342 and Ki-67 = point maps=20 were created, the correspondence between each Ki-67+ object and = exactly=20 one Hoechst 33342-identified nucleus was checked, for example, to = confirm=20 that the Ki-67-labeled objects were a strict subset of Hoechst=20 33342-labeled objects. To do this, we relied on the fact that the = two=20 point maps were generated from aligned images of the same tissue = piece. A=20 final point map was generated from the Hoechst 33342 point map = where, for=20 each Ki-67 point, the nearest Hoechst 33342 point was tagged as = Ki-67+ (<= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 2

).=20 If a Ki-67+ point was not within 15 =C2=B5m (roughly the size of a = cell), then=20 it was assumed that the anti-Ki-67 antibody had caused an = artifact, which=20 was then eliminated. This was found to be less than 1% of the = cells=20 examined (data not shown). Using this point map, our goal was to = obtain=20 information about the tissue oxygen level in the immediate = vicinity of=20 each Ki-67+ object. However, signal from the anti-Ki-67 was often = very=20 strong, and despite using a different fluorescent color to = quantify EF5=20 binding, there was some bleed through from the Ki-67 dye (Cy3 = vs=20 Cy5, respectively). This represented a substantial signal in = regions of=20 low EF5 binding because EF5 binding is quantified over an = intensity range=20 spanning several decades [25]. To eliminate the Ki-67 fluorescence from = calculation of=20 the EF5 fluorescence surrounding the Ki-67+ cells, the = fluorescence in the=20 central regions of the area surrounding these cells was removed = from=20 analysis. Specifically, EF5 binding was assessed in a donut-shaped = region=20 centered on each Ki-67+ nucleus, with the central hole 15 =C2=B5m = in diameter=20 and the overall diameter as 50 =C2=B5m, excluding any pixels = eliminated by the=20 overall tissue mask (<= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 2

The average EF5 value for = the entire=20 image (minus the center of the =E2=80=9Cdonuts=E2=80=9D) was = calculated based on the=20 overall tissue mask. Cumulative frequency graphs of EF5 binding in = the=20 tissue section being evaluated versus near Ki-67+ cells = was=20 determined based on the 95th percentile of EF5 binding = (CF₉₅).=20 Final analyses were based on the CF₉₅ values for the = brightest=20 slide evaluated for each patient as in our previously published = studies=20 [15,26,27].

Pathological Examination

All tissue sections = were=20 reviewed by a neuropathologist to confirm that the tissue section=20 contained tumor. Tissue sections that contained less than 20% = viable tumor=20 or more than 80% normal tissue or necrosis were eliminated from = further=20 analysis. A minimum of three tissue sections from each patient was = examined. The histologic diagnosis of the tumor in the EF5-stained = tissue=20 sections was compared with the pathologic diagnosis based on=20 paraffin-embedded tissue sections. None of the EF5-stained tissue = sections=20 received a diagnosis that differed from that rendered clinically. = A=20 minimum of three tumor sections stained for EF5 and EF5/Ki-67 was = examined=20 for each patient.

Tumor Staging and Patient = Outcome

The World Health = Organization=20 grade was based on pathological examination of the surgical = specimen.=20 Recurrence was determined by the treating physician based on = magnetic=20 resonance imaging studies (usually a change over time) and/or the=20 examination of a pathological specimen from surgical re-resection = or=20 biopsy.

Statistical Methods

Descriptive statistics = (frequency,=20 percentage, mean, and SD) were used to report distributions of = patient and=20 tumor variables. Time to recurrence was defined from the date of = EF5=20 administration (1 day preceding surgery) to the date of a = documented event=20 (recurrence or death due to any cause) or censored at last patient = contact. For patients in whom a gross total resection was not = obtained,=20 time to recurrence was defined as the point at which tumor = progression=20 (i.e., growth) was identified on imaging. In two patients (nos. 32 = and=20 58), the recurrence date could not be confirmed, so for analysis = the date=20 of recurrence was taken as the date of death. Overall survival was = defined=20 from the date of EF5 administration (1 day preceding surgery) or = censored=20 at the last patient contact. Potential prognostic factors = considered in=20 this analysis were the RPA classification [20,28], proliferation index (PI), EF5 = (CF₉₅)=20 binding in the vicinity of Ki-67+ cells, EF5 binding in the = brightest=20 tissue section examined (CF_{95 max}), and a ratio of the = latter=20 two values. Survival analysis of the ratio were based on two = cutoff=20 points: (a) the 50% EF5 value for the ratio of=20 [EF5/Ki-67_binding]/[Tumor_binding] = (Ratio_{EF5=20
50%}) and (b) the Ratio_{patients median} = value=20 (=3D75.6%; Table 1).

<= STRONG>Figure=20 2

Analysis = of EF5=20 value surrounding Ki-67+ cells: The upper left image depicts = nuclei=20 stained with Hoechst 33342 (the same process is done using=20 Ki-67-stained cells, not shown). The upper central image is = the=20 point map that results from the counting algorithm = (more ...)

The distributions of time = to event=20 outcomes were estimated by the method of Kaplan and Meier [29] and compared among patient groups defined by a = prognostic factor using log-rank tests [30]. The independent prognostic value of a factor = was=20 evaluated using a multivariate Cox proportional hazards model [31]. Statistical significance was defined as = P <=20 .05. Borderline significance was defined as less than=20 0.10.

Results

Between September 2000 = and November=20 2005, 17 patients with previously untreated GB (World Health = Organization=20 grade 4 gliomas) were entered into this clinical trial of EF5. One = patient=20 deteriorated rapidly postoperatively and died of non-brain = tumor-related=20 causes preceding the onset of radiation therapy; this patient was = not=20 included in the analysis. Of the 16 remaining patients, 15 had = died and 1=20 patient (no. 115) remained alive and without recurrence at the = time of=20 analysis. The patients' demographics and the details of their = tumors and=20 treatments are summarized in Table 2. The = patients' mean=20 age was 56.9 years (range, 23=E2=80=9377 years), with 12 males and = 4 females.=20 Fifteen patients were white and one patient was African American. = There=20 were 3, 9, and 4 patients with RPA levels of 3, 4, and 5, = respectively (Table 2). Survival = analysis=20 confirmed that RPA classification was predictive of patient = survival in=20 this group of patients (RPA 3 and 4 vs RPA 5, P = =3D=20 .0026). Despite the small number of patients included in this = trial, this=20 finding confirms that these 16 patients are generally = representative of=20 patients with de novo GBs reported in the literature [28]. All patients received surgery with the intent = of gross=20 total resection followed by external beam radiation therapy (Table 2). In three = patients,=20 the actual radiation prescription could not be determined, = although notes=20 from the outside hospitals confirmed that full-course radiation = therapy=20 had been administered. In four patients, additional radiation was = given at=20 the time of recurrence by iodine 125 (¹²⁵I) monoclonal = antibody=20 treatment (n =3D 1) or Gliasite balloon (n =3D = 3; Table 2). = Administration of=20 adjuvant therapy (chemotherapy, hormonal, or molecular therapy) = either=20 during or after initial radiation therapy or at the time of = recurrence=20 could be confirmed in 13 of 16 patients. Two patients received no = adjuvant=20 therapy, and this information was not available in one patient.=20 Temozolomide, either during and/or after radiation, was = administered in 11=20 patients. There was no relationship between temozolomide = administration=20 and outcome in this small patient group (P > = .05).

<= /DIV>

Table=20 1

Ratio = Value=20 Definitions and Details.

All 16 gliomas contained regions = of hypoxia,=20 although the level and extent of hypoxia varied considerably = between=20 patients. As shown in Table 3, the most = hypoxic=20 region, CF795 max in the 16 GBs ranged from 3.2% (mild hypoxia,=20 PO₂ =E2=89=88 2.5%) to 26.7% (moderate hypoxia, = PO₂ =E2=89=A4 0.5%).=20 On the basis of these data, most of the tumor cells in any of = these tumors=20 were at intermediate or high O₂ levels, and all tumors=20 contained many cells that were physiologically oxic. When analysis = of=20 patient outcome was performed based on the CF_{95 max} of=20 EF5-alone-stained sections, this value was not predictive for = either tumor=20 recurrence or patient survival (_P > .05).

<= /DIV>

Table=20 2

Patient=20 Demographics, Tumor Characteristics, and Treatment=20 Modalities.

Tissue sections were also = costained with=20 EF5/Ki-67 and analyzed for both PI and the EF5 values surrounding = Ki-67+=20 cells (<= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 1

=20 and Table 3). The PIs = in this=20 group of GBs ranged from 1.3% to 15.5% (median, 5%). Results of = the=20 survival analysis based on the PI or the EF5 values surrounding = Ki-67+=20 cells were not significant for either recurrence or survival = (P=20 > .05).

As described above, two cutoff = points were=20 tested for evaluating the predictive value of the=20 [EF5/Ki-67_binding]/[Tumor_binding] ratio:=20 (a) Ratio_{EF5 50%} (4 patients below = CF₉₅ =3D=20 50% and 12 patients above CF₉₅ =3D 50%) and = (b)=20 Ratio_{patients median} (75.6%; 8 patients above and below = this=20 value) (Tables 1 and 3). Using the = variable=20 Ratio_{EF5 50%}, patients had a better prognosis if the = ratio was=20 less than 50%. This discriminator was predictive of both time to=20 recurrence (P =3D .0074; <= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 3

=20 and Table 1) and = overall=20 survival (P =3D .0196) (<= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure = 4A

=20 and Table 1). When = considered=20 along with RPA classification for overall survival (recurrence was = not=20 tested because RPA is not predictive of recurrence), the = Ratio_{EF5=20
50%} was found to be an independent prognostic factor = (P =3D=20 .038).

<= /DIV>

Table=20 3

Patient = Survival=20 and Recurrence End Point Analyses.

<= STRONG>Figure=20 3

Analysis = of time to=20 tumor recurrence in 16 newly diagnosed GB patients based on = their=20 [EF5/Ki-67_binding]/[Tumor_binding] = ratio.=20 Patients with a Ratio_{EF5 50%} less than 50% = (n =3D=20 4; dotted line) have a significantly longer time to = recurrence than=20 those with = (more ...)

Using Ratio_{patients =
median} as a=20 discriminator, there was no predictive value for time to = recurrence=20 (P =3D .17; Table 1), but it = was=20 predictive for overall survival (P =3D .038) (<= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 4

=20 and Table 1). When = considered=20 along with RPA classification, the Ratio_{patients median} = value=20 was found to be only borderline in its association with overall = survival=20 (HR =3D 2.8, P =3D .09).

In addition to performing = a=20 multivariate analysis, we performed a univariate analysis of=20 [EF5/Ki-67_binding]/[Tumor_binding] ratio = values but=20 only included the RPA class 3 or 4 (n =3D 12; <= SPAN=20 style=3D"TEXT-DECORATION: underline">Figure 5

).=20 Although this further reduces the sample size, the remaining = patient=20 subset was somewhat more homogeneous. This analysis will not = answer the=20 question of whether=20 [EF5/Ki-67_binding]/[Tumor_binding] ratio is = an=20 independent predictor of RPA but rather whether the predictive = ability of=20 this ratio will hold in patients with RPA =3D 3 or 4. = Ratio_{EF5=20
50%} had a hazard ratio of 4.4 (95% confidence interval = 0.90=E2=80=9321.1)=20 and a significant log-rank test P =3D .048. = Ratio_{patients=20
median}, using cutoff point of 75.6%, had a hazard ratio of = 3.4 (95%=20 confidence interval [CI], 0.89-13.3) and a borderline significant = log-rank=20 test (P =3D .059; Table 1).

<= STRONG>Figure=20 4

Analysis = of time to=20 patient survival in 16 newly diagnosed GB patients based on = their=20 [EF5/Ki-67_binding]/[Tumor_binding] = ratio. (A)=20 Patients with a Ratio_{EF5 50%} less than 50% = (n =3D=20 4; dotted line) have a significantly longer time to = recurrence than=20 those = (more ...)

Discussion

In this pilot study, we = have=20 identified that GBs are characterized by varying degrees of = hypoxia as=20 assessed by EF5 binding and that most cells in GBs are either oxic = or at=20 intermediate levels of hypoxia. We have previously reported that = EF5=20 binding generally increases with tumor grade when considering all = types=20 and grades of brain tumors [9,26], in keeping with our former studies in = sarcomas [32]. This is in contrast to our studies in head = and neck=20 squamous cell carcinomas where tumor recurrence was associated = with high=20 EF5 binding irrespective of tumor grade [15]. Our results in brain tumors are distinct from = previously published studies using Eppendorf needle electrodes [26,33,34]. We find that virtually all GBs = contain=20 some hypoxic regions, in comparison to grade 3 tumors that can = contain=20 rare regions of hypoxia and grade 2 tumors that are essentially = oxic.=20 Because our methods allow quantification of both the extent and = degree of=20 tissue hypoxia at a cellular resolution, our most general = observation has=20 been that all types of tumors contain physiologically oxic cells, = with the=20 main clinically relevant difference being the relative fraction of = tissue=20 existing under moderately or severely hypoxic conditions [15,26,32]. Thus, our central hypothesis = has been=20 that tumor aggressiveness is best characterized by the most = hypoxic cells=20 present, and we have substantiated this in sarcomas, head and neck = cancers, and high-grade glial brain tumors [15,26,32]. Our findings confirm studies in = several=20 other tumor types using other hypoxia measurement techniques [35=E2=80=9337]. However, this pilot study = demonstrates that=20 EF5 binding alone was not successful in predicting outcome for the = small=20 number of newly diagnosed GB patients studied herein.

We next considered PI as a means = of predicting=20 outcome in patients with GB. The PI contributes to prognosis for = some=20 tumor types (i.e., breast cancer [38] and squamous cell carcinomas of the oropharynx = [39]) but has not consistently been associated with = outcome=20 in brain tumor patients [10=E2=80=9312]. This inconsistency should = perhaps be=20 expected. Non-cycling cells are known to be resistant to both = chemotherapy=20 and radiotherapy, and hypoxia can cause cells to exit the cell = cycle [40,41]. However, rapid growth can contribute = to a lack=20 of tumor control, and it has been suggested that it is important = to=20 characterize a tumor's growth fraction before protracted = treatments such=20 as radiotherapy [42]. The balance between cell proliferation and = death has=20 been noted to be an important factor in determining overall tumor = growth,=20 and this consideration makes the understanding of the role of the = PI, in=20 the absence of quantification of the balancing factor cell death, = complex=20 [43].

Despite numerous investigations of = hypoxia or=20 proliferation individually, little is known about how these = combined=20 parameters (their quantitative and/or spatial relationships) = contribute to=20 outcome in human cancer. Several studies have combined analysis of = endogenous markers of hypoxia in combination with proliferation = markers in=20 human cancers. One of the advantages of using endogenous=20 hypoxia-associated markers (carbonic anhydrase 9, = hypoxia-inducible factor=20 1, glucose transporter 1, and vascular endothelial growth factor) = is that=20 large retrospective studies using banked materials can be = performed.=20 However, all of these markers are known to measure factors in = addition to=20 tissue PO₂ [44]. Despite the expectation that proliferation = would=20 decrease with hypoxia, Saarnio et al. [45] showed expression of CA9 in areas of = colorectal=20 neoplasms with high proliferative capacity. Hoskin et al. [46] studied bladder cancer and found that = proliferation was=20 significantly higher in those tumors with the highest levels = (>10%) of=20 both GLUT1 (P =3D .025) and CA9 (P =3D .029) = compared with=20 those tumors that either were negative or had low levels of = expression;=20 colocalization studies were not performed because of the = requirement to=20 develop complex algorithms and methods. Neither the endogenous = hypoxia=20 markers nor PI (based on Ki-67) predicted for local control or=20 metastases-free survival in this study. Hoogsteen et al. [47] studied CA9 and iododeoxyuridine (IdUrd) = labeling in=20 biopsies of head and neck squamous cell carcinomas, reporting that = colocalization between IdUrd and CA9 ranged from 0% to 53%. The=20 interpretation of the data in all of these studies is complicated = by the=20 absence of actual PO₂ values to correspond to the = regions=20 stained for endogenous markers. The study of Hoogsteen et al. used = distance from blood vessels as a surrogate for tissue = PO₂; the=20 fraction of IdUrd-labeled cells positive for CA9 was highest at an = intermediate distance from the blood vessels (100=E2=80=93150 = =C2=B5m). We have=20 recently reported that in brain tumors, distance from blood = vessels is not=20 a good surrogate for oxygen partial pressure, as measured by EF5 = binding=20 [19]. Nonetheless, the fraction of IdUrd-labeled = cells that=20 were also positive for CA9 in the head and neck cancer study of = Hoogsteen=20 et al. correlated with the worst disease-free survival rates = (P =3D=20 .04). The latter observation parallels the findings reported = herein.

Nordsmark et al. [48] studied tumor oxygenation in human sarcomas = using=20 polarographic oxygen needle electrodes, proliferation, and = potential=20 doubling time (T_pot) with iododeoxyuridine = flow=20 cytometry and IHC. There was a significant correlation between the = median=20 PO₂ and the tumor cell potential doubling time = (P =3D=20 .041). Interestingly, the fastest proliferating tumor cells were = found in=20 the poorest oxygenated soft tissue sarcomas.

Studies have been performed using = pimonidazole=20 as a hypoxiamarker in human colorectal [18], head and neck [17], bladder [16,46], and cervical cancers [49,50]. In some studies, colocalization of = pimonidazole=20 and proliferation markers was found [17,18], and in others, there was an inverse = relationship=20 between these end points [50]. In bladder cancers [16], increased vessels in pimonidazole-positive = areas and=20 increased numbers of proliferating cells near these vessels were = reported.=20 The percentage of IdUrd-positive cells in pimonidazole-positive = areas were=20 not associated with survival in head and neck cancer [51].

The Ratio_EF5 50% was = initially=20 selected for analysis because there was a clear break in the data = between=20 patient 38 = ([EF5/Ki-67_binding]/[Tumor_binding] ratio=20 =3D 46.6) and patient 33 (ratio value =3D 61.2; Table 3). The = selection of a=20 Ratio_EF5 50% between these values seemed appropriate in = the=20 absence of any comparative data analysis of this type in the = literature.=20 In addition, a cutoff point based on physiologic measurements = seemed more=20 meaningful than a statistical value of 50% of patients above or = below a=20 random ratio value (Ratio_{patients median}; Table 3). = Considering a=20 Ratio_{patients median} of 75.6%, the values immediately = above and=20 below only differ by 0.3 (75.3% and 75.9%). These are very = unlikely to be=20 physiologically different because this difference is beyond the = accuracy=20 of the measurement techniques. Nonetheless, we present both data = sets=20 because the Ratio_{patients median} is commonly used in = the=20 literature. The results of the analyses of both cut points are = similar=20 although not identical (Table 1).

We find that for the most = aggressive tumors=20 (12/16 patients; EF5_{EF5 50%} > 50%), irrespective of = the=20 Ki-67+ fraction and degree of hypoxia found, there was virtually = no=20 overall relationship between hypoxia and the presence of Ki-67+ = cells.=20 That is, the distribution of EF5 binding around Ki-67+ cells was = not=20 different from that of the rest of the tumor. In contrast, for the = less=20 aggressive tumors (4/16; Ratio_{EF5 50%} < 50%), Ki-67+ = cells=20 had a distribution of EF5 binding values that was lower (e.g., = these cells=20 were relatively oxic) compared with the tumor tissue as a whole. = The=20 findings were similar when the Ratio_{patients median} was = considered. The observation related to most aggressive = versus=20 less aggressive tumors represents a subtle difference, made = possible only=20 by the quantitative nature of EF5 binding calculations. The impact = of this=20 difference was significant, even using multiparametric analysis = combined=20 with RPA; Ratio_{EF5 50%} was a predictor for tumor = recurrence and=20 patient survival in the therapy-responsive patients. Because of = this, we=20 thought it important to bring these results forward despite the = pilot=20 nature of this study. In addition, the new image analysis methods=20 described herein should be very useful in the evaluation of = EF5-stained=20 tissues or other marker binding. We propose that this result may = help=20 elucidate basic mechanisms of GB aggressiveness.

Because the methods described in = this report=20 are new, we do not know whether other tumor types will behave like = GBs.=20 Indeed, it is not certain what to expect because there are no = previous=20 studies where proliferation data have been colocalized with the = actual=20 PO₂ of Ki-67+ cells.

A characteristic feature of GBs is = the=20 presence of infarcted vessels leading to the phenomenon of=20 pseudopalisading necrosis [52]. If much of the hypoxia found in GBs were = related to=20 these (presumably) irreversible blockages of blood flow, then = perhaps the=20 PO₂ of dividing cells reflects the physiological = consequences=20 of the pseudopalisade formation (i.e., trapping of the cells) = rather than=20 a specific effect on cell cycling. If this were true, then the=20 aggressiveness of the tumor might relate to the frequency and = extent of=20 vessel infarction leading to a higher probability of trapping = cycling=20 cells in these volumes; this may lead to the impression that the=20 PO₂ around these cells was similar to that of the tumor = as a=20 whole. Tumor vessel infarction has been commonly described in GB = [52], and abnormalities of the clotting cascade are = not=20 uncommon in patients with any malignant tumor type, especially in = patients=20 with GB. There is an interesting discussion in the literature = arising from=20 the observation of Brat and van Meier about whether cells actively = invade=20 toward or away from these infarcts. Our observations are more in = keeping=20 with the latter.

Currently, an understanding of the = factors=20 that cause cells in tumors to exist in a cycling versus=20 noncycling state (proliferative =E2=80=9CP=E2=80=9D vs = quiescent =E2=80=9CQ=E2=80=9D [53]) is incomplete. =E2=80=9CQ=E2=80=9D cells were = originally thought to=20 arise from insufficient supply of cytokines or nutrients, = including=20 oxygen. Data from in vitro studies are not very = informative=20 because cell growth is virtually unaffected by oxygen tensions of = 0.2% or=20 even less (considered as =E2=80=9Csevere=E2=80=9D hypoxia) [40,41,54]. Current thinking about the = cycling status=20 of individual tumor cells would undoubtedly invoke a multitude of=20 molecular signaling mechanisms affecting many physiologies in the = tumor,=20 as well as that of supporting tissue cells and tumor stem cells. = However,=20 studies of oxygen dependence of such phenomena under carefully = controlled=20 and monitored conditions have not been performed. The data = presented in=20 this report emphasize the importance of detailed evaluations on=20 PO₂ both in vitro and in vivo. An = important=20 clinical ramification of our results is that there may not be a = consistent=20 or general relationship between absolute PO₂ and = inhibition of=20 cell cycling, suggesting that tumor aggressiveness is modulated by = the=20 PO₂ dependence of cell cycling in individual tumors. = Our=20 observations and hypotheses are undergoing further testing and=20 study.

In summary, the = understanding of why=20 GBs are treatment-resistant remains poor despite decades of = research. The=20 predictive factors currently in use rely on various clinical and=20 pathological factors determined in a detailed statistical = analysis, for=20 example, RPA [18]. In many cancers, hypoxia and/or proliferation = are=20 documented prognostic factors but not in GBs. This pilot study = identifies=20 a unique interaction between these factors and seems to show = prognostic=20 importance for recurrence and survival, independent of RPA status. = Three=20 translationally relevant insights are provided in this article:=20

Hypoxia is always found in GBs, and therefore, its=20 measurement, treatment targeting, and modification are likely to = have=20 important roles in patient's evaluation and therapy.
Future studies are necessary to identify the = mechanisms of the=20 findings herein, particularly whether they are the result of = molecular=20 modifications of tumor metabolism or a temporal vascular = phenomenon. On=20 the basis of these results, specific therapies might be=20 developed.
Future prognostic studies must evaluate the biology = (including=20 molecular) and physiology of individual tumors rather than = emphasize=20 differences between patient=20 groups.

Acknowledgments

The authors thank Deborah Smith = and Susan=20 Prendergast, Associate Directors of Clinical Research, for their = help in=20 patient care and Deirdre P. Magarelli for her initial studies = related to=20 this project.

Footnotes

¹This study was = supported by=20 National Institutes of Health grants RO1 CA 75285, RO1 CA 113561, = and R21=20 CA 93007 (to S.M. Evans, PI).

References

1. = Stupp R, Dietrich PY, Ostermann = Kraljevic S,=20 Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, = Miralbell R,=20 et al. Promising survival for patients with newly diagnosed = glioblastoma=20 multiforme treated with concomitant radiation plus temozolomide = followed=20 by adjuvant temozolomide. J Clin = Oncol.=20 2002;20:1375=E2=80=931382. [PubMed]

2. = Wen PY, Kesari S. Malignant = gliomas in=20 adults. N Engl J Med. = 2008;359:492=E2=80=93507. [PubMed]

3. = Brahimi-Horn MC, Chiche J, = Pouyssegur J.=20 Hypoxia and cancer. J Mol Med.=20 2007;85:1301=E2=80=931307. [PubMed]

4. = Evans SM, Koch CJ. Prognostic = significance=20 of tumor oxygenation in humans. Cancer Lett.=20 2003;195:1=E2=80=9316. = [PubMed]

5. = Shannon AM, Bouchier-Hayes DJ, = Condron CM,=20 Toomey D. Tumour hypoxia, chemotherapeutic resistance and = hypoxia-related=20 therapies. Cancer Treat Rev.=20 2003;29:297=E2=80=93307. [PubMed]

6. = Loges S, Mazzone M, Hohennsinner = P,=20 Carmelliet P. Silencing or fueling metastasis with VEGF = inhibitors:=20 angiogenesis revisited. Cancer = Cell.=20 2009;15:167=E2=80=93170. [PubMed]

7. = Fernandez Y, Espana L, Manas S, = Fabra A,=20 Sierra A. Bcl-xL promotes metastasis of breast cancer cells by = induction=20 of cytokines resistance. Cell = Death Differ.=20 2000;7:350=E2=80=93359. = [PubMed]

8. = Deryugina E, Quigley J. Matrix=20 metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25:9=E2=80=9334. [PubMed]

9. = Evans S, Judy K, Dunphy I, Jenkins = W, Nelson=20 P, Collins R, Wileyt E, Jenkins K, Hahn S, Stevens C, et al. = Comparative=20 measurements of hypoxia in human brain tumors using needle = electrodes and=20 EF5 binding. Cancer Res. = 2004;64:1886=E2=80=931892. [PubMed]

10. Brown DC, Gatter KC. Ki67 protein: = the=20 immaculate deception? Histopathology.=20 2002;40:2=E2=80=9311. = [PubMed]

11. Torp SH. Diagnostic and prognostic = role of=20 Ki67 immunostaining in human astrocytomas using four different = antibodies.=20 Clin Neuropathol. = 2002;21:252=E2=80=93257. [PubMed]

12. Bouvier-Labit C, Chinot O, Ochi C, = Gambarelli D, Dufour H, Figarella-Branger D. Prognostic = significance of=20 Ki67, p53 and epidermal growth factor receptor immunostaining in = human=20 glioblastomas. Neuropathol Appl = Neurobiol.=20 1998;24:381=E2=80=93388. [PubMed]

13. Koch CJ. Measurement of absolute = oxygen=20 levels in cells and tissues using oxygen sensors and = 2-nitroimidazole EF5.=20 Methods Enzymol. 2002;352:3=E2=80=9331. [PubMed]

14. Koch CJ, Evans SM, Lord EM. Oxygen = dependence of cellular uptake of EF5=20 = [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluorop= ropyl)=20 acetamide]: analysis of drug adducts by fluorescent antibodies = vs=20 bound radioactivity. Br J Cancer.=20 1995;72:869=E2=80=93874. [PMC = free=20 article] [PubMed]

15. Evans SM, Du KL, Chalian AA, Mick = R, Zhang=20 PJ, Hahn SM, Quon H, Lustig R, Weinstein GS, Koch CJ. Patterns and = levels=20 of hypoxia in head and neck squamous cell carcinomas and their=20 relationship to patient outcome. Int J=20 Radiat Oncol Biol Phys. 2007;69:1024=E2=80=931031. [PMC = free=20 article] [PubMed]

16. Hoskin PJ, Sibtain A, Daley FM, = Saunders MI,=20 Wilson GD. The immunohistochemical assessment of hypoxia, = vascularity and=20 proliferation in bladder carcinoma. Radiother Oncol. 2004;72:159=E2=80=93168. [PubMed]

17. Wijffels KI, Marres HA, Peters JP, = Rijken=20 PF, van der Kogel AJ, Kaanders JH. Tumour cell proliferation under = hypoxic=20 conditions in human head and neck squamous cell carcinomas. = Oral Oncol. 2008;44:335=E2=80=93344. [PubMed]

18. van Laarhoven HW, Kaanders JH, Lok = J,=20 Peeters WJ, Rijken PF, Wiering B, Ruers TJ, Punt CJ, Heerschap A, = van der=20 Kogel AJ. Hypoxia in relation to vasculature and proliferation in = liver=20 metastases in patients with colorectal cancer. Int J Radiat Oncol Biol Phys. = 2006;64:473=E2=80=93482. [PubMed]

19. Ranelli N, Evans SM, Judy KD. Role = of=20 hypoxia in human brain tumors. Neurosurg Q.=20 2009;19(1):1=E2=80=9312.

20. Curran WJ, Jr, Scott CB, Horton J, = Nelson=20 JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, = Krisch RE.=20 Recursive partitioning analysis of prognostic factors in three = Radiation=20 Therapy Oncology Group malignant glioma trials [see comments]. = J Natl Cancer Inst. 1993;85:704=E2=80=93710. [PubMed]

21. Urtasun RC, Chapman JD, Feldstein = ML, Band=20 RP, Rabin HR, Wilson AF, Marynowski B, Starreveld E, Shnitka T. = Peripheral=20 neuropathy related to misonidazole: incidence and pathology. = Br J Cancer Suppl. 1978;3:271=E2=80=93275. [PMC = free=20 article] [PubMed]

22. Koch CJ, Hahn SM, Rockwell K, Jr, = Covey JM,=20 McKenna WG, Evans SM. Pharmacokinetics of EF5=20 = [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoro= propyl)=20 acetamide] in human patients: implications for hypoxia = measurements in=20 vivo by 2-nitroimidazoles. Cancer=20 Chemother Pharmacol. 2001;48:177=E2=80=93187. [PubMed]

23. Evans SM, Hahn S, Pook DR, Jenkins = WT,=20 Chalian AA, Zhang P, Stevens C, Weber R, Weinstein G, Benjamin I, = et al.=20 Detection of hypoxia in human squamous cell carcinoma by EF5 = binding.=20 Cancer Res. 2000;60:2018=E2=80=932024. [PubMed]

24. Evans S, Hahn S, Magarelli D, Koch = C.=20 Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, = necrosis=20 and proliferation. Am J Clin = Oncol.=20 2001;24:467=E2=80=93472. [PubMed]

25. Koch CJ. Importance of antibody=20 concentration in the assessment of cellular hypoxia by flow = cytometry: EF5=20 and pimonidazole. Radiat Res.=20 2008;169(6):677=E2=80=93688. [PubMed]

26. Evans S, Judy K, Dunphy I, Jenkins = W, Nelson=20 P, Collins R, Wileyto E, Jenkins K, Hahn S, Stevens CW, et al. = Comparative=20 measurements of hypoxia in human brain tumors using needle = electrodes and=20 EF5 binding. Cancer Res. = 2004;64:1886=E2=80=931892. [PubMed]

27. Evans SM. Oxygen levels in normal = and=20 previously irradiated human skin as assessed by EF5 binding. = J Invest Dermatol. 2006;126:2596=E2=80=932606. [PubMed]

28. Scott CB, Scarantino C, Urtasun R, = Movsas B,=20 Jones CU, Simpson JR, Fischbach AJ, Curran WJ., Jr Validation and=20 predictive power of Radiation Therapy Oncology Group (RTOG) = recursive=20 partitioning analysis classes for malignant glioma patients: a = report=20 using RTOG 90-06. Int J Radiat = Oncol Biol=20 Phys. 1998;40:51=E2=80=9355. [PubMed]

29. Kaplan E, Meier P. Nonparametric = estimation=20 from incomplete observations. J Am = Stat=20 Assoc. 1958;4:57=E2=80=9381.

30. Mantel N. Evaluation of survival = data and=20 two new rank order statistics arising in its consideration. = Cancer Chemother Rep. 1966;50:163=E2=80=93170. [PubMed]

31. Cox D. Regression models and life = tables.=20 J R Stat Soc Series B Stat = Methodol.=20 1972;34:187=E2=80=93220.

32. Evans SM, Fraker DL, Hahn SM, = Gleason K,=20 Jenkins WT, Jenkins K, Hwang W-T, Zhang P, Koch CJ. EF5 binding = and=20 clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. = 2006;64(3):922=E2=80=93927. [PubMed]

33. Lally BE, Rockwell S, Fischer DB,=20 Collingridge DR, Piepmeier JM, Knisely JP. The interactions of=20 polarographic measurements of oxygen tension and histological = grade in=20 human glioma [see comment]. Cancer = J.=20 2006;12:461=E2=80=93466. [PubMed]

34. Rampling R, Cruickshank G, Lewis = AD,=20 Fitzsimmons SA, Workman P. Direct measurement of PO₂=20 distribution and bioreductive enzymes in human malignant brain = tumors.=20 Int J Radiat Oncol Biol Phys.=20 1994;29:427=E2=80=93431. [PubMed]

35. Brizel DM, Sibley GS, Prosnitz LR, = Scher RL,=20 Dewhirst MW. Tumor hypoxia adversely affects the prognosis of = carcinoma of=20 the head and neck. Int J Radiat = Oncol Biol=20 Phys. 1997;38:285=E2=80=93289. [PubMed]

36. Gatenby RA, Kessler HB, Rosenblum = JS, Coia=20 LR, Moldofsky PJ, Hartz WH, Broder GJ. Oxygen distribution in = squamous=20 cell carcinoma metastases and its relationship to outcome of = radiation=20 therapy. Int J Radiat Oncol Biol = Phys.=20 1988;14:831=E2=80=93838. [PubMed]

37. Vanselow B, Eble MJ, Rudat V, = Wollensack P,=20 Conradt C, Dietz A. Oxygenation of advanced head and neck cancer:=20 prognostic marker for the response to primary radiochemotherapy.=20 Otolaryngol Head Neck Surg.=20 2000;122:856=E2=80=93862. [PubMed]

38. Railo M, Nordling S, von = Boguslawsky K,=20 Leivonen M, Kyllonen L, von Smitten K. Prognostic value of Ki-67=20 immunolabelling in primary operable breast cancer. Br J Cancer. 1993;68:579=E2=80=93583. [PMC = free=20 article] [PubMed]

39. Grabenbauer GG, Muhlfriedel C, = Rodel F,=20 Niedobitek G, Hornung J, Rodel C, Martus P, Iro H, Kirchner T, = Steininger=20 H, et al. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 = can=20 identify patients at high risk for local recurrence after surgery = and=20 postoperative radiotherapy. Int J = Radiat=20 Oncol Biol Phys. 2000;48:1041=E2=80=931050. [PubMed]

40. Papandreou I, Powell A, Lim AL, = Denko N.=20 Cellular reaction to hypoxia: sensing and responding to an adverse = environment. Mutat Res. = 2005;569:87=E2=80=93100. [PubMed]

41. Koch CJ, Kruuv J, Frey HE. The = effect of=20 hypoxia on the generation time of mammalian cells. Radiat Res. 1973;53:43=E2=80=9352. [PubMed]

42. Thomlinson RH. Measurement and = management of=20 carcinoma of the breast. Clin = Radiol.=20 1982;33:481=E2=80=93493. [PubMed]

43. Evan GI, Vousden KH. = Proliferation, cell=20 cycle and apoptosis in cancer. Nature.=20 2001;411:342=E2=80=93348. [PubMed]

44. Moon EJ, Brizel DM, Chi JT, = Dewhirst MW. The=20 potential role of intrinsic hypoxia markers as prognostic = variables in=20 cancer. Antioxid Redox Signal.=20 2007;9:1237=E2=80=931294. [PubMed]

45. Saarnio J, Parkkila S, Parkkila = AK,=20 Haukipuro K, Pastorekova S, Pastorek J, Kairaluoma MI, Karttunen = TJ.=20 Immunohistochemical study of colorectal tumors for expression of a = novel=20 transmembrane carbonic anhydrase, MN/CA IX, with potential value = as a=20 marker of cell proliferation. Am J = Pathol.=20 1998;153:279=E2=80=93285. [PMC = free=20 article] [PubMed]

46. Hoskin PJ, Sibtain A, Daley FM, = Wilson GD.=20 GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer:=20 relationship with vascularity and proliferation as predictors of = outcome=20 of ARCON. Br J Cancer. = 2003;89:1290=E2=80=931297. [PMC = free=20 article] [PubMed]

47. Hoogsteen IJ, Marres HA, Wijffels = KI, Rijken=20 PF, Peters JP, van den Hoogen FJ, Oosterwijk E, van der Kogel AJ, = Kaanders=20 JH. Colocalization of carbonic anhydrase 9 expression and cell=20 proliferation in human head and neck squamous cell carcinoma. = Clin Cancer Res. 2005;11:97=E2=80=93106. [PubMed]

48. Nordsmark M, Hoyer M, Keller J, = Nielsen OS,=20 Jensen OM, Overgaard J. The relationship between tumor oxygenation = and=20 cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. = 1996;35:701=E2=80=93708. [PubMed]

49. Varia MA, Calkins-Adams DP, Rinker = LH,=20 Kennedy AS, Novotny DB, Fowler WC, Jr, Raleigh JA. Pimonidazole: a = novel=20 hypoxia marker for complementary study of tumor hypoxia and cell=20 proliferation in cervical carcinoma. Gynecol=20 Oncol. 1998;71:270=E2=80=93277. [PubMed]

50. Kennedy AS, Raleigh JA, Perez GM, = Calkins=20 DP, Thrall DE, Novotny DB, Varia MA. Proliferation and hypoxia in = human=20 squamous cell carcinoma of the cervix: first report of combined=20 immunohistochemical assays. Int J = Radiat=20 Oncol Biol Phys. 1997;37:897=E2=80=93905.=20 [PubMed]

51. Wijffels KI, Kaanders JH, Rijken = PF, Bussink=20 J, van den Hoogen FJ, Marres HA, de Wilde PC, Raleigh JA, van der = Kogel=20 AJ. Vascular architecture and hypoxic profiles in human head and = neck=20 squamous cell carcinomas. Br J = Cancer.=20 2000;83:674=E2=80=93683. [PMC = free=20 article] [PubMed]

52. Brat DJ, Castellano-Sanchez AA, = Hunter SB,=20 Pecot M, Cohen C, Hammond EH, Devi SN, Kaur B, Van Meir EG.=20 Pseudopalisades in glioblastoma are hypoxic, express extracellular = matrix=20 proteases, and are formed by an actively migrating cell = population.=20 Cancer Res. 2004;64:920=E2=80=93927. [PubMed]

53. Kal HB. Proliferation behaviour of = P and Q=20 cells in a rat rhabdomyosarcoma after irradiation as determined by = DNA=20 measurements. Eur J Cancer.=20 1973;9:753=E2=80=93756. = [PubMed]

54. Koch CJ, Kruuv J, Frey HE, Snyder = RA.=20 Plateau phase in growth induced by extreme hypoxia. Int J Radiat Biol. 1973;23:67=E2=80=9374.

<= STRONG>Figure=20 5

Multivariate=20 analysis of 16 newly diagnosed GB patients based on their=20 [EF5/Ki-67_binding]/[Tumor_binding] = ratio and=20 their RPA classification. When considered along with RPA=20 classification for overall survival, Ratio_{EF5 50%} = was=20 found to be an independent = (more ...)

PubMed articles by these = authors

Evans,=20 S.
Jenkins,=20 K.
Chen,=20 H.
Koch,=20 C.

Recent Activity

=20

Clear=20 Turn=20 Off Turn=20 On

Your browsing activity is empty.

Activity recording is turned off.

Turn=20 recording back on

Simple NCBI Directory

Getting Started
NCBI=20 Help Manual=20
NCBI=20 Handbook=20
Training=20 & Tutorials

NIH DHHS USA.gov

National Center for Biotechnology=20 Information, U.S. National Library of = Medicine=20 8600 Rockville = Pike, Bethesda MD, 20894 USA=20

------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: image/gif Content-Transfer-Encoding: base64 Content-Location: http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc3_logo_v5.gif R0lGODlhkQBLAMYAAKm5x+v0+IekvHefv+Tp7liXuQBcknmcuoapxDqGrsXP3yhpmrnEzrzL3FqG qgFmmTp1os7W3YWyysPT4Uh4peHn7Oru88TN1ip7p8nS2Rxjl6zB1ejs8d3k6mmStfP6+6zE2Nrg 5kKLsb7I0bbBy9Lm7sfP2HKlwy9tnLnU4pGswaW+0kyCqpvB1bfJ3GWRs9La4A5YkGGcvOLo7a/N 3dvi57nQ3qLD1s7c5pq1y6+8x5+zxLDG2JK4ztXc45e80cLZ5drq8eXq78vg6rXG1HmrxmGOsMne 6WCKrtnf5ZGyy1mKsDVyoMrT4rvGz3Cau9/l68PM1cDJ0k6Stunt8Rdvn2mhv1N9qNfg6dDX39Pe 6n+uyIe40MHL1OTv9XWoxefr76DG2Nbd4+Lu9J+4zRlflNnj68Xe6pexxu7w8dHa59nd6afJ2uvu 8G6Wtufs8OHo8dTb4urt8MvU2+zv9dLc5evu9ezr8maUtwBPiuzx9P///2aZzDNmmczY5Ozw9CwA AAAAkQBLAEAH/oB7goOEhYaHiImKi4yNjo+Qinx+lJWWl5iZmpuclX+foKGio6SlpqeoqaJ8gpOd lVhbVhJee2NAXC1DjEGyWxWvnqqhEHlLG0t5eTkVBG9UFp88ymBCQs/TMXksFRN52hAVMwRg0KPT edXX5qase66YTywe9EYoGgv5GvP19/ooSzy88LAEn74qCaYonFJFgxJNw0BRKebhghMGDJwgURaj TB4kAvIwUZbHDYOQKEg4yHMFwMoFOnRoIAmBBAkUynDmIcGgS4QkFai0a7XpxA8FE04YuCGkQgUw Mno0aFAgT4+mFYRIAOGiiQgDNmZAgTLDBgikCQy0mAExIigL/nA74IEAQYkFKlTe6H3DAS+Hv33x WuDBwwzew9AQBx4wwM/evnBRuYN3yUoCGQVkMDRAgwCBLwkyY66yFMyME1MKqC7wIAEUpxIuiyYN pK3bT1S0LTHBQNuAYi9MqDCiQoWyC8bzSBmhTACDlShGSNEmwAROI8zzqBgRJYKYDmCinZocrLz5 87dD3W3aIUSSJCFqdOhQo379+fjz068RIr78+fz1199/ZAnBznhEVeJBHwzq4aCDDEYo4YQUVtgH hBZ6cEkoZFiIoYUghjjhhxfqMaKJHkpIRijkVaIABSLGKCOIFEywoURIzKjjjjyCiIRQoLR43pBE 3pjekUgm/hlkgkU2OaSSUEY5jJBOFhHaLnsEcYIIJzgpjJRghrnkO5mgwUIZEDiAhANXoLDAFQ6w ecWcdNZp5510rolCGS8QkcltFhRDUkkM4PTCHCO5QYYyGUShDBo5iBRSMUhshIITOJXBhEduuCFS EovmYYIJGcBQwwxAkkLlJUWwsYYWWzyAQQK00npDE2pURasIIiSAwQRNmDGFARj0SusPE7z6FRub AApGBTX4AIMPIXQARQdJZJHBBVF00cUFJkQB7qgZzDFHBuVmQCq65Z5LLrrmqktuFklAIYR4qjKJ yRc0YNHAF0sR4BRUNkxV1VUD93BEV1+FNd8MKQDRxARp/rXQ7JHe5LFCEjAI0CcR3zwRQwxYgKCM BjPFQICgInlaTF15oDCAMmTMoMzGSXSQVapDkenlz68gScUMNcDQaBfiXsDtCBg54bR0F40wghPS Lef000hHIcVFNvFE9QX0QvFGKqsCbbYlYqYNJpUUPtjggx/CXWKEJM5tt4RG/gEihBjyjaLfdP+N YomAB34i4YPXzaK+Zzfuh9qQK1m240BHbnl6k1Pu5eWcT8n4z7063vnoCPpMpAQFbFFLALi0EAAh eqAmQZPpKcEYYyvAhS8oODAmSu+M4QCX7QPYtfsowLuVeSU9bLFFEIIMEQYbQHwQCSFAfLHFDx1w Amgx/k+IcYEyLyTaQTEDbKAMBRSI1MEKeUAwEhEs5OGBSFmAHIPIJGOhDR46SYIYcjaD8PSMMpVQ AQ6ux8BBNOAKf3JLoOx3AQZ0DSdIGMF1kmPBRxkHBQzwSB508BIdjAQJUhiOCjyFAuEoAyPdAQrP VvE5SmAGAzjEQBUewEMe5hCHO+yhrH4oRB8SsQo4sM0wLECAom3rAhmIQBayMAeLYKRrFvRaRqSG kSzypGlTa9rTwrhFE8AgBEE5YFGOkhQDsCENcpBDGqJisDz8AI5y3ArDDDCDNoABDG1IwVkoppaL SfANQpiBOK7BATAQAAo1eM97BAQf/1hLP/q5ln3u/kMfAcmngAcaxfKMghSl3OCRWaEjVazySCgQ QI9eAUsF5lMBs6ClkEq8TTJiQAYEKGMCzXjG8UahDBD8UZimKKY1yhEZydSQElsowR7SsAU3vmEc crBCLTpQlR/IQQiAnMLr7jAsIGAFDH6wHhy+EgZD3gYdZKiity6QqU2VJFSgUkYcYPCoCxghD2WI wLQ24AYmaMMN/MwDGsp1xgqMzZmmu0QPEmCFihZBBAvAgrV+IIKKVlQEGMBBBaAgg4561FdmmM8P MCCBim5BBFWoTQTTw4E6jIQkByjXAmhCgpDk4SQvJIGgUAAdnugkBsVwgA6awwApzOE7BiwdAjX3 /jMkWeCaNYjDHEa1LneRilTmOldY5xABr4JVimU1gdKiEAWwZuE7qCLbM6laJCjBBS98QYxfAqNX vXJAL3z1C2D5qjvPRdQPIIBRjxY7IQqAABOigEKOGEvZyk4ICVCgYUQN1za3va1vnpXb3OrGoLzt TXCgfRviEJe40A7ubqpdrWgZtLjNxna0grNb4XRrotROKG+KjW3hhtvb1qo2tSSqG3FhS4HaTrUJ AoCAZXcEAQE0YaYSIUNwp8tdGVGADDP8w/Lo+iTSmVezDUyvetfL3vZKgg/wja9850vf+tr3vvjN r373y9/++pe+cyUves5LYPEGWMDlKTCBx4vg/mAo+LwMbnAnHmzeCAfjDUoQgQxK+oWzUZh0Fi7K FE4AvQAM4XV78MJLt7C5D3cuxJYoQgG+UAsvpIALXMCSIbRwggIUwQzldQvLlMECMAgTX+i4CzQG Q5IB/GUm8fvLkkmRZMEMU7NTzcQNkEWDAHzgCC2gARCk+QgvsIEGPbiBg28DPmwpww1GgIAKhDAX JaDjBXlYgAsIYLJixCAEvmwfE/qTg5mgwAZwWcFMkpGHkRYolFjeBGa+AAQH0aAIW6ABHOwgBDh4 +tOgDnWohUAHOgDBCiLocC5TMUEmeGCnedgBTjwghpE8AX6iAlkeXLAoJiTjAGVAAZ5RcAE8/i8h CU9YRqQ0UIFI5SELUswZAa78ickJQAVNaAAPQLABHrigAS4AgbjHTe5ym/vc3vbDACAIWQkWgwVo UMEFPxKFWaNBGVJggDKKEzMAkEQARcWJsF/wAjTgmQlZuHcepAY2NIZ3TFl2AxoasIINWLwBCsh4 xnlg8YtrPOPc7vjHQb6CG5jcBUCILnZVMREKehEnEDiANkDSnAN8A6gpGckCXJJnHbCwUNpROAk2 8tOe/CSNpcicBMKwhwAEoARp6aEBwuD0p3+Fh8QCQtWHIEQDVIEGH/BCAMaQgDxgYdWosIALVkAE EyxHXCY4gBEAoAIB7AAAAsC7AwTAE7yj/oEBeN+BDuoub5u4wQFu6JoOBqIDATiHAVGgF9LzdVhL pKYIJ0hAEXlYgBOcAAMGKGIVZHCCLwRRiBiwwhdOsMMioHPlrBZCB8RQ1jnAYIBiMFoXyEg1p0nh 99+6QBeksHupER9pwgf+PIVftShkIA6neni150pKBSilB2nI/hx78O2qbEH7FdgCVybwFRxoPw00 OIsNKuZOVdzlkfdpRiKhwDFoR0CKU8Q/DG4vBh/4QAz7FAf+938AuH/7FwdikHtTlAW31wEz8AbU ZmCVVwmk1EY3wAGeIQeqdDAYSAByAEsNc062REgWg3ZpdxdvYGRLRgUckEhO4RQzoEgv/jgO1lCD QuAZNniDMbiDnhGDMOgMkBZpmlCBpoRKQrCBrDQWr8QVsWQDs6QzI8h+JqgKOKANJIEH4AQZEfgJ ysADutNMo2ABXXgYYChVa1RKAfMaR/gDddQDApMVIAgWM/AwUYhLsBcRyvAEkDQTCJAEhRYziGYD dKEEI2MXeJATL6ACdbEEEGABA5AyA3AXyrABYzEDQsABWzh9E0gJRXAGadAAShEGWPEGMlACarBK PWAaHigCXqAGTdhKBDABY9AB62eH7ZYe6LACRqNWJoBnRhACyZYDuFYHuEYfNBMB95MHRkAECAAB K3A+efAENUAzDAhX0udcm4ABUyAB/lZiAAXgSARgBhiQOlZAGlPwR2BwA6NXBKb3ACeAFVggA7Nw AhpgAFPQfhHhB8qQA40id2QwEkxAcAWncBGgcOqybyNgKeAyMzFwJnkQHPvWVmHzUGaYCSfABSVw BEOQAmVHA+JgBT0wBBrJkXlwSlAgAmwgkkeQAjxkLRXQAxipkWcAejJ1i7fBAcmWBw6AEzHQBSjR BThRd8owAj6FEcqABCoAHRnRHDtwlPqWBwLgBF3wVOCRiTAmYTbpFlRQAUkwHG4AAOMSd0iQeCTQ eFFplhakA0+ABAewA9d2RR6ABADgloLneDpgdFAlV5uIlUFzJBYge7QXLmylNOEC/nzEt1bBB3fc 4i3ztC7MNzVUgzSlgkYcoJdZxpd9eSRU0BTRsoAM6AP7ZIDT0n8C2H8JKC0wMEX7l4AKaH8MKIA5 kxWZKIGXiZnekyR34UgzSAA6uIPj4BnAyZu9CYM0SAA+uJu8iUyWaZtB5mJlGCZl0wQH0F06cgDX lZV/YAHaRZ3cGSLfNUxU0gDS1Z06AgENkDdUMFnkuZ4W8iPYWAmcBVuWRVp4gzagsF0SQp/UmVyv JSIk0lwQZwn5yZ/HZThxk1tuQ1qm5SHFdVwIalyjZaCvpVwNilsT8p6UwKDyiVwQylkKap+fcFq8 NaIH6qAmGp+3JTeKE6CVMJ2fXHWgMLpbqzWiEnIAedMhAxqjgZOgEApaPJqjPzqjd7MiLFoJDYCf 7EkhFHCeefMHkpWkUMogmCWEzJlgLsY5V8mcV4qlB1alILqlkDMZ/zWmZFqmZnqmaApfexAIADs= ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: image/gif Content-Transfer-Encoding: base64 Content-Location: http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/logo-transoncol.gif R0lGODlh9AFIAPcAAP//////zP//mf//Zv//M///AP/M///MzP/Mmf/MZv/MM//MAP+Z//+ZzP+Z mf+ZZv+ZM/+ZAP9m//9mzP9mmf9mZv9mM/9mAP8z//8zzP8zmf8zZv8zM/8zAP8A//8AzP8Amf8A Zv8AM/8AAMz//8z/zMz/mcz/Zsz/M8z/AMzM/8zMzMzMmczMZszMM8zMAMyZ/8yZzMyZmcyZZsyZ M8yZAMxm/8xmzMxmmcxmZsxmM8xmAMwz/8wzzMwzmcwzZswzM8wzAMwA/8wAzMwAmcwAZswAM8wA AJn//5n/zJn/mZn/Zpn/M5n/AJnM/5nMzJnMmZnMZpnMM5nMAJmZ/5mZzJmZmZmZZpmZM5mZAJlm /5lmzJlmmZlmZplmM5lmAJkz/5kzzJkzmZkzZpkzM5kzAJkA/5kAzJkAmZkAZpkAM5kAAGb//2b/ zGb/mWb/Zmb/M2b/AGbM/2bMzGbMmWbMZmbMM2bMAGaZ/2aZzGaZmWaZZmaZM2aZAGZm/2ZmzGZm mWZmZmZmM2ZmAGYz/2YzzGYzmWYzZmYzM2YzAGYA/2YAzGYAmWYAZmYAM2YAADP//zP/zDP/mTP/ ZjP/MzP/ADPM/zPMzDPMmTPMZjPMMzPMADOZ/zOZzDOZmTOZZjOZMzOZADNm/zNmzDNmmTNmZjNm MzNmADMz/zMzzDMzmTMzZjMzMzMzADMA/zMAzDMAmTMAZjMAMzMAAAD//wD/zAD/mQD/ZgD/MwD/ AADM/wDMzADMmQDMZgDMMwDMAACZ/wCZzACZmQCZZgCZMwCZAABm/wBmzABmmQBmZgBmMwBmAAAz /wAzzAAzmQAzZgAzMwAzAAAA/wAAzAAAmQAAZgAAMwAAAP///wAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAEAANgALAAAAAD0AUgA AAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mix48ESLKKIHBkFSgmPKFOqXMmypcuX MGPKnDmxRBQpOHPqlBKFRQCaQIMKHUq0qNGjSD/e3Mk0Z5QVSaNKnUq1qtWrHG023ZqTBdavYMOK HUvWY0iuaKVAKcu2rdu3cJNqTYvWa9y7ePPq3etwLt26fAMLHkwYLJS/dKOcLMy4sePHLEsg/msX suXLmDMnPDw5rWLNoEOLHhxgaWfAo1OrXj2WxenErGPLnn2U82uuUX7S3s27t0rTt5t+9k28uPGI wIPvfHq8ufPnApMrdwoVuvXrtKVP51kdu/fvobVP/x8Ovrx5x+KVkz/Pvr1e19uX6+7LAspIFiwW u99fMECJEvPxp5Jk8elU2UIgiSRcTwEWtMKDEEYoYYSMUSjTCk90FxeEFCVIkkgmDWbTenil9xqJ BwVwVmIHDrSCFTDGKOOMMmoY2ItW2JjRgwnhmCNeOOqIoG1boXgXZ1HwBV+BSSJoonD6CeQjjVTG KKReQXaU5UE+XlnWEzB6edCKOim4U4t3LdWkXqUxGaVSt5E44YNWzllhmFriidCLVYg51pYNkdkT gAH4R6ZaeyEZmF/KraUQo6cZSRCOT2QGqEaXGrQCCXll2qNpUDQ40JJSoPmWooGRGqeoBLU53kKU qv+AmacX0SqYrQX5ZSpBS0rKFqqBERnpmwY9idiuUsL4hKyX4UqRs3tBK9CSji7UK6u/4rRmqnES m6uxiHmbrBXLNsSji+dyaadCHEopIacMrbunngipIK+DD1YRZruTptvjvXumC/C/E7JLb0Jz+VqQ mt6WAEVl9Y30sEMq2nefuP1FfPFCwCIEksUi5feQhyEvhl+AKvqE8MkQHepZqAyBi1i1mioLr8E/ TqmjvVX6OymeK+hLo5gYUtnnvD8iTaWNUw7t4MH49ixmjADQ6TS7Ql/NJdRjLoWsQdQetNR/2ikM gMtOYXy2eL52nDHbagMQgLDargDfgUvRXBB8ejP/5PCTITcE6XjYxhrvvjPaqAKYyj7IONdVWxlj FU9knXTNjedr5daXPw1jn1YfXDSVGRbE+JVTgm75lSpIHmPlNfY4OYRZow55QUjG3aqaDbpq5khl YkwkSWmnCBzxdSPk9kCuagu8thgz+ryZNPMOJ081hfShxLqPWqCBSJcLa5iv+xy56EIL2TSEJIRu xc0/dx66jrR22Z3VTM/P70Cnc24F6O7q0kFaJ6MMQcVxm8Ncju4nQMz5yXfYQgjD+nO8h/2HTLvq VX4uaJrcGMQ2g7qgfaB3kOVFxyn5MVQHxdXBDf4NfN7DialW4DWLXBA/KwAQcr7nlPAxC2efsx3X /3BUBf91blxHPF+lHMhEgySwX5DrH0Kk6LmjFYRn/9tZAZn2xPgt0XPqu91AEhbBMZFwdzAco/W+ dUbmmaZF1wJbDz+oLTO2MYbY01TxePVGNOZxb3ecSfO+ty0v/lB2XfTcF59mxfjBaIpDvJ2+6BfJ R3JOSFQ0SCaRiLr0GYSAkKPVJscVxiSyEVEt01aLmmcq+KDINg1bo9wmWMJAAsCEssRdTohFS0DK cGGB9N1QBredQrpIWYdUmp/2Fz9K3s5TRFSf+epnPlIexJOQTKKzPAVKIUrTm5d00i9TyZNV5jKG JBImQrR3oLkgay59Wx6BSoWwvPWnKx6rIUHm2f8idw5TZp3x4eH+Z5EGOhKcniOXn5oZEfxdU4yj xCbSGimQbiJtoVEzJbT8Sc6eULCOHwkkR9epMjyq7ZzLc+VJQTpGWw5EnwRRky550r2VEPNVnBMf zjDaLwjFLqGILOW+Fiote/k0kQKRaBMJotRPbtKi4YwX7ZB6Pj/BMyIq/Sg9Q0pTX0qhpugsY1YJ sjwTkpWl03KpQDiDprHOEid9m8lN1RM++F3UIVOlEUWRGFSllc9LuILQ4xL3UFNa86DjOyJUl6qp o2qNoY8650J6KRBX7YpAJFpSGWv5x3UGcnkyVciSouTKCN7NIJZVY1eHMkgmCTSxRG2aAR0K1Lv/ BmxppZTmjEBH24I0lSCb9JFdGQuAxYJxT5ZbYG8hmxDfgRWCWr1sIDW7w87akUSgRasdv8orbUWQ rWLzblp5stmXABQxxhyXTvsKROUy95iWjCrBVpfMqhqEBI9jH3yF9Fv+Qc1H9T0uQYz7XvhmUWCh FONAcjey0PpRuqvFY3lnmt7uRnit2gWAgz2LkwC5tVjjzBUJU1sUVcVnV4aDbWI1WkkrsNdcBt2v AnNbWC9tkgT9BS7UCCzjhNKYuNuNq/LwGV2PTXeXCKKwWD+bYbOi05eSIjGIEaUVs/UFJDjUIUTm epvCIXOgRMvxb330YnQJ0cUCJghV7WuQHLOZ/6kKjuYV1wzNz9k2zfVU6ylRJGURXxgAIy1hSebz 4Sl78KzWPZueNaxdfuYzxFBWkXgrQrLtPWzCJ/yekJUYYDzP2H/ORLN8BdI+wwIgkZ6iM+TcPMpt co3Hhy1wjz3N4USHF9JuxHVL/6xOrpIn0KdEkzyJfD00SZbRuhZIleuT7L6MEC2BExwPMZbinWIt wS0uc9VyjGquUTXGA2F1izv5alVr83bfVrBq4coxp7Cqz/u0JSwl2MZey/HPt8wwsiucb5wQq1dR kjSxDX0TK6/zvAY/L1e+Vm1ta7LF544vkOtnZ1pTSlO1G7XpVq2s8A3Q3KEOucbz7FK/RBmmfv9G UcL+PXBFs/vetjbhklq54VyrkoNnQph8JmLiv1iZyz5P7HrvrEx0Eba2I7cfYi1eJwNje4EjP5/o 8vvxZ7a4ke77caA6GEK7mQnfNoewkTRIKJPzEoU/8Q8IvWXWFqbd7I8uEsq12mxrqUd38+yW0Imq 7qDJqAq1q7PEaS31A/+U8KkL/NODSPjCk2uwhoX1mx2prNlhm6fKBpfC4L1rSQkrOUZq7dfBvm+E DPJ5iyamT8CbEIBLpOedsTIN9a5iMMcL8kDLIsYJSnTKHx3ISIydrdbHSMDivnEKEdpwY53QGskK TFp/CNpQ2JC5q9ZX0ye93Oi2x+s2l/uLHqP/9gaV6a+RMSJAD7rfFG7wqlVTXQ8pGLoCRrRlTqjT 7mKX/N2vEKNO8/09JSFSVX+AtX/MNH8dMn4lMzIT03oepRAVQxIi4zcKSH4QWB9xU2kW+CgldWtf w3kxwyRfwzywxxQPKCAoaB2YZXrWt08FB1bKxkOHRoHpwSApeIPQ4Uo052+ipW+TJYMjaBAfIzET iING2BzzlFk11yo6GBGttR2bdoRSuB+kUhJQ8Gy8hjzk1VA8NGlT+IUoiIUmiCZ5F37bRUgwCIZq +Bw0tD0lwUIfkoaZBoRrWIf78R8g8R9lZCj/UREKxyJ2GIiC6IddWE6DeIiIGIJdeIKJ2IiOdgh+ d+eIktiIJRgc7TeJmHiDZRgfM5iJngiGTzgdQfiJpMgflTgspZiKUph+6KWKrmiEp4hecviKtOgc oXgao1iLuqiCf6gTUbiLwHgdrCgcmBaMxmgcw+iLx7iM5jE3k8GIzBiN2AF0NiiN1vgdGggiHUgT AQEAOw== ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: image/gif Content-Transfer-Encoding: base64 Content-Location: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887645/bin/tlo0303_0160_fig001.gif R0lGODlhZABAAPcAAAYICQkMDAwTDhEUDgoOEwsPGxIOFRQNHBwOHBkPFAwTFAsRHAwZHA0ZFRMU FBMTGxwaHRgWGCcNHDYPHCUWGTcZHRMkGA0iHDApGgsPIwoOKwcOKxMNJBsNIxMNLBsNLQoRIwwZ JAoSKwsaKwcRKxMTJBwTJBMSKxwTLBcaJwcPMwsNMwYOPAwNPBQMMxsNMxQMPBsMPAcRNAkSMwsa NAcSPAkSOwoaPAYbOxMSNBsUMxIUOhkYOiMNJCQNKysMKiwNJDQMIzwMLDcMKScXJzwcIzcXJiMM MywLNCMMOysMOzQLPDgLNicYNzgWNg0lKBgjJwsmNRckNQ43OikmNTAkLEcXG1gUHEwNHm0RG00h HEgMJlcNKEcZKFcXKEcMOFcLOEgYOFcYOGgNKWcWKHYUKGgMOGcXN3cUNXYNNEghKFQhLEcjOFgi NWQmJAYORAsNQwUOSwsMSwkHQhMLQxsMRBQLSxwLTBUHSAYSQwkSQwoaQwYSSgkSSwgZShcWRgUO VAsKUwQNWwoHWxMLVBsMUxMLXBgHWAYSVAUSWwgYVhgXWCMMRCkLSDIMRDwMQzgLTCcXRzcWRyML VCkKVzcKVCcUVzcYWAskSQw1SgYoWBcoTzMnTgQNYwMNawsKagoHZhgJZwUSZAMTaggUZhcXZgYL dxYGdwQVdxESfScJZjgLZScZaCUJeTgKdjMVcgciZhUhYSYoZ0cLSFUMS1gJR0cYR1cZR0kKWFQK WkoXVlYYVGcLRnQMRmcXSHcUSGgXWHYUVm4MWEchRVgjVEwlU20kTUYLZVYLaUgJeVEWb3YNZmkN eG8ScFYqa3IjcX5CSRtAVoQSKIQNM4kWOZYVNpQWKagWOageKJcdKccbN+QcONMiP4cMRocVSZQY R4QNVJQVWIwVU6gYS60WV4knS4gYaI4UcKoXZq8XcqcmZfIkUtQcavIqatoiWgENhwIViQENkgsL kzEMkAQokQwKqjANrlYPiW4Yh1oglRJNgIkRiqwnmfcmiMUonb4uwyH5BAAAAAAALAAAAABkAEAA AAj+AAMIHCgQgMAZDhK4KBBgxgwQIUCQoAFiAQgVIBB5ArRgwTsRNlCpIBFnDw4GHSsSAACAgICX DQQ0sOBgQAQHEQbIbECjgQIGCi6E2DPiZwhNMvjgkLGAhaAMfEhEYbEhgwYNBLIS3CqwAIECHgpk +LoCBNOKKjYUUGFDxBuqozaAwDSjQIENIggEACEKxEoAAhTIlGmhwYABEIgQgQKlhIAQDEY0YACT hGQSCmzIqAFoFKA4GaIk2kDC6oqrHDIEMFhwIGA+GrwGYOiVwIgFbzbo3hCHBAE/nuK8E3tRxAIS CwQSGLnAIIEGMQW/dOCAgokqVG70FGABU5QnUaL+RF6gKM/RPDJwCNLA4o2GFYJUrIhjd8VprgQd 2Fixn8DYBRuMIKAMa72BAwksgKDgAiKAEAAJeoBAgyAb6EVADQSQwFJgPjHQwE2GDeAAA01QkIID DYTwxxR+JIIDDiZpYpl5NuSBiAxvCDIHIH1k0AIdc7SABwcI4EdQBiDoEdYKdlUkESYqpCWCChmI kEEBDGJFAggb1EACH8k96JtBCkgHXQQvPeAABIcdNtkfJfQhSgh8jMBHCCOQIENaI4wiQwYkzDHH H4MsgsccLuChKAdGDlTHGyuAAkIg8+UhUVpxbEDVGyCIYBcBDDBEgggzVCgRARItsFIAC7y0EwP+ IkZwYhUD/AEFdCPQQIomS4mAyHE0iILIG1OC0F4ggexASAs+vOBBoh500KhAjeRQwA6fZMApCwWE UIBEZ22wF5YFbPmglV5ZpKpAzbUkmGAeivhAFURwogMPDqSQQggNjNDHHiEsoIl5isigSSKJoCLC H4bYQcgJHnhghxwcHODBAUVO+8EKX9WllkXG2pAjH3HIgFwABNgggA0L2EBCCziUvIAMAQjAEJmu yjRAA1A0QQQVP2PAQwrRKDKCH4iMcIMCUVgKQia53rAJDaGkYoIHOsTigSERu1BHEhIIsBpXAwRw wreqpqvAlhXVwIIMI8ygwAIhZLjASHspoJf+DTUoSICqZJYZEwMilMBDJD5D4EAkkZSQSSqI0IPJ KNtBtsBPccBRQg5ymBBDHTA84EIgcryQxCAwIMCaa609sJVuTEIVcwYblOngljPLUFEcFuXREQ5y LcAQq/Au0IADD5hweCRVQCAFFBYsUsoisaCi9II2+JTICDwg9EcMJhRSSCgwnPLHIh8c4YIEY6++ +lZZpUqS22+QMJFfW6owA4Ag1LBBRBUpClNW8jcQCAAlLylBCiAQCQpcogoOoMIfNjGCRehDETTQ ww0UAZSilCAOOcgBIUpwBxeU4BSssMMLTnEHGBzgBT4AzLQIwqA3LMdXIogDDkCQB5aJoBP+PZSB XCoytyeoSgFDBEFLFkAZGmiiAQQogQ50cAnmQaAJUpCFLFKgCD/QYAQhuMH2cCOKG/TBEDkoxQkm UYdCyEMWHoiBHRbxAjzQAQkCeN/Y2KUXgcxNXQ6RgR7i0BYuyYAFM+BU3WTAAAYQQIhMjMiWDHK5 uRVOAQpswM/q1QQqzMMSIUiBH0YwhT2QIA98EIEMEKEHU3yCDjlooQ4oQYl5fMIDePAAkT7QAYPI EH7+GQgBVgAIGhBLEDKwwQb4MIMQsGABSEqlWeynABmEq0kErJ0CihIdFJTIAhGgQhMiwQnp7eEJ UshEFHAwAhmEIIyC+IQ86fC5VbhiHqr+wEMMVHEKGHzAB0nI4x7HJoivKEcgfZCDkxo0A0/oLm3B e0gBgmipuVmqALpzTmByYBxM/oEII3ACBCDACSKkQAp+8EMInqDSyFjSBqYYhAhOgIIczJIRD0BB DEBBiXtMIgY+OIIeB1KDrSjgBHcIhQ2+BQI+ZKA97UyOWTrimzd4SQQ1wFEUANQRdzXgAg1oUMtQ wAodVMFED0iBAh5wgzyRQBB8eAMrb5AJVMDBBjyQQwkmQYlJTIIQKOCAKl7wBUoMFgEClSFrLDSQ O9ihEoOIwgzsl0MWmAIRD0mOpSbbVBHEtYALGEGDNES8ufHBBlI4gQN0QIUGXNEBOYj+Agj6UIMN 8kEGo+BDHvTAgAjl4AShqMMkHOGBBzTBBQYIxQE60IEeNOIIYgMMawTQx4GIAA4tWEQLbBCAEfQQ NPDQgwiM80gGiWBLM9BtR+bWP5S1xH4MimsUMlGCOuTAEqXo3h5IIYIbwC0Ro5iIJwQhNwXkABSF uAMt5/FTHrggBjE4AgI6gDGh5nF1jhRmCzpihz80SCyetUHCAGGDOJTlTnbCCAFwcJx29g05BFyQ bEWQAwU0YAcokIIUdkCDG9igTgvIBCJowAASiAIQ4rUBCgixA0aogq+TQIASlFCJFzQCY7xMwkCF KRC/rGABJQiEKMCEGRuAIA5veAP+H+IxCv7kZgZxWNvfVMViVCWTtAqSSA3WagMHlEB5U5DDDUxB pzxk4kU06AgsPLGDEthBB4zgwRGOMNwXJEACTEBGJZCgCkq44AUuwI8vAxAbP56gfqhiKKRYIApF vMETJPMECR6Ckr+NAEle7J8SZ5OVELBSBIFAQQMWsIMGACIH79QDkmOtBz7QQA42GB8ljpAEJ+jA EZBwxBImMAskLOEHjfipBkLNOoIQAA7DC4ABdMABy4igLL56QyJsAAgSuCwRW531t0iACOQoYg8L omQl7d0JT7DsBIHwwxNoMANf8eQGN9BDPOnAgRREohJEwIUtmKEEJDxiFj6YxT3+GtGIF3CAAy7I wAG2EqaBgAAOJyhBCXqghA4UACTHWYEIEgGIROjhRsxk2UP00JYbPIFVnx1bukz5AD3kgGXGMsUM EAGIEUTBBjYI2ALu2mEe3GMWjwACMMJQiS/8IAg96MESXHEEPBxgUS0gCEQG+pUHTAIJJviBDkCg NxEAgiqdYIEemlkDT3SCFDRAzg3eIN4GkOAJN2gQAQmgtzy45waJfEDLWNCCFnRCBA8AwQMKV4KY o8AHSoAEM3AhhHF8oQcJmEUPfkALRlQiFHhoAcozoJpGKQAAB0jAEYAAhi0cgIekekMBBMECL/En h4lAxA2O6BEQvOE4v+oqykD+cIG1zeENGVBBHNyyAjnJQQ8tAAFeT1CIDpjgFbqYBS1ugYQhpEMY YPjBLJCxBAkw4gih8CwcUwBxtxWr83sFAAMoYABdMAup0SkgoAF/IgNxIE0q0AfMJETq5xDq5xsR gSosoTd9oC4L0AIEtgAOsACp1AIrUAI7QAepEAqOgAursAv4wAxfAAS8sAzjsAzCgAy4gAuQ8AGM UAeHgAfIUgAHsAIzJBAG0AEOgAAvgCp+oSB28RaewAKEhHUg4AeqkiDLoSAw5hVLpDd/JAAbkH4L oAcK4Ad/oAM7kAMHgAKTUAmSYAS+8AWz0Au80Az70Av8IAzngA9MQAlGeHL+KMeCHLNyWxYAHtAV WfEASAAETuACGqAAAbACJKACacYWBMZDyqcqqsJ3BWADKvAcWNIcBLAB69UUxsEChbMCJrgDctAw OzAJkLAEtDABYCAGtMAL6BAOZgAG+8AMuQAGudAKcdQCBwADgQAKqXEALSA2XFE4AvEBSeAAAbAE QwADsVEuqlIDM5AHqDADz2cDM2BmFWEZFdERDKIgBiEW5aIgccAeyLIDkTIIORAKq3AJnOAIwAAG YVALY8AFvNALf8gLTCAMtMAEuHAKHKBLS+gBLJgVBzBUAZADA/ECYScBQrALulQb5fIeGNFZC5AH K8ApMvA3BACLatYpecH+EgsQZ+onArcGCG8ABy4wA3LgCTzgA7qADLcwBLvQDFwABudgBmYQDuQA DmAwBD/wCJUACargAgfgAhxgABmwAgfAATDQe1tBXQJxAD+AC7SQBuHQDVWpAVt5FwUAeZnwJQqA VQUwAmahFwugAQ0SEoCACBlgEBhxRFyCF7LYAg3iAH+gC8mgh2EABrwADmPQDeQQDmAADrxQC1/A BMnQCJRwCDFwAKpxAAcQJF3JiFuRAMIkAZTAC18wDceQBC1wJWMRAD/2VjOgAZ2CJSqQJzWACBA4 ayIzCjYQjwTQAgrgIE2xAhmwAF0ZXCiwCpKAlGRwlGjglOeQlL2ADFH++QVTeQoeoAEGYABKSAcS KZrwgzKrcQAGwAFJwIdm0AuNEAgegzIkUBXMlAGacUCWIQN50BvrSCwSQQPT5SouUSY2JiJNAAUY 4AROoAa20AVhEAZWsAZF0AVd4ARGQASOYAmN0AMmoAMesAAXUwBY0QIFUDGo2YjpeWUHwAtbwAuz QAgesD9qcReEFDwBkBtEcSUscAMKAhJxNQOwOKCuYmMh4AACMAAPQAQVgAG2sAa3oAYVGgZG0AXE YAu28Ao6oBg+wAg6kAMPMHqYqAAHoITRmACr00deUQAGQAtCIARBUJlM4I0iIAe6AQJPBX6qQnlb UgAsgEhbwor6Iwr+P3cDBpEzL6EAT/AAUHATFMAJGLAGbcAGbLAGGFAMuuAERWAEtlAFTdAEJoAC JoAAJiAFHeABgRAWX0GiJ+cBqGkQDMAySvgXMUALYDAN34CDMYAkIFAbXAJ+sSE8vpEgYjEDvPob 8nkDBRCPgXFAPmEBFwAFOFEFVYABWqAFFaAGauAEk7qpDNoEKSBzOuEAJvAAV0meqlExXXkxCaCN ASACrQYCBvABASABvPgFB7kEH+ABY6EbWaEXN6cBQxQVoQUCTCIR3OUbWJIClNSsIAArEUATEQAF FFAEbOAEFcAGFhsGmjoMaiAJTsAKVBABUpADKXBwBkAHdtABdND+lR3wAkcQYRmzAJ3wDqZAID8w aT3gA0wge175AhpwilWhFvS5HGqhKRDhLV5xEf7hF44UOCEwHR+SAj9TDGrABrdADF2QsUXQBmow DGvgj/NABVRQAnugA5GgAw9AAA6Ach5QBx/AS0fQAQhQDVuwJcLiCZ5QgFZ5ohxAYRZDYaf4r1Qh EOG3tD/GAsrxFXtKAuXCADjjEzLxABFgAlBQBFXwtRarBlTABl3ABrbgDGrgj5YAASkwRSbwB6Hg AIXwCR9gADEQCjGgBKrABD8QlVsQB4gAC4IQD/EwA2NpAAfwuhkAAwRAB+pzJSBjFw2hP+KCKlkl LhbBil4hAhv+oAKrAQAWYGMKUBMOQAQYWwRqgAEW2wWSgKXFQAxtQAHFwAl/IAUp8AdvqDyFwAhL UA/ygAJ38AJWhgQ/wARMUH+oMAqKkAidIAgKYBcGIBA+cABzSwCH0AgmUAe04TcLwgIqcJx/mgE1 oCq6w1RCSjeBQx3JEwlOQAzPsAbZagUW2wZdMKnGAA38gA3PkAKWQAWMwwOLEAqRUAiEoArysAMn 8AEv8H/aNguNMAH0gAg4kAcBVgJYwQH/SgBYyQFTdgRlOhsrYHkV8Uy8UxUzU8HCIxF8VxRl6GeH QQTAgAZbCwxnMAxtMAy24ARr4AbEsA/qUA7+YA+yYAmLYAn+PBABEpAEk/AHdHgKJjAJB9ADlBAJ PyABQSAEqKAJLIAKhmcIcwADcVQCFWOJGQCzjiCNVUE7mvhIzjQDI1EDUcCKeGoRt1UWKDGW1IEA EJAATuAFV3AGZ2AOxIAGxvC5a6DCz4AP6VsOw1AMyfAKrxAJPMAIjPAKlqADhvACMPCZPhAKR5B2 PvAD9aAJnhAPmWIRgXAHK7ADWnkA64ICjBAWXjFEAlsAcYCnfCAIcSAIwzIWjzRZb6COBvEACOBN QEABtlAOxmAMbfALBe0LYmClbbAG/OC15sAGw+AMnEAFl/AKKOBNhmUJjIACRNwBMTBtHXAEjfAF 9AAL8BD+DyygGqUIxZx8JV6RwIEQ03chJd+SIIfkCZh1AyrgTrZBFVW4KgRgAlSAoUTgBV0gBtBQ DuWwBsZwBsQQBsNQBJzwDMRA0AvKBsVwD5ewCpZgCZFgD43sCMegCozACvPQCkngAz3wARPgB6MQ 1yamBwRAkXTwFQrAexoABwXFa8u5F6VRilSBJBuwFMuJHHzwK3JxMwRgAA8gAUAgBl5wBmSwBlqw BubgBmdwC8AgpRTgBPzwD25gqUUwDMOQD5wgCUtgCV3tCI3gCE4ACavwZI3ACD5ACYwABKgAD4CQ B1nICOi3A3khPGXip5yCMoTzH0gCIArAFjjiEE/VJMj+eRerYgASAL5hUAZn8A3f8Atk8Ate4AW7 AAxsgAHG8A/qsAY8ULG6oAv3gML48ApO4AhEsAREgASO8Ai5iARIkARJwAj+6wn08A6C4AmmEAMF IAeTwDHVBa9v4y3qxxt5oD97ckhvkAdzIze4EyVO0nIIQAFGsAxocAa5HA7lQAYsLAZnoAXW6g/t oA6Ter7AsAvOoAu7oAtzPAuO0ARIgAuzMAtfgAuPQAk9cASV8AESYCP9JgrxUAczUAIeUF0CEQKe gBG30RQY3CBsCVrR1KfHgZz/2hwB8OG+UAtngAZlkAVnQA3ZcAZiMKEV6uLYUA5qsAttcAu3sAu7 IAT+YaAMtrDVQUALQD4LQ0ALX0ALyQAJ/N0BSW7g8FCzdmCwZcFyvIEkbEOBfCARIoADy0kDGTJV fhoHf+MbezE2EvADW8AFbuAF0nAN1uANZxAMubwGXqAO7sAN57DiWCsGzRAMYWALEfoFkJAETICQ +JALX/AFtVALuMAEX7AKPdAB8WAKqIAKpgAKn8BRIoCJchd+W0ICOIAqJRMld+pdfYCTCFKKHawC YdIuAXBpXXAGYFAGVxAO1pAF3lAGvuwG4TAO7qAO6qAGYdAFtxAMuzCIt/AFzCAGwJAMt7AMz4AM XxDJZiAMs5ALzSAEPSABo/AO8BAzgWAHzNhyKAP+EvXGJR0sEH+qgSDTVHowgl5hP9/yNyuZvRRA fGl+BV5QBr8gDdjwDebADuNwDtrADb+A589gDF4QBjMeBmIQBregC8xwDLRgBruwDLlQC8fgg2BQ Cwo5BEswA4KQB77TAjDwCQ4iTPtWMhbSRzOAk7mjICoACHzQF7YBAg/hR6u4GgSAAEGwBdRgDdXg DVlQDdlgDWUQDtKQDuNwDdXwDV2w9F0ABr6wC10QDLQQkGIwC1sg6GYpBF+QC81eCxKwBZk5BDLQ l6PA13rQsnPJR3ryFlLOKoLQCZiBKmxjb22TZ3/DKoATAEHQBUZwBWYwDdSQBdIwDuVQBt+gDez+ oA3XIA1iQA1ogAZ47gvYLwa7kIezEAaz0AXJgARCgAyzUAvIwAWcz+xB8AWiIAewUMCfwIIugIkR uGG9yfZbYX3MhDJYIhclyUMAAYIFCQULCCwgUQAAAQlDrFwZM2bcrzLf1KkLt20bu3Zurpz5Ja4c vjC6Zt26hw/frC+1lCGbJeberFq1vvCqCWaLGVGd+NiYMQhOCzoEAiw4kiHDhjdvohAQEEBqAEB8 WowAUUMGgTgg4pAAsWBGwg02Fiw4OnXCFy5YrpQpgyZLmXTVvK1b168asDO9pnnBB05MmC6zHuG6 V6mSq2OJj7GklesLGDC5mIDhRaBTnE4z4Bj+akFoQQkCBVjMAfRGRAa0UwmAsAGCBAkbYG1sIAEo dogMARQcLGA0AIACE3RiMRNOWpYs5MKlQdOuXb9pFMOFBLZv5ipXShTPWxJ+FaVGSGYds9wyFxgh QgIQEGSq04o5LVzQqcOBQAZAchDNEEGBqQKQ4Q1T4mBBNRxIWAAEEGRwMCyjXpMNhOEM2MIKLLjI AhxyqiFHr2rEIScddqYRp5t0wgnHjGWUqUSVVRhJYpI6klBCiWTG8wGJSnzABZItlmBiliAEXCAQ OfAYZA4ODHFhuALiAIWFFWYYMAAQ3mBBEBDyUAEEPh6UYQbZSBDhoNIQGrAtLCLqRppprrn+hhow vsHGmm+C+SWNc4JZZpZKHKFEFUZM0OGUOzy444hGTlFFiUuOKW8WSL44AoEgCgjABw/okGMFDTq4 w8IACtBgkAxQyUMEU7VUwcvgCgBhg+ASMZOAGUIAoQAkZWgQAAOwwEKCDdMYo5tzqhmjF3/cQQed XtKg5k9mjlnllUlCeeFTQvCAAY87GDnkg0lUoeQIH35o5IcegJAggBE6wKMOGAIJ5I5COJWKgzvw HaG22EAApEwCVLDhDRXyuECPAt7IYIY8FIiDDy1JUGEBEQAIYIstuEiDizGm6SUcctLoJZhmlhGm GTPSMCcYXFZRJYlQPpHHDlNOceEFF1z+qOeUQeqo4xAXOvDhCCR+UEKCgziAwYMd6KCDETxcq8MO DVQTRJAa3khEEAgJ0MOGON6IA6sZzBwrD4NIOJgAuaUSOYuduOBlmWnAqQadacQ4BhgwzDCjly9o ZkSHQ0A5RY538JhjkFDwAGUOy/Ho4IUOODiggw56kMAAA1xQoAARBKHkkE9cu9JVG1zNowb5OEUo gzhUmGEDPUhgSgQVNEGoABLiCA4AjreIyIwxsOhF2jSmOaebXJJJhplfkGmmknRDceGUOeiYA49A WlgBlMpdAIWDnz2AIeoYPEdAgwzkLiCDOQox5A7h5NaAhRlY2EAN4mCKd7DAKLEpQAFOaiAIjWkA ESoYwQxGsYIFACUK71EIAT7GBZFxoRfM6sU4hFGZSjwiHysDgyssUYdAuIBypojcAVYgQ/KtoAVK cUELOMABDxigAwhAQEAAADs= ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: image/gif Content-Transfer-Encoding: base64 Content-Location: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887645/bin/tlo0303_0160_fig002.gif R0lGODlhZAAtAPcAAAICAgcJCQsMDBMLDhsMDgsSDQ0aDgwPFBUNERsMER8PGA4TEQ4RGBMTExIb ExsSHBsbGyEODjwHDTULDz8KCyMMEisLEiUPGikOGjMKETgMFDMMGSUQHQ8iDg8vDhAnDhUmFhMp ExAUIB0VIx0XKR8XMCEUJCsQISIWKSkUKSMaNSwYNiMcPC4aPjMUMD4UNjMXOjAYPCMjIysrKzMz Mzs7O00CBUMECkcJD00JClMBA1kBAloGCFIJCksGEkEJGVgFFmICAmoAAGUGCWwCCn0DA2YHEXcK F00NLVYKK0QPMEoOMVoLMkQRNE0ROWYKLmkLNGUNO2kQM3QRPSUeQiodRCcfSisfSzsXRDcYQjYd TTQcUD0bVjsdWh8jTyogTSsgUisjXTIiUzQhWyslZC0mbCYobDAjZTEkazohai4mcSspcy4ofTEn djkicDsocjMoe04USEMYT1sRSU4VU0IcWU0ZXmkTQ2ESSWMUXEgbZkgbalIWYV0VYl8YZ1sXaFoZ b0UeclUbdlwefmUZZ3kVYnUeZHgWaHwcbGEad0Ehc0gifUNDQ0VKS0tMTFFMT0pSTk1ZTlVMUE1S UlNTU1pQVFtbW25ubnR0dHt7ey0rgywsizAngTIqii0tki0umzErkTEsmykwmSsvoy8vqjItozQu qjksriUxoiswoiwxqjQvsz0ssycztCoytCczuCsyuzMxtTIxvVMeiFkfjEYhg0kghE0hklIjkV0h k1Yjn2cjinYjg3AgjG4hn0cnokwlpEMopUonq00or1Qko18joVYmrk0os0UruUspuFsns10tslQp u1ovvWEkpWojp2kkqXcqoGknu2Isvio0wi40yzYxxjsyzCk21So32yc55yg56zM25jg14jU360kt ylUqwF0qwkgv1Uww3GMu2WYz0VE19YKCgoyMjJWVlZ2dnaOjo6urq7CwsL6+vsTExMrKytTU1Nvb 2+Xl5e/v7/b29v///wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABkAC0A AAj+AAUEADAQQAEAAgZAEAAhwIABMxrImMihQQOHDSAAGDDxHDsAIEOKHCkyQEGSId9BMslSoMkD AQQUMFnAQAADB3DOpPmyZgOEBHcOSBhzAYSLAY4KMJBRAMMZEIzOQPcRpdWrKOFFYhmT5cyZAm0G +GpSbAGZXw0AsAiSw8KCC0A6GCjAYt0FGSfSkNGAxoxMVbGSPDmS8DtHMmkW2DnWq0mBZ8fONFDA g0zKARoMZRg1LsEBhCXOmDFRxgwae2WgBiy4tdUA7ho57QqWq+2bNTuMpdxhcQfKIIcmlQFBRsGC oNdCKCCjInEQmovLYO0aK+GUjWIKRCvWtsuvZxf+Ly27WCSHuAkFEAQpYIEABCEbOIBOPKnmAJnW obxefeS77I/tFJltjDU2GUyNCVQSQQ0sMABBCz1YAAQDXCQRBwWYAAFUxglAXX/9xXZbYwEKOKAB ZlFmVkgyIYQXQwOgV9BRDRV3EXEQUAgAJvqBeNV1/zlmIGQEkohZTZKZFJdD6hE00H1nJUejSDki 1OQlgfnYmjtbPXZbbYklyZVZXCFEYUEWxiXcZwX89NNIm13So5atBamdSwZ66SVMBeoZ02cgnHTQ Ru05RVQDAshgZkkDYEmnayoFyBWeXA14E0+VOvQQSxs5SJB6Gi2kXkIALMBBkyLx6Bp/dTZSG0v+ CHpFFqaWlmmScgNpF52ZFjUlEAioghQAJlk+alWQkBX41QLa2VQAnyTe1lCuRmXEUoOIKqjURsUx 5BkAjhqLlTuQULoYY2ER+J2zBeIFFIMyDAUAAiBw4MCDmf0UAAKPEYfQsMWK65+rt9k02wHnstSd V2QiN1S8DFlkH19RJZdUZgBodGXAAmPn2AEuhYmkAeYmRulJNF10lHIyCMBhA/A1FDFQFwkQbsck 2SkpniieG160ryIY3FD3yfRer3zpO1FGiP6bcQOq4pwzgLMJqF2JNFGWcKbv1qVRvMPlKJDENSd0 kQN1SZSfYLlqqTNPJtc04KzffYVWfDE+2LT+RBlDUIPMdQk7VkUKyUCV1FM/5hRY32XtgeLqSqZW SG2DlFFxYgNQAwIcPdmQyhl5hPjAI8oqt5IkL6Y4ZGhJZFFUTGdEAyWj+dXADCDk6AAHpOV4OQSZ tFOXoS86hWivvdaFgPHJp93AO5MgCvKzCJ/VQAghOKB9AQs4sMABByzQwQLkn0X+AvSkr/767Lfv /vr12CP//PTXb//9+Oev//72wCMSDfUIoAAHSMACEnAe7fiddCaioYmM5jQ1YAQjKEEJRzhCghh0 RCMsEY9KGMokCbhABSoQCzG8AQMWsIAGcMCDITSDF4gowhSW0Qwp3GEXhihHNOZhCZBAgB3+/Aui PebBjjb1ygTE6VWOclQa1dTgiRGUoAUfYcF4SIJfJhnACCuQADjAogURGKEFKpCBGwDDGE+IgjLM EQ5p9IIchYDGIeZhj3gAIB1CDCIRkSedo2jmdUs0AQRp8EQpWrAREoSHJAawvAAkIIUV4BwCEkBJ LlbAAjcAQh/m8AdCFOMIvpAGNKZQjFzQ0R7qkEce+UfEClnEARDgAHTcg5fLyQAEEIQiISP4RL8o kpEPSUAFYCALNTxkAAQggDAvaUY8EIIZxBgHM4pBhDwM4hhLcAQm3KFKe3RzlfcjYkxi9LqMuBKQ MjABCEyDmnaiZjQTgUd2EoJMArQBDKb+OOYkxXgBCwRCGMOYBS7EwQQd2OAGTdhABVj0jkvIAJz4 E+djHFRO8inQdxBAYu380pyjyLMloEEAGUzAOTCQYYQnWMUqLhDCDGQgGEj4xi32gIw0UJIkQISo /YgYsqHUUjNGgUC9lkijJZYmdzALkpMQMkkCmKAFn2gDDCqQglKcwhSwSEECtrAKblzjBdzQgisG YIKRPFSnO03gZqKEl3MS1XfIU6BmBPA2hCDzAbCgBjZkIUICVCEGq7hCGQbACSqQQgXVaEMnqPAQ kqTjlGiVHwItUiH3OMWifEReATZjqPSA722PGcADSEGKEVCSksokwyZcgYAHmIEEx4z+rVUgi1YE UrR5D+nVA5BHvs7OxlBDAW1oR4CCK4zhtAhAQBXU8IrlDaAEVKDnQ4IlknVEVrLtIGeO3BOAny6x VwgowPKc0siuOOU/TspVFhHAgU9wYgWoHQAVNtGKh5BAFKIYwWYai5J4XHeI7LBojogGSKH6kbLZ Gh6l6AogTjlkkgkIxSkwgFwFrMEEQxmFGV7BgPTIKyQ1WIclZkBbnSLQlXBV4oZwFDsEJ9hLb+Oc QyppAQmMkZIIIMUayPCQUWiCDAI4AGdH8s3/nhiQBS7OAw98FAe1lbMOeZsATrvMMi6hC5E8QzVK cYXlXcETriDBK1AxXRYBwLr/lSz+O+6CziY+MIm98mmDpmuow3BFBKVAYQotUMZk8MENoMhGFdgA TBZ8ghquWEMrQPYgkMzDv0MssonXnLZYOvCBpxnNgX2aN8rORqla5EQasIDJG0hAAjcYhhO80YVR qEEB70kuCqywhk6oID0hIbE96kGDTBiZHTFpwDod6E6/kCaJlz0fOQfwLAazZABcCEQCAqADg9rA BnTYQx2sgYaHjMAVrvg2LDQRBtkCgAYNcEcdASBpiPJ0QkrOZS+PLQMHIGqz5ISZkLl3AJ0NoIwD iIAQgrADQBxDCayoQxcSwDkSfKIM2EhFKkbwbU3wN6eopIH82p1HBO5rd7WrASL+533silhEyAvY bJvEaxFkPXICNwhADooQhCAwYw56kEM30nABBJhgFNpYrQpKgAAwhMEVYHCFD+Nnj3TIAB7nOOuk zaZkQjICijUwNjz9ON3NHgABtbSTFssYgAn0QAASgAIgfGALO8ShFljohBVgoYIRaKIVVECAGdiw iSuA+BznmEFIMBFZBHIvL6fxC2p6qXXSWMR8zD6eRT66XhS0ZAeJIIYg+PALZPxiEdbYhBUGcIBW kIEMCAiDJrZRBZFYIh2XuIQlBFDiVSLQjxCggQRTs8usk2adUXlPmxLSpuQ+r8EHKMMVqOAFBiQg CbQwAi2S8AMLuIAVpuDcAFQMEIZRbAIFowAzJwICADs= ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: image/gif Content-Transfer-Encoding: base64 Content-Location: http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/table-icon.gif R0lGODlhZABMAKIAADMzM8zMzJnM/5mZmWZmZv///wAAAAAAACH5BAAAAAAALAAAAABkAEwAAAP/ OLrc/jDKSassOOvNu/9gKI6dQp5oqqpmMRBBQAxyjMV1DN/vXdM+2SIHgwVuM9xghWoBnoOnFICR Rq3VaBX6zHIB1yl4C4YyTy0ZYU0L9Fzr3wxDI/DUSzhbEXvN2nRtcWckLYSHiImBioyNKQoCkZKT lJWWl5iZmpucloaOoKEbn6KljmkZRzgdR444O3atR7EFNq2KLUZru2saNb2MvMJqu8TAuHmmyoyk y85Mzc/SaAOd1tfY2dnR090g3N7ho8ni5Rzg5uG5wrwduxns8fLz9PX2x+NBOPusNumN6P5NC0ji nsGDCPF9ICjQGcOGyh6GSEixorwQEiGKyqgR2xTHjgDz0HN3zKJJhE3y7Ft5y1dLkCs+wkwkk8PJ mxUXkpv5rCbPMz414Ey4cefPiEaPlgqqNCWGkTZLDp0qzGktlqs4ZG06ginXrklVUB1br0TYr8zO oqWp9gTZt+10rl3adi7QunZjipxH0s5TuBeL6mPZ72XeDF4P50MEWKGpxIoR441caPLExnxPWaaM cTNnuZ8PrQu84d1fzAZFq8Tqb8NWzpApJ0ZtkYXn0Odu49Ywm/bUb7p3LxKul7hebciTK78WO/Lo Xu1M3zttmmdzxRaya9/OvbuCBAA7 ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: image/gif Content-Transfer-Encoding: base64 Content-Location: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887645/bin/tlo0303_0160_fig003.gif R0lGODlhZABPAPfGABkZGSUlJSoqKi0tLTQ0NDY2Njk5OTo6Ojs7Ozw8PD09PT4+PkFBQUJCQkND Q0VFRUZGRkdHR0hISElJSUpKSktLS0xMTE1NTU5OTk9PT1BQUFFRUVJSUlNTU1RUVFVVVVZWVldX V1hYWFpaWltbW1xcXF1dXV5eXl9fX2BgYGFhYWJiYmNjY2RkZGVlZWZmZmdnZ2hoaGlpaWpqamtr a2xsbG1tbW5ubm9vb3BwcHFxcXJycnNzc3R0dHV1dXZ2dnd3d3h4eHl5eXp6ent7e3x8fH19fX5+ fn9/f4CAgIGBgYKCgoODg4SEhIWFhYaGhoeHh4iIiImJiYqKiouLi4yMjI2NjY6Ojo+Pj5CQkJGR kZKSkpOTk5SUlJWVlZaWlpeXl5iYmJqampubm5ycnJ2dnZ6enp+fn6CgoKGhoaKioqOjo6SkpKWl paampqenp6ioqKmpqaqqqqurq6ysrK2tra6urq+vr7CwsLGxsbKysrOzs7S0tLW1tba2tre3t7i4 uLm5ubq6uru7u7y8vL29vb6+vr+/v8DAwMHBwcLCwsPDw8TExMXFxcbGxsjIyMnJycrKysvLy8zM zM3Nzc7Ozs/Pz9DQ0NHR0dLS0tPT09TU1NXV1dbW1tfX19jY2NnZ2dra2tvb29zc3N3d3d7e3t/f 3+Dg4OHh4eLi4uPj4+Tk5OXl5ebm5ufn5+jo6Onp6erq6uvr6+zs7O3t7e7u7u/v7/Dw8PHx8fLy 8vPz8/T09PX19fb29vf39/j4+Pn5+fr6+vv7+/z8/P39/f7+/v///wAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABkAE8A AAj+AI0JHEiQYJCCCBMqXMiwocOHEA1GnEixokWIBy9q3KjxlQMjqAQKygUmVxtTAjNyXMmy4SwN FlwZCzXhChgNSWzscmXD1atXPn3uepXr1ayjuVoqpZjLDp9ZAqNEkVPTRqQoDqRqjRKhUBREW+S0 GaNyqVmGnXw0iSSw0Ksks7ZkEugDIVyEfM7qZTgWGMOyAptALdhkr+GCoSI0CbkQsLG7BcccnjzT whbGCh2raYOQDOXDwNTw8dsYYSTOBZN8NhxKgY1Jf02jJiho9d5dSVTHLngaoWPbLE1FyUU6M0JT ORAiAn42lIwkKEsjTF7wN/ONpoyY2rW7IHWCda/+K3V15YpM6d59ix/fxAJs9AQ1+B5zRU8QR0YQ 3TdiJ8qYNkkUosd6C70CxghswTdQeAQBA8wuD0YIIYQSGlMIgQoBo8eA3Um0kXUETpIEGBcqmBJH JWKIUBRGNPQbiBC1qGJBuYwQxSsdDgTjQ2rMWJArCjgQnXHqbQSGjwTJ4YgjneR44kZRIDmQBhOM wJ2Jxui0EYdSooBCJElheUUoGzGIpB1o4oglGWRqtJyUCuWSAx9XzGXMb2o0qZGZPu6SAwxhGmOH Alts0VMkNiRERooWwRBKJ5mgMskrk7gy6SSoZBJKKJVe+koklpoCqSnvbdRJEFc4MlAhYHxghA3+ ocghQ0KmwLClI4XwMYkdsfYqxyR8FOKIHZ3I4WsndjgiiCCReMbRLmM1SMYucjBm3XczGlHcRT74 AECbRE4nZW0cTRKEmlgaI4MrrgyGYRPbWjRCDkEMmZB1ahS6wow9frYjtuuREW9Fs5jCrpMFJapi lBzlMAEMmN3bEMDi5cXRKyj4YG+RC8mnYhADU2RKEq+ErKOLM6rKEXlXRMxxuASCvNAVD7nykcvV oayijDAXCBO6EjOURBBEEy2eVHYEoR8iPjDNx74ONaWHu0FDRDGcaOWwFsILXY21QrOMwWXPE38N kSkyIEL1yw6tEIQPdpodJxltrJ1zRA4OK/f+Qqgo4AO4CfH50K57K7SLDSgEWnVEkchReEIwSKbz RJGsYPHjA9mgMNcMAYOK13KPMEK9nE+Oeec+kLtjuqcTNAkZPhSrgRy01257G7bnPrtYuffue++4 5x487cP7XnzugCuEdg6uOILCktBHL70jMAg7/fVy+HD99iNsf30OengffSR0PhTJYAw/BMaVDqHS 70OFQUQG0Ay94mxE7DM0IYWdJ8Vd/gjZBYSIY7KBOMgYBwTgQEwxi0KYQhAO1FNDtqCBjSEEFSjI gWsQV0AUfCAJH6AgowpSiAnIIQBbcNVCjAAGFNgABiNowgfOQ5BXzO4KKxBAE0bwgYeAb4T+CXFE G3wwuiYorjofkIEeJjCJIy2kaU1AwRhAV4grRCEIOejWrxKihkmMoVkogIGtHEKGCdBQIagwwBhc 6AMUFDAHKLiCBdoQgQQlpHGJIYMG0oeQUKzRB4i7ggbsZgxE8AEFamiCHMiwhdY58pGQjORGUJEb NSRPILlQFSokSBtJLmQSV9iVD4zgA0o2qQ2TUMMKYDcGNeSCDDlQwxgs6MmZgMERW4iCDHIZwsfs AgZ6IIMMPtCtSUTOkLW8oBwygbsryKFyqspTFGBghxXkwBEaQMUKtkAGTibTIa8YYTcHYocCfvOc 6EynOtfJzs+UTCAyyUUuZuGKpByRIPbXHExSDpiQpMxCgD7qhCNywQc+tEEGhQGDDVqoRA0IYhI9 FEgnBGGKgrZmFjDwgV+SgwLYhGIW4SQTKgrgCi81bkY5mGIUmvC35CRHA2Awgpxw85092kAqoUhC JwgwAmPkogl6eI0xrKiHAkRpFtrCGDBAZxsfRCEJbWiDHUYZCTUkYQsygFUSQmEDA2TCLzYwhQ+i mguSwRAYP92CBXrUCQG4Igc9NYYRZjGBKAnuOkFARXFCsRNjNMknwBjMK/jAnZK5C0c+oYtPr4QS U6ipZJ3oBDI1EhAAOw== ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: image/gif Content-Transfer-Encoding: base64 Content-Location: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887645/bin/tlo0303_0160_fig004.gif R0lGODlhZAChAPfNACAgICMjIyQkJCUlJSgoKCoqKiwsLDAwMDIyMjU1NTg4ODo6Ojs7Ozw8PD4+ Pj8/P0BAQEFBQUJCQkNDQ0VFRUZGRkdHR0hISElJSUpKSktLS0xMTE5OTk9PT1BQUFFRUVJSUlNT U1RUVFVVVVZWVldXV1hYWFlZWVpaWltbW1xcXF1dXV5eXl9fX2BgYGFhYWJiYmNjY2RkZGVlZWZm ZmdnZ2hoaGlpaWpqamtra2xsbG1tbW5ubm9vb3BwcHFxcXJycnNzc3R0dHV1dXZ2dnd3d3h4eHl5 eXp6ent7e3x8fH19fX5+fn9/f4CAgIGBgYKCgoODg4SEhIWFhYaGhoeHh4iIiImJiYqKiouLi4yM jI2NjY6Ojo+Pj5CQkJGRkZKSkpOTk5SUlJWVlZaWlpeXl5iYmJmZmZqampubm5ycnJ2dnZ6enp+f n6CgoKGhoaKioqOjo6SkpKWlpaampqenp6ioqKmpqaqqqqurq6ysrK2tra6urq+vr7CwsLGxsbKy srOzs7S0tLW1tba2tre3t7i4uLm5ubq6uru7u7y8vL29vb6+vr+/v8DAwMHBwcLCwsPDw8TExMXF xcbGxsfHx8jIyMnJycrKysvLy8zMzM3Nzc7Ozs/Pz9DQ0NHR0dLS0tPT09TU1NXV1dbW1tfX19jY 2NnZ2dra2tvb29zc3N3d3d7e3t/f3+Dg4OHh4eLi4uPj4+Tk5OXl5ebm5ufn5+jo6Onp6erq6uvr 6+zs7O3t7e7u7u/v7/Dw8PHx8fLy8vPz8/T09PX19fb29vf39/j4+Pn5+fr6+vv7+/z8/P39/f7+ /v///wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABkAKEA AAj+AJvxqNOsoMGDCBMqXMiwocOHEBMCu+IjosWLGDNibMNjwi2NIEOKjDikGaowI1OqXAkRDcuX MC1CiUmzZkImNnOmLHYLVTFVsQri1Ek0Iy8eXWjgoFGi4MyiUC2imnIlBRQao440OMK16xEFRxQd qdPFTZg2iY4kGvJIbdgheK7UCWOWSVqxeI/0WYEq6sJYhXxsOoKy2VCER3LeKubX4uGDiW266dsY 4lOEJW1+4uV3lGdgDh8bHDJLsiq/eMJMsRRaYZugNTc3VkDgkcPLB9HAplmHclQ0R3YvxG1Qt01K H/1OecS4oeiCbaEwSRGzj/CiZCiwdt4a5qPSUUf+XcFzPSFx8zH/lFdMZhNo7vBfujntV5EC2/EX MoESnCUeH5xFxQQeATJ0nkJ/bPLSJgUWNUQxyHTnUIIv1UEfVEww4Zt+EFHIkmxRQVECfgZ2GMN6 IE3m1yND/CGhQ31Q8mGDOsXSBxkR5tfQHzKu1FtUHkyBQ48ldkhkSiAWxcEKUHzy4o44XEHVlFMk opGKUCFTTHM6MoQML7wAA0yYYT4HkSU0VqbQgReZ+RAeFxLVhgdHHAlMA2HEEINQI7npEJZF8eLD FXHeMgQOZGgIxZ4ipbCfdExkNiEThTBxpBuKTPHHFWH00cUfUCjChKg2YrTCLFw2w0sMR6xAnWH+ MEmaE5sM4XDEKAjx8uV7foIUmU4kRtRGG+8x1KtGv86KEQUYbFckS0wkW5MiGCVSSLEcwkQrS9sq lEIbhTyp0rEqUXsRRzk+yy1R3SY0BLbZvpQhEy5Ni9EVV2yoELkhSSsvRh7w4GRD7fZr01P6MjTF CskZa5Os2hbkr0Jh4AERvyDh8Mgjimy8ccIa+aBILBAvtMKDDxUM0iYcc9yxG4yOxLIqICe0wgoa ipuTKjGrqbNNqtDgs2V+qeLBJpvEOTRCGK8EDB5Q87B0vI2VPHUzKsc08dRNw8QDUKqAHQuKGPrc x7BtuIG2B+lWlnVRU7RdlJh8Xm1Q3H4Bk0L+CV8OASYvtwAOZuCE/y344IEfnvjhgzN+y+KC38LE LJFX3njjiRcOZkS3kAGFKmFgEMbopJduuuimp046AF2orjrqrptOQeypYxBRMTcXNIVFu0dEgUVX 8O5YRsgcyZAivPyByicNJ1SM8orcMkrzCM3yhyqPUMI8Q7HwwiDzni0E1CfYWzILrhBR5OxCm5DB wQCUxIADQ4kQ0AUTOMQg9UKCugEAGfpbCDA40IUVLIUHNOCAQnjhgTBcgQb/m8AKIkIpczUEDX3o wxQidbw+NMASQ8iQl4ZACTekYIMMcQMTwuCDLgxhCltTWyISYUIKYMwSMYBXQjbhgT+s4BP+UGgD Q2YRA0XEQIVuYEjybnEEFQpxIYmgBA7q0EQm7C8hicADB9wwlvvZ7YtgDKMYx9iYKUCBArfYBOWQ MYtNpIqMMZnJI9BQAhowoQ1TwIDx4CivMAwhEQjgwRCalQKL8ZEmPAENL4qBg6Ck6ZCQjKQkJ0nJ SjYGGUwgQzOYaIlb1CErsUBD7xKCDDQUI5PNQEYhimG1ghQDDcBgwiPaQL3KKMIHR2gDE67gBigA gwyjUIBYfICHCUygCwZpledkSYO9WEwRf0ADAQpChjAwgQYKakYhaLA8HiiiMEP7QxtwgAYo4MsH t0CDIiaAtVvyAAcpaI6ljiCdU+LBDQj+aMYfHoEBAJymhVcYkjyB8UNkjNJnf+iCBcFlCWCEoTSU sEQYnvfNglBiFr6hBDLIEJRRuMSQloiFIrowCspQAhVd6MN4pgaMNz5EhwsBT0RqZsma2vSmOM1p QqYwBQvqdCQlueJPRSK6ng3VV81A2VFDIiWfLmSPS81I16K6L6pa5BZjGpNTrNohHPBAf4ya6lGR cYQhCHIIWdmKV45AgxRcQYN/YMLAotoHPNThbFtFyCgMWZBbIJOrTEvIXg9SjPUBFmsJ+QRfN/nX mwLuFnK7iWAX69ecbmo14hoFQQxyiytEtpIJGECw1pSQoxDWDY21KRl8QNO6IQYhxYD+KiXpVcvA JkRawEhtTY/gA6Wh57YIQYZhKymqnHUpqbnSrSXDQDaDmCkGHmMMMAT2iep+YhSbQEV2LYEKSqjC u+CNxSPEG4vaQsUNBpCtQQ7ksiM4CRmK2IQlkGaJT9SXEqPA7yNQsV9FqMK/iVBFFJ3qF+VWNYXo Swl/hzaBfP2sIJ9cCSoIHBWethaxCF7Jd4fGizZQ+CC9irBKNrHYxkSqubBiyB98IB1ItRgKJLTI KIqopiu0oQQXfhtCSIyRrenknWh58EN4fBErVSYWlhjubzVCZIu00me8QBWvQtLkiPg4J4pYwXIQ MgEa+CCsVC7xQ65sk6Mw4TpXWAH+V1BxzZCowgf72c8QNsuQOjw5JyUYBbzagIa5uDYlnXvIaKGC AyjkmCWBvo2aXihTqo3kFuA8nppSQIEEO1okiT4uUfDwCPOuF9GR5hAyIkRqojBp0LZVCSs12ZA+ hCGhhbhCIqaABlSzpA1KTrVKMn0RVPj2JQ0wtKIRzepqfXglf8DDZ0H8El5bJGw5mYAHbO3cZhe7 yNROySwUcexqI/oISMNIIdrQxll8IhbnPvcoVLFukOhp2QfRsUOe94emXOQWfxhFvgvxiUJsIhH/ tsQt3c2BMPya2VqjybUv8lh4/5klZAaJmCOW8DgWZOLjoknENTKUjXOcJhvMEBT+WryfOoGkC4kw Z03kPRJUJJGMYm35y8cYc5Gogs5201Jeo6KKmdvNB0JLMc99frUMjYIJExB5nJfu4hLMC1JxdjH+ WMz0qJuVP0xSOtNd7KhHPX1ecZ5fRtAQPKE7xOMecoizHXaxkaDYIG8vSJggggxPIyTuzcD7QvDg geZ+IgU+GEAXeihAAkzBKlpmyBVKgIEYDCHoEimBFgcfBg8YGSFTACAPCJBmA4cmEd1uhtrCwAFK sKmzNFitFxfihk1MgQZHcFMxEkWJCTyiASNVyCPwoIg6BJQMHj9I/B5pEB7uJREryKbzfFAHH7hh CEQ/iCa7MIUw0IpHK0A+8uf+epCbc6AOPPgPxg9L/vKbf1k0eIQqZgFZ6TkcsEfAJA4oAJczZhuw GCADHhQwgTp4wBIp0AfnhxDrt0nplAjIoArvN4AM2IAO+IAQCBM6JyafEAPhQhF9YIE4gGv10gzF 0FIt9QdnwwOlQQZXwAO4Mmo6pyo44AOFcHA+owiwJyU4wERY4wbWEgOLAkQGgQEUgEeFkAhoQAE4 AAxkxQMY0BfR4gMrABrAQAEpEAueF4NMMCgb1AWG5lVtQAGJwAS7wwT0kUmiVAixME5D4BOvxwOs cQRkMIRudAt7wwtTqCa9VyCsUV6+RgmxQAmgEQt1ECGxMAs5Unc9URA+AAwP6EM5bQRZzaAKnpRr DxEQADs= ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: image/gif Content-Transfer-Encoding: base64 Content-Location: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887645/bin/tlo0303_0160_fig005.gif R0lGODlhZABNAPfTAA8PDx4eHiEhISMjIyUlJSYmJigoKCkpKSsrKy4uLjAwMDExMTIyMjQ0NDU1 NTY2Njg4ODk5OTo6Ojw8PD09PT8/P0BAQEFBQUJCQkNDQ0REREVFRUZGRkhISElJSUpKSktLS0xM TE1NTU5OTk9PT1BQUFFRUVJSUlNTU1RUVFVVVVZWVldXV1hYWFlZWVpaWltbW1xcXF1dXV5eXl9f X2BgYGFhYWJiYmNjY2RkZGVlZWZmZmdnZ2hoaGlpaWpqamtra2xsbG1tbW5ubm9vb3BwcHFxcXJy cnNzc3R0dHV1dXZ2dnd3d3h4eHl5eXp6ent7e3x8fH19fX5+fn9/f4CAgIGBgYKCgoODg4SEhIWF hYaGhoeHh4iIiImJiYqKiouLi4yMjI2NjY6Ojo+Pj5CQkJGRkZKSkpOTk5SUlJWVlZaWlpeXl5iY mJmZmZqampubm5ycnJ2dnZ6enp+fn6CgoKGhoaKioqOjo6SkpKWlpaampqenp6ioqKmpqaqqqqys rK2tra6urq+vr7CwsLGxsbKysrOzs7S0tLW1tba2tre3t7i4uLm5ubq6uru7u7y8vL29vb6+vr+/ v8DAwMHBwcLCwsPDw8TExMXFxcbGxsfHx8jIyMnJycrKysvLy8zMzM3Nzc7Ozs/Pz9DQ0NHR0dLS 0tPT09TU1NXV1dbW1tfX19jY2NnZ2dra2tvb29zc3N3d3d7e3t/f3+Dg4OHh4eLi4uPj4+Tk5OXl 5ebm5ufn5+jo6Onp6erq6uvr6+zs7O3t7e7u7u/v7/Dw8PHx8fLy8vPz8/T09PX19fb29vf39/j4 +Pn5+fr6+vv7+/z8/P39/f7+/v///wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABkAE0A AAj+AKcJHEiw4DQvBhMqXMiwocOHEBcaiUixosWLEIlgxMiM2caPBndNY5WsFzCBOEBW7GNIpUpW CUR5qHJChUAYwHIe67UzmcuEfPh4/IkxWRVDfZjg8CAKyAEgRIBIBZIjARBDQC4BkUREkRNBVc64 CWPHSCMimYAoAtJ0rSEmhricOSN1IlGMdnap4OOEikC7BJkBvjuwE2GigwUyA3KYYJXGLhNPS5YD skBRloGGCbPKoeRpHjL7zVywE9JanhNyyXyJtEEKCfikNghDtOuCfGC0bPjZpmXMtwfmsOOTd8Iq OXLgEHF4dPBpghZkmr2wNuHWz1nBFWmcoe+7j5/+r+JjCHX3hSKSHbsr6blApZ3PK6zCZMHdNO6n EWFinuFngxoRZUd+QKyynnwLpfQTM5W5F4YX8fn3kIIuMRNDfh40sJuEDrkBAVFEIPScHFS4QV1D TBCVjGHBMdOJG0Nx6NAJRPWyWnAxMBHDgAii15FHHU0TI0XJTBdcDie4waOMDYVBxJNQGgHBKRbZ +BwwvbDy0H8QhQEcRcxQ+ZwszMhi0Cm7sGLmNFw+VEUGxUVkZXByBEDBhgLtcoAiKth0TIAYVQEB T8cUOqRCK7rHRRVfClRLHzjk4EEnONC4kSEq4KDpciY2NOeRmRw4UC07ViFimxaxsuRCx2AXHBX+ TojJ5EtyOPTpbTgQ4apEd60ShkPJtPfcCRT0caJKp/za0DG1PteIIL0cCxKpDS4EDH7PMXGJsrO6 RKFCvXB7mxExaNkjSBYSFOFAvTjhngeXRHvuR718Nw1jBQHTQBhnUCFHDo3g0AgMksRwSQwFN2KE G06EkQYRJ1GUxhn98XpXLxysssopq5yg8ccvYRuRBzEYO+9GzKSh8soTT8yBSsA0+lAMDeyqEKqE fYsRKyI/9PChN7un80XHyNxQDlVEfHJjQ1sky6oOSaoCi91m1nRFvRh5GM532YtRLbI1xjVRXl+0 SyOQjf0TFZu2vWkGNie0C553qe1aI8Iy9Gj+2vkxhLetcf9kN2l/NyRLp1v3vZAieVtLNWGDZyZH 4AXJIuJPOQQYuWVyNK4QK+KqtNQpVBxARRWop6466rDCQMXrqr8u++tE4DD76bjDjnrmqcdgu+xV nB6861QYoULswKNuHUQxNDh2Mvg69DREfBitUPQOXRhRkNM83pD3C5UJ0SpKfx+R1hSx4kSc8wmi CBeyGMF+QWc0omQmVAAt0ClVNHKGIXboGUGO0YdaMKEXTMiEHcJWkF0I4hJOOAYXMuEE8C2kCm5A 20KCVSkmUOEMglAIMyAgBxg8qQoWfI8oGtAHGFzNEEhLgxH+BQTtFSQMRhAFEeyQgTDI4WX+EKEP +gwyQkHwQTlGUIQIBSECDuQqB+sqCBGSIQggeMBSCQGCF5jgBCfkIAbLI0gyZniCUwiCA0xgDkR6 ASOGHMMLfLiEHYBxBv0JRA6nUEQjVtGshDCjNW44RSPoRpBL0DEZbpCFJDw3kEsYwgu1CMMu5GAu xVnykpjMpB9zMr+BFMeOIjSIT7inyYSsggIeCEMmRMEK8olJI5SqhSjIJItToEYSbjgGi3YBx1X0 Yhei4EMjOMDKM5RyIWEQhBukkoAMUKABgthFWGhChQDggAtGGIC7SASDvkxDBEAwQgNEwAUCwMAO B8CBKGx4zBv2QQ5AyIQKYsABFYhCmm7+WM4AFmAIALBCBBmYBldciBARnIAJEDACARJ6BhGkQRRX OyZPelGLZMiiFsBgkUYyIYtViEIQKREFasIEDCMBM2ZZEqmadnEKY7azIvNLBiiBNdOX2vSmOM2p TnfK04T0ogrRkoQdbAQMOxAyT6yoBRd8cgpmiEJeBqlFLTLhhVN08pJhoEInVDmNNMjCmF5IwyUa kRvAcCENggjDKYxgCCe4IVphSAYxBdoJI4iMCJIQhCEk0UdNVjANcpgOfgYriFVcogpPGogX/ofH uRlBEILlAg4GJEMnhGckkpCFE1LWzhNwQVSdmKAo5FAFSXjBEFTgghKho8FpZA0sIjEfZic6cwo+ hIELYmIpESjm0lIedSEVW4gkrpqQp14kIAA7 ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: application/octet-stream Content-Transfer-Encoding: base64 Content-Location: http://www.ncbi.nlm.nih.gov/stat?jsdisabled=true&ncbi_app=pmc&ncbi_db=pmc&ncbi_pdid=article&ncbi_phid=84D93AF3C2CCA481000000000025CF22 R0lGODlhAgACAIAAAP///wAAACH5BAEAAAAALAAAAAACAAIAAAIChFEAOw== ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: text/css; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Content-Location: http://www.ncbi.nlm.nih.gov/corehtml/pmc/css/pmcstatic.css BODY.pmc-body { MARGIN: 1px } BODY.pmc-body-table { MARGIN: auto auto auto 1px } BODY.pmc-body-figure { MARGIN: auto auto auto 1px } .span-content { =09 } .search-reference-note-section { MARGIN: 8px 0px; WIDTH: 675px } .search-reference { FONT-SIZE: 80%; LINE-HEIGHT: 1.75em; FONT-FAMILY: arial, sans-serif; = BACKGROUND-COLOR: #e8e8c0 } .front-matter-section { MARGIN-TOP: 0em; MARGIN-BOTTOM: 1.2em; WIDTH: 650px; WORD-WRAP: = break-word } .section-content { MARGIN-TOP: 0em; MARGIN-BOTTOM: 1.2em; WIDTH: 650px; WORD-WRAP: = break-word } .section-title { MARGIN-TOP: 0em; MARGIN-BOTTOM: 1.2em; WIDTH: 650px; WORD-WRAP: = break-word } .toc-section-title { MARGIN-TOP: 0em; MARGIN-BOTTOM: 1.2em; WIDTH: 650px; WORD-WRAP: = break-word } .back-matter-section { MARGIN-TOP: 0em; MARGIN-BOTTOM: 1.2em; WIDTH: 650px; WORD-WRAP: = break-word } .footer-section { MARGIN-TOP: 0em; MARGIN-BOTTOM: 1.2em; WIDTH: 650px; WORD-WRAP: = break-word } .back-matter-section { FONT-SIZE: 80% } .section-content { MARGIN-TOP: 0px; LINE-HEIGHT: 1.31em } .section-title { PADDING-BOTTOM: 0.1em; PADDING-TOP: 0.1em } .toc-section-title { PADDING-BOTTOM: 0.1em; PADDING-TOP: 0.1em } .banner-color1 { BACKGROUND-COLOR: #3c78bc } .banner-color2 { BACKGROUND-COLOR: #a0c0e0 } .banner-text { PADDING-RIGHT: 0.3em; FONT-WEIGHT: bold; FONT-SIZE: 135%; COLOR: = #ffffff; FONT-STYLE: italic; TEXT-ALIGN: right } .banner-text-sans { FONT-WEIGHT: bold; FONT-SIZE: 120%; COLOR: #ffffff; FONT-FAMILY: = sans-serif; TEXT-ALIGN: right } .banner-generic-logo-background { BACKGROUND-IMAGE: url(../pmcgifs/logo-generic.png); WIDTH: 500px; = BACKGROUND-REPEAT: no-repeat; HEIGHT: 75px; BACKGROUND-COLOR: silver } .banner-journal-publisher-over-image { MARGIN-LEFT: 84px; MARGIN-RIGHT: 10px } .banner-journal-name { FONT-WEIGHT: bold; FONT-SIZE: 20px; COLOR: white; PADDING-TOP: 5px; = FONT-FAMILY: Calibri, "Trebushet MS", Arial, sans-serif; HEIGHT: 48px; = TEXT-ALIGN: left } .banner-publisher-name { FONT-WEIGHT: bold; FONT-SIZE: 0.8em; COLOR: #a11; FONT-FAMILY: Calibri, = "Trebushet MS", Arial, sans-serif; TEXT-ALIGN: right } .banner-logo-with-journal-title-over { HEIGHT: 75px } .banner-logo-with-journal-title-over-placeholder { FONT-SIZE: 20px; Z-INDEX: 1000; LEFT: 105px; WIDTH: 390px; POSITION: = relative; TOP: -75px } .banner-logo-with-journal-title-over-placeholder-content { FONT-WEIGHT: bold; COLOR: black; PADDING-TOP: 5px; FONT-FAMILY: = Calibri, "Trebushet MS", Arial, sans-serif; HEIGHT: 48px; TEXT-ALIGN: = center } .over-logo-journal-title-sageopen { COLOR: #0055a5 } .over-logo-journal-title-sfesd { COLOR: #ffffff } .over-logo-journal-title-acssd { COLOR: #1e73b3 } .over-logo-journal-title-apasd { COLOR: #1e73b3 } .over-logo-journal-title-esesd { LINE-HEIGHT: 45px } .over-logo-journal-title-srfsd { LINE-HEIGHT: 45px } .over-logo-journal-title-tea { COLOR: #861316; TEXT-ALIGN: right } .over-logo-journal-title-rcpsychsd { COLOR: #44448a } .over-logo-journal-title-npgopen { COLOR: #ffffff } .menu-link { FONT-WEIGHT: bold; FONT-SIZE: 13px; COLOR: #0000c0; FONT-FAMILY: = Verdana, Arial, sans-serif; TEXT-ALIGN: center; TEXT-DECORATION: none } A.menu-link:visited { FONT-WEIGHT: bold; FONT-SIZE: 13px; COLOR: #0000c0; FONT-FAMILY: = Verdana, Arial, sans-serif; TEXT-ALIGN: center; TEXT-DECORATION: none } .menu-curr-page { FONT-WEIGHT: bold; FONT-SIZE: 13px; COLOR: #ffffff; FONT-FAMILY: = Verdana, Arial, sans-serif; TEXT-ALIGN: center } A.menu-link:hover { COLOR: #ffffff; TEXT-DECORATION: none } .header-link { FONT-WEIGHT: bold; FONT-SIZE: 110%; COLOR: #0055aa; FONT-FAMILY: Arial, = sans-serif } .inpage-link { COLOR: #004080 } .sans75 { FONT-SIZE: 75%; FONT-FAMILY: Arial, sans-serif } .sans80 { FONT-SIZE: 80%; FONT-FAMILY: Arial, sans-serif } .sans80b { FONT-WEIGHT: bold; FONT-SIZE: 80%; FONT-FAMILY: Arial, sans-serif } .sans90 { FONT-SIZE: 90%; FONT-FAMILY: Arial, sans-serif } .sans90b { FONT-WEIGHT: bold; FONT-SIZE: 90%; FONT-FAMILY: Arial, sans-serif } .sans { FONT-FAMILY: Arial, sans-serif } .sans105b { FONT-WEIGHT: bold; FONT-SIZE: 105%; FONT-FAMILY: Arial, sans-serif } .sans125b { FONT-WEIGHT: bold; FONT-SIZE: 125%; FONT-FAMILY: Arial, sans-serif } .msg-error { FONT-WEIGHT: bold; BACKGROUND: yellow; COLOR: red } .msg-warning { FONT-WEIGHT: bold; BACKGROUND: yellow; COLOR: brown } .eqn-image { MARGIN: 5px } A.navlink { COLOR: #0055aa; TEXT-DECORATION: none } A.navlink:hover { TEXT-DECORATION: underline } .navlink-box { FONT-WEIGHT: bold; FONT-SIZE: 80%; PADDING-BOTTOM: 2px; WIDTH: 683px; = PADDING-TOP: 2px; BORDER-BOTTOM: #cccccc 6px solid; FONT-FAMILY: tahoma, = verdana, Arial, sans-serif } .navlink-box-black { BORDER-BOTTOM: #000000 6px solid } .navlink-box-brtblue { BORDER-BOTTOM: #649afc 6px solid } .navlink-box-dkgreen { BORDER-BOTTOM: #006666 6px solid } .navlink-box-gray { BORDER-BOTTOM: #cccecc 6px solid } .navlink-box-green { BORDER-BOTTOM: #dce6e4 6px solid } .navlink-box-ltblue { BORDER-BOTTOM: #9ccefc 6px solid } .navlink-box-slateblue { BORDER-BOTTOM: #6c9acc 6px solid } .navlink-box-teal { BORDER-BOTTOM: #9ccecc 6px solid } .navlink-box-navy { BORDER-BOTTOM: #003399 6px solid } .navlink-box-bcwm-combo-blue { BORDER-BOTTOM: #639ace 3px solid } .fm-related-articles { BORDER-RIGHT: #ccd8e4 1px solid; PADDING-RIGHT: 5px; BORDER-TOP: = #ccd8e4 1px solid; PADDING-LEFT: 5px; PADDING-BOTTOM: 5px; MARGIN-LEFT: = 10px; BORDER-LEFT: #666699 1px solid; LINE-HEIGHT: 140%; MARGIN-RIGHT: = 15px; PADDING-TOP: 5px; BORDER-BOTTOM: #666699 1px solid } .nihms-highlight { FONT-WEIGHT: bold; FONT-SIZE: 0.8em; BACKGROUND: yellow; FLOAT: left; = MARGIN: 0px 0.2em 0px 0px; WIDTH: 4em; COLOR: #990000; TEXT-ALIGN: = center } .retraction-notice { FONT-WEIGHT: bold; FONT-SIZE: 1.2em; COLOR: red } .retraction-notice A { COLOR: red } TR[content-type=3D'shaded'] { BACKGROUND-COLOR: #cccccc } TD[content-type=3D'shaded'] { BACKGROUND-COLOR: #cccccc } TR[content-type=3D'shaded-medium'] { BACKGROUND-COLOR: #cccccc } TD[content-type=3D'shaded-medium'] { BACKGROUND-COLOR: #cccccc } TR[content-type=3D'shaded-light'] { BACKGROUND-COLOR: #e2e2e2 } TD[content-type=3D'shaded-light'] { BACKGROUND-COLOR: #e2e2e2 } TR[content-type=3D'shaded-dark'] { BACKGROUND-COLOR: #aaaaaa } TD[content-type=3D'shaded-dark'] { BACKGROUND-COLOR: #aaaaaa } TR[content-type=3D'nowrap'] { WHITE-SPACE: nowrap } TD[content-type=3D'nowrap'] { WHITE-SPACE: nowrap } TABLE.rendered TD { PADDING-RIGHT: 10px; PADDING-LEFT: 10px; PADDING-BOTTOM: 0.2em; = PADDING-TOP: 0.2em } TABLE.rendered TH { PADDING-RIGHT: 10px; PADDING-LEFT: 10px; PADDING-BOTTOM: 0.2em; = PADDING-TOP: 0.2em } TABLE.rendered TD { VERTICAL-ALIGN: top } TABLE.rendered TD[valign=3D'top'] { VERTICAL-ALIGN: top } TABLE.rendered TD[valign=3D'middle'] { VERTICAL-ALIGN: middle } TABLE.rendered TD[valign=3D'bottom'] { VERTICAL-ALIGN: bottom } .head1 { FONT-SIZE: 120% } .head2 { FONT-SIZE: 110% } .head3 { FONT-SIZE: 105% } .head4 { FONT-SIZE: 99% } .head5 { FONT-SIZE: 90% } .acknowledgment-journal-title { FONT-STYLE: italic } DIV.exception-box { BORDER-RIGHT: silver 1px dashed; PADDING-RIGHT: 0.3em; BORDER-TOP: = silver 1px dashed; PADDING-LEFT: 0.3em; FONT-SIZE: 0.87em; = MARGIN-BOTTOM: 1.31em; PADDING-BOTTOM: 0.3em; BORDER-LEFT: silver 1px = dashed; PADDING-TOP: 0.3em; BORDER-BOTTOM: silver 1px dashed } DIV.exception-box .front-matter-section { FONT-SIZE: 1.14em } .exception-book-link-block .book-link { =09 } .exception-book-link-block .book-thumb { VERTICAL-ALIGN: middle; BORDER-TOP-STYLE: none; MARGIN-RIGHT: 0.5em; = BORDER-RIGHT-STYLE: none; BORDER-LEFT-STYLE: none; BORDER-BOTTOM-STYLE: = none } .exception-book-link-block .book-title { =09 } .box { PADDING-RIGHT: 0.5em; PADDING-LEFT: 0.5em; PADDING-BOTTOM: 0px; = PADDING-TOP: 0px } DIV.p { MARGIN-TOP: 1.31em; MARGIN-BOTTOM: 1.31em; WORD-WRAP: break-word } DIV.p-first { MARGIN-TOP: 1.31em; MARGIN-BOTTOM: 1.31em; WORD-WRAP: break-word } DIV.p-last { MARGIN-TOP: 1.31em; MARGIN-BOTTOM: 1.31em; WORD-WRAP: break-word } DIV.p-first-last { MARGIN-TOP: 1.31em; MARGIN-BOTTOM: 1.31em; WORD-WRAP: break-word } DIV.sec { MARGIN-TOP: 1.31em; MARGIN-BOTTOM: 1.31em; WORD-WRAP: break-word } DIV.sec-first { MARGIN-TOP: 1.31em; MARGIN-BOTTOM: 1.31em; WORD-WRAP: break-word } DIV.sec-last { MARGIN-TOP: 1.31em; MARGIN-BOTTOM: 1.31em; WORD-WRAP: break-word } DIV.sec-first-last { MARGIN-TOP: 1.31em; MARGIN-BOTTOM: 1.31em; WORD-WRAP: break-word } .box { MARGIN-TOP: 1.31em; MARGIN-BOTTOM: 1.31em; WORD-WRAP: break-word } DIV.p-first { MARGIN-TOP: 0px } DIV.sec-first { MARGIN-TOP: 0px } DIV.p-last { MARGIN-BOTTOM: 0px } DIV.sec-last { MARGIN-BOTTOM: 0px } DIV.p-first-last { MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px } DIV.sec-first-last { MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px } SUP { FONT-SIZE: 0.8em; LINE-HEIGHT: 0.8em } SUB { FONT-SIZE: 0.8em; LINE-HEIGHT: 0.8em } .footnote-char { MARGIN: 0px 0.1em; WIDTH: 1em; HEIGHT: 1em } .footnote-char-irp { MARGIN: 0px 0.1em; WIDTH: 1em; HEIGHT: 1em } .footnote-char-ec { MARGIN: 0px 0.1em; WIDTH: 1em; HEIGHT: 1em } .footnote-char-irp { WIDTH: 1.5em; HEIGHT: 1.1em } .tocentry .footnote-char-irp { WIDTH: 1.5em; HEIGHT: 1.1em } .footnote-char-ec { WIDTH: 1.5em; HEIGHT: 1.1em } .tocentry .footnote-char-ec { WIDTH: 1.5em; HEIGHT: 1.3em } ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: text/css; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Content-Location: http://www.ncbi.nlm.nih.gov/corehtml/pmc/css/pmcbase1.css BODY { BACKGROUND-COLOR: #f8f8f8 } .small-caps { FONT-SIZE: 80%; FONT-VARIANT: small-caps } .monospace { FONT-FAMILY: monospace } .pmctop-bg { BACKGROUND-COLOR: #fffeee } A.pmctop { FONT-SIZE: 12px; COLOR: #004080; FONT-FAMILY: Arial, sans-serif; = TEXT-DECORATION: none } .pmc-body A:active { TEXT-DECORATION: underline } .pmc-body A:hover { TEXT-DECORATION: underline } .pmc-body-table A:active { TEXT-DECORATION: underline } .pmc-body-table A:hover { TEXT-DECORATION: underline } .pmc-body-figure A:active { TEXT-DECORATION: underline } .pmc-body-figure A:hover { TEXT-DECORATION: underline } .pmc-body A:hover { TEXT-DECORATION: underline } .pmc-body A:hover { =09 } .pmc-body-table A:hover { =09 } .pmc-body-figure A:hover { =09 } HR { COLOR: #0072a8 } .base-highlight1 { BACKGROUND-COLOR: #ebebeb } .base-highlight2 { BACKGROUND-COLOR: #cccccc } .controls { FONT-WEIGHT: bold; FONT-SIZE: 75%; COLOR: #000000; FONT-FAMILY: = Verdana, Arial, sans-serif; TEXT-DECORATION: none } .formtext { FONT-SIZE: 80%; FONT-FAMILY: Arial, sans-serif } .link { COLOR: #0055aa; TEXT-DECORATION: none } .footer-link { FONT-SIZE: 80%; FONT-FAMILY: Arial, sans-serif; TEXT-ALIGN: center } .side-head { FONT-WEIGHT: bold; FONT-SIZE: 90%; FONT-FAMILY: Arial, sans-serif } .side-subhead { MARGIN-TOP: 10px; FONT-WEIGHT: bold; FONT-SIZE: 75%; FONT-FAMILY: = Arial, sans-serif } .side-item { FONT-SIZE: 75%; PADDING-BOTTOM: 2px; MARGIN: 2px 1px 2px 4px; = BORDER-BOTTOM: #c0c0c0 1px solid; FONT-FAMILY: Arial, sans-serif } .side-curr-item { FONT-SIZE: 75%; PADDING-BOTTOM: 2px; MARGIN: 2px 1px 2px 4px; = BORDER-BOTTOM: #c0c0c0 1px solid; FONT-FAMILY: Arial, sans-serif } .side-item A { COLOR: #0055aa; TEXT-DECORATION: none } .side-curr-item { COLOR: #808080 } .toc-header-vid { MARGIN-TOP: 1.1em; FONT-WEIGHT: bold; FONT-SIZE: 120%; MARGIN-BOTTOM: = 1.1em; LINE-HEIGHT: 1.1em; FONT-FAMILY: Arial, sans-serif } .more-iss-text { MARGIN-TOP: 1.35em; FONT-WEIGHT: bold; MARGIN-BOTTOM: 1.35em; = FONT-FAMILY: Arial, sans-serif } .more-iss-link { COLOR: #0055aa; TEXT-DECORATION: none } .arc-issue { FONT-SIZE: 80%; COLOR: #004080; FONT-FAMILY: Arial, sans-serif; = TEXT-ALIGN: center; TEXT-DECORATION: none } .toc-entry { LINE-HEIGHT: 1.12em } .portal-tocentry { LINE-HEIGHT: 1.12em } .toc-comment { FONT-SIZE: 70%; FONT-FAMILY: Arial, sans-serif } .toc-title { FONT-WEIGHT: bold; FONT-SIZE: 80%; FONT-FAMILY: Arial, sans-serif } .toc-author { FONT-SIZE: 75%; FONT-FAMILY: Arial, sans-serif } .toc-cit-ver { FONT-SIZE: 75%; COLOR: #666666; FONT-FAMILY: Arial, sans-serif } .toc-cit-jour { FONT-SIZE: 75%; COLOR: #666666; FONT-STYLE: italic; FONT-FAMILY: Arial, = sans-serif } .toc-cit-vol { FONT-SIZE: 75%; COLOR: #666666; FONT-FAMILY: Arial, sans-serif } .toc-cit-page { FONT-WEIGHT: bold; FONT-SIZE: 75%; COLOR: #666666; FONT-FAMILY: Arial, = sans-serif } .toc-cit-date { FONT-SIZE: 75%; COLOR: #666666; FONT-FAMILY: Arial, sans-serif; = WHITE-SPACE: nowrap } .toc-pmcid { FONT-SIZE: 75%; COLOR: #666666; FONT-FAMILY: Arial, sans-serif; = WHITE-SPACE: nowrap } .toc-link { FONT-SIZE: 75%; FONT-FAMILY: Arial, sans-serif; TEXT-DECORATION: none } A.toc-link { COLOR: #004080 } .toc-divider { FONT-SIZE: 75%; FONT-FAMILY: Arial, sans-serif; TEXT-DECORATION: none } .toc-corrected-citation { MARGIN-LEFT: 1em } .toc-corrected-prefix { FONT-SIZE: 75%; FONT-FAMILY: Arial, sans-serif } .toc-corrected-1st-author-etal { FONT-SIZE: 75%; FONT-FAMILY: Arial, sans-serif } .toc-corrected-citation-title { FONT-SIZE: 75%; FONT-FAMILY: Arial, sans-serif } .toc-corrected-prefix { FONT-WEIGHT: 600 } .toc-corrected-citation-info { FONT-SIZE: 75%; FONT-FAMILY: Arial, sans-serif } .toc-corrected-citation-info .citation-abbreviation { FONT-STYLE: italic } .toc-entry-abstract-toc { PADDING-RIGHT: 2em; PADDING-LEFT: 2em; FONT-SIZE: 75%; PADDING-BOTTOM: = 0px; COLOR: #333; PADDING-TOP: 0px; FONT-FAMILY: Arial, san-serif } .cited-article-fm { BORDER-RIGHT: 1px solid; PADDING-RIGHT: 8px; BORDER-TOP: 1px solid; = PADDING-LEFT: 8px; MARGIN-LEFT: 0px; BORDER-LEFT: 1px solid; = BORDER-BOTTOM: 1px solid; BACKGROUND-COLOR: #ebebeb } .citing-article-fm { PADDING-RIGHT: 8px; PADDING-LEFT: 8px; MARGIN-LEFT: 0px } .sidefm-pmchead { FONT-WEIGHT: bold; FONT-SIZE: 85%; COLOR: #0055aa; FONT-FAMILY: = Verdana, Arial, sans-serif; TEXT-DECORATION: none } .sidefm-pmhead { FONT-WEIGHT: bold; FONT-SIZE: 85%; COLOR: #0055aa; FONT-FAMILY: = Verdana, Arial, sans-serif; TEXT-DECORATION: none } .sidefm-pmsubhead { MARGIN-TOP: 10px; FONT-WEIGHT: bold; FONT-SIZE: 75%; COLOR: #000000; = FONT-FAMILY: Arial, sans-serif } .sidefm-pmclink { FONT-SIZE: 75%; COLOR: #004080; FONT-FAMILY: Arial, sans-serif; = TEXT-DECORATION: none } .sidefm-pmart { FONT-SIZE: 75%; COLOR: #004080; FONT-FAMILY: Arial, sans-serif; = TEXT-DECORATION: none } .side-section { FONT-SIZE: 75%; COLOR: #004080; FONT-FAMILY: Arial, sans-serif; = TEXT-DECORATION: none } .side-caption { FONT-SIZE: 75%; COLOR: #004080; FONT-FAMILY: Arial, sans-serif; = TEXT-DECORATION: none } .figure-table-caption-in-article { FONT-SIZE: 75%; COLOR: #004080; FONT-FAMILY: Arial, sans-serif; = TEXT-DECORATION: none } SELECT.sidefm-pmart { WIDTH: 145px } .figure-table-caption-in-article { COLOR: #000000; LINE-HEIGHT: 1.5em } .sidefm-pmclink-item { PADDING-LEFT: 10px } .sidefm-pmclink-item A { DISPLAY: block; PADDING-LEFT: 5px; PADDING-BOTTOM: 2px; LINE-HEIGHT: = 1.5em; BORDER-BOTTOM: #c0c0c0 1px dotted; TEXT-DECORATION: none } .sidefm-pmccurrent-item A { DISPLAY: block; PADDING-LEFT: 5px; PADDING-BOTTOM: 2px; LINE-HEIGHT: = 1.5em; BORDER-BOTTOM: #c0c0c0 1px dotted; TEXT-DECORATION: none } .sidefm-pmclink-item A:hover { DISPLAY: block; PADDING-LEFT: 5px; PADDING-BOTTOM: 2px; LINE-HEIGHT: = 1.5em; BORDER-BOTTOM: #c0c0c0 1px dotted; TEXT-DECORATION: none } .sidefm-pmccurrent-item A:hover { DISPLAY: block; PADDING-LEFT: 5px; PADDING-BOTTOM: 2px; LINE-HEIGHT: = 1.5em; BORDER-BOTTOM: #c0c0c0 1px dotted; TEXT-DECORATION: none } .sidefm-pmclink-item A { COLOR: #004080 } .sidefm-pmclink-item A:hover { BACKGROUND-COLOR: #b8c8d8 } .sidefm-pmccurrent-item A:hover { BACKGROUND-COLOR: #b8c8d8 } .sidefm-pmccurrent-item A { CURSOR: default; COLOR: #808080 } .sidefm-pmccurrent-item A:hover { CURSOR: default; COLOR: #808080 } .sidefm-pmccurrent-item A:hover { BACKGROUND-COLOR: #dcdcdc } .side-section-curr { FONT-SIZE: 75%; COLOR: #808080; FONT-FAMILY: Arial, sans-serif; = TEXT-DECORATION: none } .sidebar-cell .sidefm-supplink { FONT-SIZE: 75%; FONT-FAMILY: Arial, sans-serif } .sidebar-cell .side-supplink { FONT-SIZE: 75%; FONT-FAMILY: Arial, sans-serif } A.sidefm-supplink { COLOR: #b55a00; TEXT-DECORATION: none } A.side-supplink { COLOR: #b55a00; TEXT-DECORATION: none } .side-section-group { PADDING-RIGHT: 3px; BORDER-TOP: #0077aa 1px solid; PADDING-LEFT: 3px; = LINE-HEIGHT: 100%; TEXT-DECORATION: none } .head-separate { MARGIN-BOTTOM: 1.2em } .links-box { BORDER-RIGHT: #ccd8e4 1px solid; PADDING-RIGHT: 5px; BORDER-TOP: = #ccd8e4 1px solid; PADDING-LEFT: 5px; PADDING-BOTTOM: 5px; MARGIN: 1em = 0px; BORDER-LEFT: #666699 1px solid; PADDING-TOP: 5px; BORDER-BOTTOM: = #666699 1px solid } :unknown { BORDER-RIGHT: #336699 1px dotted; BORDER-TOP: #336699 1px dotted; = BORDER-LEFT: #336699 1px dotted; BORDER-BOTTOM: #336699 1px dotted } .main-table-content { MARGIN-LEFT: 9px } .main-figure-content { MARGIN-LEFT: 9px } DIV.fm-author { MARGIN-TOP: 16px! important; MARGIN-BOTTOM: 16px! important } .fm-affl { FONT-WEIGHT: normal; COLOR: #5e5e5e! important } .fm-footnote { FONT-WEIGHT: normal; COLOR: #5e5e5e! important } .fm-editor { FONT-WEIGHT: normal; COLOR: #5e5e5e! important } DIV.fm-affl { MARGIN: 0px } DIV.fm-footnote { MARGIN: 0px } .fm-footnote .fm-affl { FONT-SIZE: 1em } .fm-footnote .fm-footnote { FONT-SIZE: 1em } .fm-affl .fm-affl { FONT-SIZE: 1em } DIV.fm-copyright { MARGIN-TOP: 12px! important; MARGIN-BOTTOM: 12px! important } DIV.fm-pubdate { MARGIN-TOP: 12px! important; MARGIN-BOTTOM: 12px! important } DIV.fm-citation { MARGIN-TOP: 0px! important } .fm-citation-ids { PADDING-LEFT: 1em; FONT-SIZE: 85%; FONT-FAMILY: Arial,sans-serif; = WHITE-SPACE: nowrap; TEXT-ALIGN: right } .fm-citation-ids-label { COLOR: #666 } .fm-citation-pmcid { =09 } .fm-citation-manuscriptid { =09 } .fm-citation-other-versions-label { CURSOR: hand; COLOR: #0050a0 } .fm-citation-this-version-label { COLOR: #666666 } .fm-citation-versions { POSITION: relative } .fm-citation-versions .fm-citation-verions-list-canvas { BORDER-RIGHT: #444 1em solid; PADDING-RIGHT: 0.5em; BORDER-TOP: #444 = 1em solid; DISPLAY: none; PADDING-LEFT: 0.5em; RIGHT: 0px; = PADDING-BOTTOM: 0.5em; BORDER-LEFT: #444 1em solid; PADDING-TOP: 0.5em; = BORDER-BOTTOM: #444 1em solid; POSITION: absolute; TOP: 1.1em; = BACKGROUND-COLOR: #444 } .fm-citation-versions:hover .fm-citation-verions-list-canvas { DISPLAY: block } .show-hover .fm-citation-verions-list-canvas { DISPLAY: block } .fm-citation-versions .fm-citation-verions-list { BORDER-RIGHT: #639ace 3px solid; PADDING-RIGHT: 0.5em; BORDER-TOP: = #639ace 3px solid; PADDING-LEFT: 0.5em; PADDING-BOTTOM: 0.5em; = BORDER-LEFT: #639ace 3px solid; PADDING-TOP: 0.5em; BORDER-BOTTOM: = #639ace 3px solid; BACKGROUND-COLOR: #f8f8f8; TEXT-ALIGN: left } .fm-citation-verions-list .version { MARGIN-LEFT: 15px } .fm-copyright { MARGIN-TOP: 6px } .links-box .fm-footnote { MARGIN: 0px } .tocentry { MARGIN-TOP: 1.12em; MARGIN-BOTTOM: 1.12em } .toc-entry-alt-lang { MARGIN-TOP: 1.12em; MARGIN-BOTTOM: 1.12em } .toc-entry-alt-lang { MARGIN-LEFT: 2.5em } .toc-entry-alt-lang-msg { FONT-SIZE: 75%; FONT-FAMILY: Arial, sans-serif } .portal-tocentry { MARGIN-TOP: 1.6ex; MARGIN-BOTTOM: 2ex; MARGIN-RIGHT: 1em } .button-elsevierwt { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: = 0px; BORDER-RIGHT-WIDTH: 0px } .elsevierwt-sponsored-label { FONT-WEIGHT: 600; COLOR: #f8f8f8 } .banner-journal-publisher-over-image-elsevierwt { MARGIN-LEFT: 20px; OVERFLOW: hidden; COLOR: #9a7947; LINE-HEIGHT: = 1.5em; MARGIN-RIGHT: 145px; FONT-FAMILY: Georgia, "Times New Roman", = Times, serif; POSITION: relative; TOP: -30px; HEIGHT: 75px } .banner-journal-name-elsevierwt { FONT-WEIGHT: 600; FONT-SIZE: 1.2em; MARGIN-LEFT: 1em; COLOR: #954a4a } A.elsevierwt-button-link { LEFT: 360px; POSITION: relative; TOP: 40px } A.elsevierwt-button-link:hover { BACKGROUND-COLOR: #f1e8ce } .fm-elsevierwt-disclaimer { MARGIN-TOP: 12px; FONT-SIZE: 0.68em; MARGIN-BOTTOM: 12px; FONT-FAMILY: = Arial, sans-serif } UL.back-ref-list-1st-line-shifted { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; = PADDING-TOP: 0px } .ref-cit-blk { MARGIN-TOP: 1.4em; LINE-HEIGHT: 1.4em } .back-ref-list-1st-line-shifted LI { MARGIN-TOP: 1.4em; LINE-HEIGHT: 1.4em } .back-ref-list LI { MARGIN-TOP: 1.4em; LINE-HEIGHT: 1.4em } DIV.ref-label { BORDER-RIGHT: #f8f8f8 1px solid; BORDER-TOP: #f8f8f8 1px solid; FLOAT: = left; BORDER-LEFT: #f8f8f8 1px solid; WIDTH: 45px; BORDER-BOTTOM: = #f8f8f8 1px solid; TEXT-ALIGN: right } DIV.ref-cit { MARGIN-LEFT: 55px } SPAN.ref-label { FONT-STYLE: italic } SPAN.ref-cit { =09 } .back-ref-list-1st-line-shifted LI { MARGIN-LEFT: 2em; TEXT-INDENT: -1.5em; LIST-STYLE-TYPE: none } .array-table { MARGIN-TOP: 1em; MARGIN-BOTTOM: 1em; WIDTH: 100%; LINE-HEIGHT: 1.31em; = BACKGROUND-COLOR: #f4f4f4 } .array-table-inline { MARGIN-TOP: 1em; MARGIN-BOTTOM: 1em; WIDTH: 100%; LINE-HEIGHT: 1.31em; = BACKGROUND-COLOR: #f4f4f4 } .array-table TD { PADDING-RIGHT: 0.5em; PADDING-LEFT: 0.5em; PADDING-BOTTOM: 0em; = PADDING-TOP: 0em } .array-table-inline { DISPLAY: inline } .list-item-w-pw { BORDER-RIGHT: #f8f8f8 1px solid; BORDER-TOP: #f8f8f8 1px solid; = BORDER-LEFT: #f8f8f8 1px solid; BORDER-BOTTOM: #f8f8f8 1px solid } .list-item-w-pw-prefix-word { DISPLAY: inline-block; POSITION: relative; TEXT-ALIGN: right } .list-item-w-pw-content { POSITION: relative; TOP: -1.35em } .list-item-p-question { FONT-WEIGHT: bold } SPAN.underline { BORDER-BOTTOM: black 1px solid } SPAN.double-underline { BORDER-BOTTOM: black 3px double } SPAN.bold-double-underline { BORDER-BOTTOM: black 3px double } .verse-group { FONT-SIZE: 1.12em; MARGIN: 1.31em 2em; LINE-HEIGHT: 1.16em; = FONT-FAMILY: "Monotype Corsiva", "Apple Chancery", "URW Chancery L", = cursive } .internal-control { PADDING-RIGHT: 0.5em; PADDING-LEFT: 0.5em; FONT-WEIGHT: bold; = PADDING-BOTTOM: 0.5em; MARGIN: 1.5em auto; WIDTH: 95%; PADDING-TOP: = 0.5em; BACKGROUND-COLOR: #f0f0f0 } .sidebar-menu-square-image-holder { PADDING-RIGHT: 0.35em; VERTICAL-ALIGN: middle; _padding-top: 0.35em } .figure-role { DISPLAY: block; MARGIN: 1em 0px } DIV.signature { MARGIN: 1.8em 0px; FONT-FAMILY: "Monotype Corsiva", "Apple Chancery", = "URW Chancery L", cursive } DIV.simple-list-item-w-label { FLOAT: left; TEXT-INDENT: -2em } .selective-deposit-msg { BORDER-RIGHT: #f4f4f4 0.5em solid; BORDER-TOP: #f4f4f4 0.5em solid; = FONT-SIZE: 80%; BORDER-LEFT: #f4f4f4 0.5em solid; BORDER-BOTTOM: #f4f4f4 = 0.5em solid; FONT-FAMILY: Arial,sans-serif; BACKGROUND-COLOR: #f4f4f4 } .fm-title { MARGIN-TOP: 16px } .fm-trans-title { MARGIN-TOP: 16px } .ukpmc-tocentry-icon { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: = 0px; VERTICAL-ALIGN: text-bottom; MARGIN-RIGHT: 0.25em; = BORDER-RIGHT-WIDTH: 0px } .holding-tocentry-icon { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: = 0px; VERTICAL-ALIGN: text-bottom; MARGIN-RIGHT: 0.25em; = BORDER-RIGHT-WIDTH: 0px } .i18n-debug { BACKGROUND-COLOR: #fff0df } .i18n-debug * { BACKGROUND-COLOR: #fff0df } .i18n-debug .i18n-debug { BACKGROUND-COLOR: #ffe2bf } .i18n-debug .i18n-debug * { BACKGROUND-COLOR: #ffe2bf } .i18n-debug .i18n-debug .i18n-debug { BACKGROUND-COLOR: #ffd39f } .i18n-debug .i18n-debug .i18n-debug * { BACKGROUND-COLOR: #ffd39f } .i18n-debug .i18n-debug .i18n-debug .i18n-debug { BACKGROUND-COLOR: #ffc47f } .i18n-debug .i18n-debug .i18n-debug .i18n-debug * { BACKGROUND-COLOR: #ffc47f } A.i18n-switcher { FONT-WEIGHT: normal; FONT-SIZE: 0.75em; FONT-FAMILY: Arial, sans-serif; = TEXT-DECORATION: none } A.i18n-switcher:hover { FONT-WEIGHT: normal; FONT-SIZE: 0.75em; FONT-FAMILY: Arial, sans-serif; = TEXT-DECORATION: none } A.i18n-switcher-current { FONT-WEIGHT: bold; FONT-SIZE: 0.75em; FONT-FAMILY: Arial, sans-serif; = TEXT-DECORATION: none } A.i18n-switcher-current:hover { FONT-WEIGHT: bold; FONT-SIZE: 0.75em; FONT-FAMILY: Arial, sans-serif; = TEXT-DECORATION: none } IMG.i18n-switcher { VERTICAL-ALIGN: super; WIDTH: 11px; BORDER-TOP-STYLE: none; = MARGIN-RIGHT: 2px; BORDER-RIGHT-STYLE: none; BORDER-LEFT-STYLE: none; = HEIGHT: 8px; BORDER-BOTTOM-STYLE: none } TD.content-cell { PADDING-LEFT: 0.5em } TD.thumb-cell { WIDTH: 110px } TD.caption-cell { TEXT-ALIGN: left } A.icon-reflink { DISPLAY: block } DIV.thumb-ph { PADDING-RIGHT: 0.5em; PADDING-LEFT: 0.5em; PADDING-BOTTOM: 0.5em; = PADDING-TOP: 0.5em } DIV.caption-ph { PADDING-RIGHT: 0.5em; PADDING-LEFT: 0.5em; PADDING-BOTTOM: 0.5em; = PADDING-TOP: 0.5em } DIV.thumb-ph { PADDING-RIGHT: 0px } .figpopup { CURSOR: hand; WHITE-SPACE: nowrap; POSITION: relative } .figpopup > DIV { CURSOR: hand; WHITE-SPACE: nowrap; POSITION: relative } A.fig-table-link:hover { Z-INDEX: 10; COLOR: #444 } .figpopup:hover { Z-INDEX: 10; COLOR: #444 } .figpopup:hover .large-thumb-canvas { Z-INDEX: 10; COLOR: #444 } .large-thumb-canvas { BORDER-RIGHT: #444 1em solid; PADDING-RIGHT: 0.5em; BORDER-TOP: #444 = 1em solid; DISPLAY: none; PADDING-LEFT: 0.5em; PADDING-BOTTOM: 0.5em; = MARGIN: 0.5em; BORDER-LEFT: #444 1em solid; COLOR: #444; PADDING-TOP: = 0.5em; BORDER-BOTTOM: #444 1em solid; POSITION: absolute; = BACKGROUND-COLOR: #444 } .large-thumb-canvas-1 { BORDER-RIGHT: #eee 0.25em solid; BORDER-TOP: #eee 0.25em solid; = DISPLAY: block; BORDER-LEFT: #eee 0.25em solid; BORDER-BOTTOM: #eee = 0.25em solid } IMG.large-thumb { WIDTH: 450px } DIV.small-thumb-canvas { BORDER-RIGHT: #444 1px solid; BORDER-TOP: #444 1px solid; MAX-WIDTH: = 104px; BORDER-LEFT: #444 1px solid; WIDTH: 104px; BORDER-BOTTOM: #444 = 1px solid; WHITE-SPACE: normal; WORD-WRAP: break-word } DIV.small-thumb-canvas-1 { BORDER-RIGHT: white 1px solid; BORDER-TOP: white 1px solid; = BORDER-LEFT: white 1px solid; BORDER-BOTTOM: white 1px solid } IMG.small-thumb { BORDER-RIGHT: #444 1px solid; BORDER-TOP: #444 1px solid; BORDER-LEFT: = #444 1px solid; WIDTH: 100px; BORDER-BOTTOM: #444 1px solid } .canvas-figure-ref-outer { BORDER-RIGHT: #999999 1px solid; BORDER-TOP: #999999 1px solid; MARGIN: = 1.31em 0.5em; BORDER-LEFT: #aaaaaa 1px solid; BORDER-BOTTOM: #aaaaaa 1px = solid } .canvas-table-ref-outer { BORDER-RIGHT: #999999 1px solid; BORDER-TOP: #999999 1px solid; MARGIN: = 1.31em 0.5em; BORDER-LEFT: #aaaaaa 1px solid; BORDER-BOTTOM: #aaaaaa 1px = solid } .canvas-media-ref-outer { BORDER-RIGHT: #999999 1px solid; BORDER-TOP: #999999 1px solid; MARGIN: = 1.31em 0.5em; BORDER-LEFT: #aaaaaa 1px solid; BORDER-BOTTOM: #aaaaaa 1px = solid } .canvas-figure-ref-inner { BORDER-RIGHT: #f0f0f0 3px solid; BORDER-TOP: #f0f0f0 3px solid; = BORDER-LEFT: #f0f0f0 3px solid; BORDER-BOTTOM: #f0f0f0 3px solid } .canvas-table-ref-inner { BORDER-RIGHT: #f0f0f0 3px solid; BORDER-TOP: #f0f0f0 3px solid; = BORDER-LEFT: #f0f0f0 3px solid; BORDER-BOTTOM: #f0f0f0 3px solid } .canvas-media-ref-inner { BORDER-RIGHT: #f0f0f0 3px solid; BORDER-TOP: #f0f0f0 3px solid; = BORDER-LEFT: #f0f0f0 3px solid; BORDER-BOTTOM: #f0f0f0 3px solid } DIV.fig-label { PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 0px; = PADDING-TOP: 0px } .figpopup-sensitive-area { FILTER: alpha(opacity=3D0); CURSOR: hand; COLOR: transparent; POSITION: = absolute; TOP: 0px; BACKGROUND-COLOR: transparent; TEXT-DECORATION: = none; opacity: 0 } .canvas-media-player-outer { BORDER-RIGHT: #4a4a4a 2px solid; PADDING-RIGHT: 2px; BORDER-TOP: = #4a4a4a 2px solid; PADDING-LEFT: 2px; PADDING-BOTTOM: 2px; MARGIN: auto; = BORDER-LEFT: #4a4a4a 2px solid; PADDING-TOP: 2px; BORDER-BOTTOM: #4a4a4a = 2px solid } .canvas-media-player-inner { BORDER-RIGHT: #4a4a4a 2px solid; PADDING-RIGHT: 0px; BORDER-TOP: = #4a4a4a 2px solid; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; BORDER-LEFT: = #4a4a4a 2px solid; PADDING-TOP: 0px; BORDER-BOTTOM: #4a4a4a 2px solid; = BACKGROUND-COLOR: #4a4a4a; TEXT-ALIGN: center } .canvas-player-screen { DISPLAY: block; MARGIN: auto; CURSOR: hand; POSITION: relative; = BACKGROUND-COLOR: #4a4a4a; TEXT-ALIGN: center; TEXT-DECORATION: none } .splash-ph { MAX-WIDTH: 100%; MARGIN: auto; HEIGHT: 100% } .player-play-btn { VERTICAL-ALIGN: middle; POSITION: relative } IMG.player-splash { LEFT: 0px; WIDTH: 100%; POSITION: absolute; TOP: 0px; HEIGHT: 100% } .supplementary-material-media-label-caption { PADDING-RIGHT: 0.5em; PADDING-LEFT: 0.5em; PADDING-BOTTOM: 0.5em; = PADDING-TOP: 0.5em; BACKGROUND-COLOR: #f4f4f4 } DIV.tileshop-panel-canvas { BORDER-RIGHT: gray 1px solid; BORDER-TOP: gray 1px solid; DISPLAY: = block; MAX-WIDTH: 100%; MARGIN: auto; BORDER-LEFT: gray 1px solid; ; = WIDTH: expression( (this._w =3D this.clientWidth), (this._max_width && = this._w > this._max_width ? this.style.width =3D this._max_width + 'px' = : 0), "auto"); BORDER-BOTTOM: gray 1px solid; ZOOM: 1 } .tileshop-panel-canvas A { DISPLAY: block; ZOOM: 1 } .tileshop-panel-bar { MAX-WIDTH: 100%; MARGIN: auto; LINE-HEIGHT: 2em; BACKGROUND-COLOR: = #ecf0f4; TEXT-ALIGN: center } IMG.tileshop-image { MAX-WIDTH: 100%; ; WIDTH: expression( (this._w =3D this.clientWidth), = (this.style.width =3D 1 + 'px'), (this._w > this.parentNode.clientWidth = ? this.style.width =3D this.parentNode.clientWidth + 'px' : = this.style.width =3D this._w + 'px'), "auto" ); CURSOR: = url(http://www.ncbi.nlm.nih.gov/corehtml/jsutils/cur/zoomin.cur), = pointer; BORDER-TOP-STYLE: none; ZOOM: 1; BORDER-RIGHT-STYLE: none; = BORDER-LEFT-STYLE: none; BORDER-BOTTOM-STYLE: none } UL.ui-ncbiautocomplete-options { BORDER-RIGHT: #336699 1px solid; BORDER-TOP: #336699 1px solid; = FONT-SIZE: 12px; MIN-HEIGHT: 1em; BORDER-LEFT: #336699 1px solid; = MAX-HEIGHT: 218px; BORDER-BOTTOM: #336699 1px solid; HEIGHT: auto; = BACKGROUND-COLOR: #f6f8fc } UL.ui-ncbiautocomplete-options LI SPAN { FONT-WEIGHT: bolder; COLOR: #ff6d30 } DIV.ui-ncbiautocomplete-holder { MIN-HEIGHT: 1em; MAX-HEIGHT: 218px; HEIGHT: auto } ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: text/css; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Content-Location: http://www.ncbi.nlm.nih.gov/corehtml/pmc/css/pmcbars-black.css .doc-group1 { FONT-WEIGHT: bold; FONT-SIZE: 110%; COLOR: #ffffff; FONT-FAMILY: = Verdana, sans-serif; BACKGROUND-COLOR: #000000 } .doc-group2 { FONT-WEIGHT: bold; COLOR: #000000; FONT-FAMILY: Arial, sans-serif; = BACKGROUND-COLOR: #cccccc; TEXT-ALIGN: center } .doc-group3 { FONT-WEIGHT: bold; COLOR: #003399; FONT-FAMILY: Arial, sans-serif; = BACKGROUND-COLOR: #cccccc; TEXT-ALIGN: center } .doc-group4 { =09 } .toc-supp-link { FONT-SIZE: 75%; COLOR: #e64a00; FONT-FAMILY: Arial, sans-serif; = TEXT-DECORATION: none } .toc-highlight1 { BACKGROUND-COLOR: #ffffd0 } .toc-highlight2 { BACKGROUND-COLOR: #ace4ff } .head1 { BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; = FONT-WEIGHT: bold; FONT-SIZE: 110%; BORDER-LEFT: #000000 1pt solid; = COLOR: white; BORDER-BOTTOM: #000000 1pt solid; FONT-FAMILY: Verdana, = sans-serif; BACKGROUND-COLOR: #000000; TEXT-ALIGN: center } .head1A { FONT-WEIGHT: bold; COLOR: #004080; FONT-FAMILY: Arial, sans-serif; = BACKGROUND-COLOR: #cccccc } .append-head1 { FONT-WEIGHT: bold; FONT-FAMILY: Arial, sans-serif; TEXT-ALIGN: center } .colorbar-link { COLOR: #ffffff } .head1 A:link { COLOR: white } .head1 A:visited { COLOR: white } .head1A A:link { COLOR: white } .head1A A:visited { COLOR: white } ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: text/css; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Content-Location: http://www.ncbi.nlm.nih.gov/corehtml/pmc/css/pmcbody1.css .fm-vol-iss-date { FONT-SIZE: 85%; TEXT-ALIGN: left } .fm-citation { FONT-SIZE: 85%; TEXT-ALIGN: left } .fm-citation-ids { FONT-SIZE: 85% } .fm-citation .fm-vol-iss-date { FONT-SIZE: 100% } .pubnote { FONT-WEIGHT: bold; FONT-SIZE: 90% } .pubnote-hilite { FONT-SIZE: 85%; BACKGROUND-COLOR: #ebebeb } .fm-dochead { FONT-WEIGHT: bold; FONT-SIZE: 90% } .fm-doctopic { FONT-SIZE: 90% } .fm-docsubject { FONT-SIZE: 90% } .fm-ser-title { FONT-WEIGHT: bold; FONT-SIZE: 90% } .fm-supp-title { FONT-WEIGHT: bold; FONT-SIZE: 90% } .fm-title { FONT-WEIGHT: bold; FONT-SIZE: 125% } .fm-subtitle { FONT-WEIGHT: bold } .fm-trans-title { FONT-SIZE: 120% } .fm-trans-subtitle { FONT-SIZE: 105% } .fm-author { FONT-SIZE: 110% } .fm-role { FONT-STYLE: italic } .fm-affl { FONT-SIZE: 77% } .fm-pubdate { FONT-SIZE: 77% } .fm-footnote { FONT-SIZE: 77% } .fm-editor { FONT-SIZE: 77% } .fm-author .fm-footnote .fm-affl { FONT-SIZE: 100% } .fm-editor .fm-footnote .fm-affl { FONT-SIZE: 100% } .fm-editor .fm-footnote { FONT-SIZE: 100% } .fm-copyright { FONT-SIZE: 85% } .abs-head2 { =09 } .abs-head2 { FONT-WEIGHT: bold } .kwd-label { FONT-WEIGHT: bold } .abs-head3 { =09 } .head2 { FONT-WEIGHT: bold } .head3 { FONT-STYLE: italic } .head4 { TEXT-DECORATION: underline } .head5 { =09 } .kwd-text { FONT-SIZE: 85% } .eqn-image { TEXT-ALIGN: center } .eqn-id { FONT-WEIGHT: bold; TEXT-ALIGN: right } .box { BORDER-RIGHT: #60cfff 1px solid; BORDER-TOP: #60cfff 1px solid; = OVERFLOW: auto; BORDER-LEFT: #60cfff 1px solid; BORDER-BOTTOM: #60cfff = 1px solid; BACKGROUND-COLOR: #e1e1e1 } .boxhead1 { FONT-WEIGHT: bold; FONT-SIZE: 105%; FONT-FAMILY: Arial, sans-serif } .boxhead2 { FONT-WEIGHT: bold } .fig-table-link { COLOR: #0050a0; TEXT-DECORATION: none } A.cite-reflink { COLOR: #0050a0; TEXT-DECORATION: none } A.int-reflink { COLOR: #0050a0 } A.ext-reflink { COLOR: #0050a0 } .figwind-cite { FONT-SIZE: 75%; FONT-FAMILY: Arial, sans-serif } .figwind-copyrt { FONT-SIZE: 75%; FONT-FAMILY: Arial, sans-serif } .product-source { FONT-STYLE: italic } .signature-group { FONT-WEIGHT: bold; MARGIN-LEFT: 2em; FONT-STYLE: italic } TR[content-type=3D'shaded'] { BACKGROUND-COLOR: #cccccc } TD[content-type=3D'shaded'] { BACKGROUND-COLOR: #cccccc } TR[content-type=3D'shaded-medium'] { BACKGROUND-COLOR: #cccccc } TD[content-type=3D'shaded-medium'] { BACKGROUND-COLOR: #cccccc } TR[content-type=3D'shaded-light'] { BACKGROUND-COLOR: #e2e2e2 } TD[content-type=3D'shaded-light'] { BACKGROUND-COLOR: #e2e2e2 } TR[content-type=3D'shaded-dark'] { BACKGROUND-COLOR: #aaaaaa } TD[content-type=3D'shaded-dark'] { BACKGROUND-COLOR: #aaaaaa } ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: text/css; charset="iso-8859-1" Content-Transfer-Encoding: 7bit Content-Location: http://www.ncbi.nlm.nih.gov/corehtml/pmc/css/pmcrefs2.css .ref-id { } .ref-title { } .ref-author { } .ref-journal { FONT-STYLE: italic } .ref-pubdate { } .ref-vol { FONT-WEIGHT: bold } .ref-iss { } .ref-page { } .ref-edition { } .ref-editor { } .ref-pubname { } .ref-publoc { } .ref-extlink { COLOR: #0050a0 } ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: text/css; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Content-Location: http://www.ncbi.nlm.nih.gov/corehtml/pmc/css/noext-menu.css DIV.sec DIV.other-sections { PADDING-RIGHT: 0.25em; PADDING-LEFT: 0.25em; FLOAT: right; = PADDING-BOTTOM: 0px; PADDING-TOP: 0px; POSITION: relative } DIV.other-sections UL { LINE-HEIGHT: 1.2em } .noext-menu UL { DISPLAY: none } .noext-menu { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; LINE-HEIGHT: 1; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; = TEXT-ALIGN: left } .noext-menu UL { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; LINE-HEIGHT: 1; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; = TEXT-ALIGN: left } .noext-menu A { DISPLAY: block; CURSOR: pointer; TEXT-DECORATION: underline; _display: = inline; outline: none } .noext-menu LI { =09 } .noext-menu A.first-link { FONT-SIZE: 0.65em; TEXT-TRANSFORM: none; WHITE-SPACE: nowrap; = TEXT-DECORATION: none } .noext-menu A.first-link:hover { TEXT-DECORATION: none! important } UL.noext-menu LI SPAN.delta { =09 } .noext-menu LI UL.submenu { DISPLAY: none; FONT-SIZE: 0.75em; POSITION: absolute } .noext-menu LI UL UL { MARGIN: -1em 0px 0px 10em } UL.noext-menu LI.submenu-item UL { DISPLAY: none; POSITION: absolute } UL.noext-menu LI.active-item UL { LEFT: 3px } UL.noext-menu LI UL.opened { BORDER-RIGHT: transparent 1px solid; PADDING-RIGHT: 0.25em; BORDER-TOP: = transparent 1px solid; MARGIN-TOP: 0.25em; MIN-WIDTH: 200px; DISPLAY: = block; PADDING-LEFT: 0.25em; Z-INDEX: 5; RIGHT: -0.1em; MAX-WIDTH: = 300px; PADDING-BOTTOM: 0.25em; BORDER-LEFT: transparent 1px solid; ; = WIDTH: expression(this.clientWidth > 300 ? "300px" : "200px"); = PADDING-TOP: 0.25em; BORDER-BOTTOM: transparent 1px solid; TOP: 1.4em; = _top: 1.6em } UL.noext-menu LI UL.opened LI { MARGIN-BOTTOM: 3px } UL.noext-menu LI UL.opened LI.active-item { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; = PADDING-TOP: 0px; BACKGROUND-COLOR: #aaaaaa } UL.opened LI.active-item A { COLOR: #ffffff } UL.noext-menu LI UL A { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 2px; MARGIN: 0px = 3px; COLOR: #222222; PADDING-TOP: 2px; TEXT-DECORATION: none } .noext-menu-hidden { COLOR: transparent! important; BACKGROUND-COLOR: transparent! important } .noext-menu-hidden A.first-link { COLOR: transparent! important; BACKGROUND-COLOR: transparent! important } ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: text/css; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Content-Location: http://www.ncbi.nlm.nih.gov/core/extjs/ext-2.2/resources/css/panel.css .x-panel { BORDER-RIGHT: #99bbe8 0px solid; BORDER-TOP: #99bbe8 0px solid; = BORDER-LEFT: #99bbe8 0px solid; BORDER-BOTTOM: #99bbe8 0px solid } .x-panel-header { BORDER-RIGHT: #99bbe8 1px solid; PADDING-RIGHT: 3px; BORDER-TOP: = #99bbe8 1px solid; PADDING-LEFT: 5px; BACKGROUND: = url(../images/default/panel/white-top-bottom.gif) repeat-x 0px -1px; = PADDING-BOTTOM: 4px; FONT: bold 11px/15px = tahoma,arial,verdana,sans-serif; OVERFLOW: hidden; BORDER-LEFT: #99bbe8 = 1px solid; COLOR: #15428b; PADDING-TOP: 5px; BORDER-BOTTOM: #99bbe8 1px = solid; ZOOM: 1 } .x-panel-body { BORDER-RIGHT: #99bbe8 1px solid; BORDER-TOP: #99bbe8 0px; BACKGROUND: = white; OVERFLOW: hidden; BORDER-LEFT: #99bbe8 1px solid; BORDER-BOTTOM: = #99bbe8 1px solid; POSITION: relative } .x-panel-bbar .x-toolbar { BORDER-RIGHT: #99bbe8 1px solid; PADDING-RIGHT: 2px; BORDER-TOP: = #99bbe8 0px; PADDING-LEFT: 2px; PADDING-BOTTOM: 2px; OVERFLOW: hidden; = BORDER-LEFT: #99bbe8 1px solid; PADDING-TOP: 2px; BORDER-BOTTOM: #99bbe8 = 1px solid } .x-panel-tbar .x-toolbar { BORDER-RIGHT: #99bbe8 1px solid; PADDING-RIGHT: 2px; BORDER-TOP: = #99bbe8 0px; PADDING-LEFT: 2px; PADDING-BOTTOM: 2px; OVERFLOW: hidden; = BORDER-LEFT: #99bbe8 1px solid; PADDING-TOP: 2px; BORDER-BOTTOM: #99bbe8 = 1px solid } .x-panel-tbar-noheader .x-toolbar { BORDER-TOP: #99bbe8 1px solid; BORDER-BOTTOM: 0px } .x-panel-mc .x-panel-tbar .x-toolbar { BORDER-TOP: #99bbe8 1px solid; BORDER-BOTTOM: 0px } .x-panel-body-noheader { BORDER-TOP: #99bbe8 1px solid } .x-panel-mc .x-panel-body { BORDER-TOP: #99bbe8 1px solid } .x-panel-header { OVERFLOW: hidden; ZOOM: 1 } .x-panel-tl .x-panel-header { BORDER-RIGHT: 0px; PADDING-RIGHT: 0px; BORDER-TOP: 0px; PADDING-LEFT: = 0px; BACKGROUND: none transparent scroll repeat 0% 0%; PADDING-BOTTOM: = 4px; FONT: bold 11px tahoma,arial,verdana,sans-serif; BORDER-LEFT: 0px; = COLOR: #15428b; PADDING-TOP: 5px; BORDER-BOTTOM: 0px } .x-panel-tl .x-panel-icon { BACKGROUND-POSITION: 0px 4px; PADDING-LEFT: 20px! important; = BACKGROUND-REPEAT: no-repeat; ZOOM: 1 } .x-window-tl .x-panel-icon { BACKGROUND-POSITION: 0px 4px; PADDING-LEFT: 20px! important; = BACKGROUND-REPEAT: no-repeat; ZOOM: 1 } .x-panel-inline-icon { BACKGROUND-POSITION: 0px 0px; MARGIN-TOP: -1px; MARGIN-BOTTOM: -1px; = VERTICAL-ALIGN: middle; WIDTH: 16px; MARGIN-RIGHT: 4px; = BACKGROUND-REPEAT: no-repeat; HEIGHT: 16px } .x-panel-tc { BACKGROUND: url(../images/default/panel/top-bottom.gif) repeat-x 0px = 0px; OVERFLOW: hidden } .ext-strict .ext-ie7 .x-panel-tc { OVERFLOW: visible } .x-panel-tl { PADDING-LEFT: 6px; BACKGROUND: = url(../images/default/panel/corners-sprite.gif) no-repeat 0px 0px; = BORDER-BOTTOM: #99bbe8 1px solid; ZOOM: 1 } .x-panel-tr { PADDING-RIGHT: 6px; BACKGROUND: = url(../images/default/panel/corners-sprite.gif) no-repeat right 0px; = ZOOM: 1 } .x-panel-bc { BACKGROUND: url(../images/default/panel/top-bottom.gif) repeat-x 0px = bottom; ZOOM: 1 } .x-panel-bc .x-panel-footer { ZOOM: 1 } .x-panel-bl { PADDING-LEFT: 6px; BACKGROUND: = url(../images/default/panel/corners-sprite.gif) no-repeat 0px bottom; = ZOOM: 1 } .x-panel-br { PADDING-RIGHT: 6px; BACKGROUND: = url(../images/default/panel/corners-sprite.gif) no-repeat right bottom; = ZOOM: 1 } .x-panel-mc { BORDER-RIGHT: 0px; PADDING-RIGHT: 0px; BORDER-TOP: 0px; PADDING-LEFT: = 0px; BACKGROUND: #dfe8f6; PADDING-BOTTOM: 0px; MARGIN: 0px; FONT: 11px = tahoma,arial,helvetica,sans-serif; BORDER-LEFT: 0px; PADDING-TOP: 6px; = BORDER-BOTTOM: 0px } .x-panel-mc .x-panel-body { BORDER-RIGHT: 0px; BORDER-TOP: 0px; BACKGROUND: none transparent scroll = repeat 0% 0%; BORDER-LEFT: 0px; BORDER-BOTTOM: 0px } .x-panel-ml { PADDING-LEFT: 6px; BACKGROUND: = url(../images/default/panel/left-right.gif) #fff repeat-y 0px 0px; ZOOM: = 1 } .x-panel-mr { PADDING-RIGHT: 6px; BACKGROUND: = url(../images/default/panel/left-right.gif) repeat-y right 0px; ZOOM: 1 } .x-panel-bc .x-panel-footer { PADDING-BOTTOM: 6px } .x-panel-nofooter .x-panel-bc { FONT-SIZE: 0px; LINE-HEIGHT: 0; HEIGHT: 6px } .x-panel-nofooter .x-window-bc { FONT-SIZE: 0px; LINE-HEIGHT: 0; HEIGHT: 6px } .x-panel-bwrap { LEFT: 0px; OVERFLOW: hidden; ZOOM: 1; TOP: 0px } .x-panel-body { OVERFLOW: hidden; ZOOM: 1 } .x-panel-collapsed .x-resizable-handle { DISPLAY: none } .ext-gecko .x-panel-animated DIV { OVERFLOW: hidden! important } .x-plain-body { OVERFLOW: hidden } .x-plain-bbar .x-toolbar { PADDING-RIGHT: 2px; PADDING-LEFT: 2px; PADDING-BOTTOM: 2px; OVERFLOW: = hidden; PADDING-TOP: 2px } .x-plain-tbar .x-toolbar { PADDING-RIGHT: 2px; PADDING-LEFT: 2px; PADDING-BOTTOM: 2px; OVERFLOW: = hidden; PADDING-TOP: 2px } .x-plain-bwrap { OVERFLOW: hidden; ZOOM: 1 } .x-plain { OVERFLOW: hidden } .x-tool { BACKGROUND: url(../images/default/panel/tool-sprites.gif) no-repeat; = FLOAT: right; MARGIN-LEFT: 2px; OVERFLOW: hidden; WIDTH: 15px; CURSOR: = pointer; HEIGHT: 15px } .x-tool-toggle { BACKGROUND-POSITION: 0px -60px } .x-tool-toggle-over { BACKGROUND-POSITION: -15px -60px } .x-panel-collapsed .x-tool-toggle { BACKGROUND-POSITION: 0px -75px } .x-panel-collapsed .x-tool-toggle-over { BACKGROUND-POSITION: -15px -75px } .x-tool-close { BACKGROUND-POSITION: 0px 0px } .x-tool-close-over { BACKGROUND-POSITION: -15px 0px } .x-tool-minimize { BACKGROUND-POSITION: 0px -15px } .x-tool-minimize-over { BACKGROUND-POSITION: -15px -15px } .x-tool-maximize { BACKGROUND-POSITION: 0px -30px } .x-tool-maximize-over { BACKGROUND-POSITION: -15px -30px } .x-tool-restore { BACKGROUND-POSITION: 0px -45px } .x-tool-restore-over { BACKGROUND-POSITION: -15px -45px } .x-tool-gear { BACKGROUND-POSITION: 0px -90px } .x-tool-gear-over { BACKGROUND-POSITION: -15px -90px } .x-tool-pin { BACKGROUND-POSITION: 0px -135px } .x-tool-pin-over { BACKGROUND-POSITION: -15px -135px } .x-tool-unpin { BACKGROUND-POSITION: 0px -150px } .x-tool-unpin-over { BACKGROUND-POSITION: -15px -150px } .x-tool-right { BACKGROUND-POSITION: 0px -165px } .x-tool-right-over { BACKGROUND-POSITION: -15px -165px } .x-tool-left { BACKGROUND-POSITION: 0px -180px } .x-tool-left-over { BACKGROUND-POSITION: -15px -180px } .x-tool-up { BACKGROUND-POSITION: 0px -210px } .x-tool-up-over { BACKGROUND-POSITION: -15px -210px } .x-tool-down { BACKGROUND-POSITION: 0px -195px } .x-tool-down-over { BACKGROUND-POSITION: -15px -195px } .x-tool-refresh { BACKGROUND-POSITION: 0px -225px } .x-tool-refresh-over { BACKGROUND-POSITION: -15px -225px } .x-tool-minus { BACKGROUND-POSITION: 0px -255px } .x-tool-minus-over { BACKGROUND-POSITION: -15px -255px } .x-tool-plus { BACKGROUND-POSITION: 0px -240px } .x-tool-plus-over { BACKGROUND-POSITION: -15px -240px } .x-tool-search { BACKGROUND-POSITION: 0px -270px } .x-tool-search-over { BACKGROUND-POSITION: -15px -270px } .x-tool-save { BACKGROUND-POSITION: 0px -285px } .x-tool-save-over { BACKGROUND-POSITION: -15px -285px } .x-tool-help { BACKGROUND-POSITION: 0px -300px } .x-tool-help-over { BACKGROUND-POSITION: -15px -300px } .x-tool-print { BACKGROUND-POSITION: 0px -315px } .x-tool-print-over { BACKGROUND-POSITION: -15px -315px } .x-panel-ghost { Z-INDEX: 12000; BACKGROUND: #cbddf3; FILTER: alpha(opacity=3D65); LEFT: = 0px; OVERFLOW: hidden; POSITION: absolute; TOP: 0px; opacity: .65; = -moz-opacity: .65 } .x-panel-ghost UL { BORDER-RIGHT: #99bbe8 1px solid; PADDING-RIGHT: 0px; BORDER-TOP: = #99bbe8 0px; DISPLAY: block; PADDING-LEFT: 0px; FONT-SIZE: 0px; = PADDING-BOTTOM: 0px; MARGIN: 0px; OVERFLOW: hidden; BORDER-LEFT: #99bbe8 = 1px solid; LINE-HEIGHT: 0; PADDING-TOP: 0px; BORDER-BOTTOM: #99bbe8 1px = solid } .x-panel-ghost * { CURSOR: move! important } .x-panel-dd-spacer { BORDER-RIGHT: #99bbe8 2px dashed; BORDER-TOP: #99bbe8 2px dashed; = BORDER-LEFT: #99bbe8 2px dashed; BORDER-BOTTOM: #99bbe8 2px dashed } .x-panel-btns-ct { PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 5px; = PADDING-TOP: 5px } .x-panel-btns-ct .x-btn { CLEAR: none; FLOAT: right } .x-panel-btns-ct .x-panel-btns TD { BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; = BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; = PADDING-TOP: 0px; BORDER-RIGHT-WIDTH: 0px } .x-panel-btns-ct .x-panel-btns-right TABLE { CLEAR: none; FLOAT: right } .x-panel-btns-ct .x-panel-btns-left TABLE { CLEAR: none; FLOAT: left } .x-panel-btns-ct .x-panel-btns-center { TEXT-ALIGN: center } .x-panel-btns-ct .x-panel-btns-center TABLE { MARGIN: 0px auto } .x-panel-btns-ct TABLE TD.x-panel-btn-td { PADDING-RIGHT: 3px; PADDING-LEFT: 3px; PADDING-BOTTOM: 3px; = PADDING-TOP: 3px } .x-panel-btns-ct .x-btn-focus .x-btn-left { BACKGROUND-POSITION: 0px -147px } .x-panel-btns-ct .x-btn-focus .x-btn-right { BACKGROUND-POSITION: 0px -168px } .x-panel-btns-ct .x-btn-focus .x-btn-center { BACKGROUND-POSITION: 0px -189px } .x-panel-btns-ct .x-btn-over .x-btn-left { BACKGROUND-POSITION: 0px -63px } .x-panel-btns-ct .x-btn-over .x-btn-right { BACKGROUND-POSITION: 0px -84px } .x-panel-btns-ct .x-btn-over .x-btn-center { BACKGROUND-POSITION: 0px -105px } .x-panel-btns-ct .x-btn-click .x-btn-center { BACKGROUND-POSITION: 0px -126px } .x-panel-btns-ct .x-btn-click .x-btn-right { BACKGROUND-POSITION: 0px -84px } .x-panel-btns-ct .x-btn-click .x-btn-left { BACKGROUND-POSITION: 0px -63px } ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: text/css; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Content-Location: http://www.ncbi.nlm.nih.gov/core/ext.ncbi/1/css/themes/xtheme-oldentrez.css .x-panel { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-STYLE: solid; BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-STYLE: = solid; BORDER-LEFT-STYLE: solid; BORDER-RIGHT-COLOR: #d0d0d0; = BORDER-BOTTOM-STYLE: solid } .x-panel-header { BORDER-RIGHT: #d0d0d0 1px solid; BORDER-TOP: #d0d0d0 1px solid; = BACKGROUND-IMAGE: url(../../img/oldentrez/panel/white-top-bottom.gif); = BORDER-LEFT: #d0d0d0 1px solid; COLOR: #333; BORDER-BOTTOM: #d0d0d0 1px = solid } .x-panel-body { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-bbar .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-tbar .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-tbar-noheader .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-mc .x-panel-tbar .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-body-noheader { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-mc .x-panel-body { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-tl .x-panel-header { COLOR: #333 } .x-panel-tc { BACKGROUND-IMAGE: url(../../img/oldentrez/panel/top-bottom.gif) } .x-panel-tl { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND-IMAGE: = url(../../img/oldentrez/panel/corners-sprite.gif); BORDER-BOTTOM-COLOR: = #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-tr { BACKGROUND-IMAGE: url(../../img/oldentrez/panel/corners-sprite.gif) } .x-panel-bc { BACKGROUND-IMAGE: url(../../img/oldentrez/panel/top-bottom.gif) } .x-panel-bl { BACKGROUND-IMAGE: url(../../img/oldentrez/panel/corners-sprite.gif) } .x-panel-br { BACKGROUND-IMAGE: url(../../img/oldentrez/panel/corners-sprite.gif) } .x-panel-mc { BACKGROUND: #f1f1f1 } .x-panel-mc .x-panel-body { BORDER-RIGHT: 0px; BORDER-TOP: 0px; BACKGROUND: none transparent scroll = repeat 0% 0%; BORDER-LEFT: 0px; BORDER-BOTTOM: 0px } .x-panel-ml { BACKGROUND-IMAGE: url(../../img/oldentrez/panel/left-right.gif) } .x-panel-mr { BACKGROUND-IMAGE: url(../../img/oldentrez/panel/left-right.gif) } .x-tool { BACKGROUND-IMAGE: url(../../img/oldentrez/panel/tool-sprites.gif) } .x-panel-ghost { BACKGROUND: #e0e0e0 } .x-panel-ghost UL { BORDER-LEFT-COLOR: #b0b0b0; BORDER-BOTTOM-COLOR: #b0b0b0; = BORDER-TOP-COLOR: #b0b0b0; BORDER-RIGHT-COLOR: #b0b0b0 } .x-grid-panel .x-panel-mc .x-panel-body { BORDER-RIGHT: #d0d0d0 1px solid; BORDER-TOP: #d0d0d0 1px solid; = BORDER-LEFT: #d0d0d0 1px solid; BORDER-BOTTOM: #d0d0d0 1px solid } .x-btn-left { BACKGROUND-IMAGE: url(../../img/oldentrez/button/btn-sprite.gif) } .x-btn-right { BACKGROUND-IMAGE: url(../../img/oldentrez/button/btn-sprite.gif) } .x-btn-center { BACKGROUND-IMAGE: url(../../img/oldentrez/button/btn-sprite.gif) } .x-border-layout-ct { BACKGROUND: #f0f0f0 } .x-accordion-hd { BACKGROUND-IMAGE: url(../../img/oldentrez/panel/light-hd.gif) } .x-layout-collapsed { BORDER-LEFT-COLOR: #e0e0e0; BORDER-BOTTOM-COLOR: #e0e0e0; = BORDER-TOP-COLOR: #e0e0e0; BACKGROUND-COLOR: #eee; BORDER-RIGHT-COLOR: = #e0e0e0 } .x-layout-collapsed-over { BACKGROUND-COLOR: #fbfbfb } .x-tip .x-tip-top { BACKGROUND-IMAGE: url(../../img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-top-left { BACKGROUND-IMAGE: url(../../img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-top-right { BACKGROUND-IMAGE: url(../../img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-ft { BACKGROUND-IMAGE: url(../../img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-ft-left { BACKGROUND-IMAGE: url(../../img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-ft-right { BACKGROUND-IMAGE: url(../../img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-bd-left { BACKGROUND-IMAGE: url(../../img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-bd-right { BACKGROUND-IMAGE: url(../../img/oldentrez/qtip/tip-sprite.gif) } .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND: = url(../../img/oldentrez/toolbar/bg.gif) #f0f4f5 repeat-x left top; = BORDER-BOTTOM-COLOR: #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; = BORDER-RIGHT-COLOR: #d0d0d0 } .x-toolbar BUTTON { COLOR: #444 } .x-toolbar .x-btn-menu-arrow-wrap .x-btn-center BUTTON { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/btn-arrow.gif) } .x-toolbar .x-btn-text-icon .x-btn-menu-arrow-wrap .x-btn-center BUTTON = { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/btn-arrow.gif) } .x-toolbar .x-btn-over .x-btn-left { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-over .x-btn-right { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-over .x-btn-center { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-over BUTTON { COLOR: #111 } .x-toolbar .x-btn-click .x-btn-left { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-pressed .x-btn-left { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-menu-active .x-btn-left { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-click .x-btn-right { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-pressed .x-btn-right { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-menu-active .x-btn-right { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-click .x-btn-center { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-pressed .x-btn-center { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-menu-active .x-btn-center { BACKGROUND-IMAGE: url(../../img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .ytb-sep { BACKGROUND-IMAGE: url(../images/default/grid/grid-split.gif) } .x-tab-panel-header { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND: #eaeaea; BORDER-BOTTOM-COLOR: = #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-panel-footer { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND: #eaeaea; BORDER-BOTTOM-COLOR: = #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-panel-header { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-panel-footer { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } UL.x-tab-strip-top { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND: = url(../../img/oldentrez/tabs/tab-strip-bg.gif) #dbdbdb repeat-x left = top; BORDER-BOTTOM-COLOR: #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; = PADDING-TOP: 2px; BORDER-RIGHT-COLOR: #d0d0d0 } UL.x-tab-strip-bottom { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND-IMAGE: = url(../../img/oldentrez/tabs/tab-strip-btm-bg.gif); BORDER-BOTTOM-COLOR: = #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-strip SPAN.x-tab-strip-text { COLOR: #333 } .x-tab-strip-over SPAN.x-tab-strip-text { COLOR: #111 } .x-tab-strip-active SPAN.x-tab-strip-text { COLOR: #333 } .x-tab-strip-disabled .x-tabs-text { COLOR: #aaaaaa } .x-tab-strip-top .x-tab-right { BACKGROUND-IMAGE: url(../../img/oldentrez/tabs/tabs-sprite.gif) } .x-tab-strip-top .x-tab-left { BACKGROUND-IMAGE: url(../../img/oldentrez/tabs/tabs-sprite.gif) } .x-tab-strip-top .x-tab-strip-inner { BACKGROUND-IMAGE: url(../../img/oldentrez/tabs/tabs-sprite.gif) } .x-tab-strip-bottom .x-tab-right { BACKGROUND-IMAGE: = url(../../img/oldentrez/tabs/tab-btm-inactive-right-bg.gif) } .x-tab-strip-bottom .x-tab-left { BACKGROUND-IMAGE: = url(../../img/oldentrez/tabs/tab-btm-inactive-left-bg.gif) } .x-tab-strip-bottom .x-tab-strip-active .x-tab-right { BACKGROUND-IMAGE: url(../../img/oldentrez/tabs/tab-btm-right-bg.gif) } .x-tab-strip-bottom .x-tab-strip-active .x-tab-left { BACKGROUND-IMAGE: url(../../img/oldentrez/tabs/tab-btm-left-bg.gif) } .x-tab-strip .x-tab-strip-closable A.x-tab-strip-close { BACKGROUND-IMAGE: url(../../img/oldentrez/tabs/tab-close.gif) } .x-tab-strip .x-tab-strip-closable A.x-tab-strip-close:hover { BACKGROUND-IMAGE: url(../../img/oldentrez/tabs/tab-close.gif) } .x-tab-panel-body { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND: #fff; BORDER-BOTTOM-COLOR: = #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-panel-bbar .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-panel-tbar .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-panel-header-plain .x-tab-strip-spacer { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND: #eaeaea; BORDER-BOTTOM-COLOR: = #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-scroller-left { BORDER-LEFT-COLOR: #aeaeae; BACKGROUND-IMAGE: = url(../../img/oldentrez/tabs/scroll-left.gif); BORDER-BOTTOM-COLOR: = #aeaeae; BORDER-TOP-COLOR: #aeaeae; BORDER-RIGHT-COLOR: #aeaeae } .x-tab-scroller-right { BORDER-LEFT-COLOR: #aeaeae; BACKGROUND-IMAGE: = url(../../img/oldentrez/tabs/scroll-right.gif); BORDER-BOTTOM-COLOR: = #aeaeae; BORDER-TOP-COLOR: #aeaeae; BORDER-RIGHT-COLOR: #aeaeae } .x-window-proxy { BORDER-LEFT-COLOR: #b0b0b0; BACKGROUND: #e0e0e0; BORDER-BOTTOM-COLOR: = #b0b0b0; BORDER-TOP-COLOR: #b0b0b0; BORDER-RIGHT-COLOR: #b0b0b0 } .x-window-tl .x-window-header { COLOR: #555 } .x-window-tc { BACKGROUND-IMAGE: url(../../img/oldentrez/window/top-bottom.png) } .x-window-tl { BACKGROUND-IMAGE: url(../../img/oldentrez/window/left-corners.png) } .x-window-tr { BACKGROUND-IMAGE: url(../../img/oldentrez/window/right-corners.png) } .x-window-bc { BACKGROUND-IMAGE: url(../../img/oldentrez/window/top-bottom.png) } .x-window-bl { BACKGROUND-IMAGE: url(../../img/oldentrez/window/left-corners.png) } .x-window-br { BACKGROUND-IMAGE: url(../../img/oldentrez/window/right-corners.png) } .x-window-mc { BORDER-RIGHT: #d0d0d0 1px solid; BORDER-TOP: #d0d0d0 1px solid; = BACKGROUND: #e8e8e8; BORDER-LEFT: #d0d0d0 1px solid; BORDER-BOTTOM: = #d0d0d0 1px solid } .x-window-ml { BACKGROUND-IMAGE: url(../../img/oldentrez/window/left-right.png) } .x-window-mr { BACKGROUND-IMAGE: url(../../img/oldentrez/window/left-right.png) } .x-panel-ghost .x-window-tl { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-collapsed .x-window-tl { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-window-plain .x-window-mc { BORDER-RIGHT: #eee 1px solid; BORDER-TOP: #d0d0d0 1px solid; = BACKGROUND: #e8e8e8; BORDER-LEFT: #d0d0d0 1px solid; BORDER-BOTTOM: #eee = 1px solid } .x-window-plain .x-window-body { BORDER-RIGHT: #d0d0d0 1px solid; BORDER-TOP: #eee 1px solid; = BACKGROUND: none transparent scroll repeat 0% 0%; BORDER-LEFT: #eee 1px = solid; BORDER-BOTTOM: #d0d0d0 1px solid } BODY.x-body-masked .x-window-mc { BACKGROUND-COLOR: #e4e4e4 } BODY.x-body-masked .x-window-plain .x-window-mc { BACKGROUND-COLOR: #e4e4e4 } .x-html-editor-wrap { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-noborder .x-panel-body-noborder { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: = 0px; BORDER-RIGHT-WIDTH: 0px } .x-panel-noborder .x-panel-header-noborder { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM: #d0d0d0 = 1px solid; BORDER-RIGHT-WIDTH: 0px } .x-panel-noborder .x-panel-tbar-noborder .x-toolbar { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM: #d0d0d0 = 1px solid; BORDER-RIGHT-WIDTH: 0px } .x-panel-noborder .x-panel-bbar-noborder .x-toolbar { BORDER-TOP: #d0d0d0 1px solid; BORDER-LEFT-WIDTH: 0px; = BORDER-BOTTOM-WIDTH: 0px; BORDER-RIGHT-WIDTH: 0px } .x-window-noborder .x-window-mc { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: = 0px; BORDER-RIGHT-WIDTH: 0px } .x-window-plain .x-window-body-noborder { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: = 0px; BORDER-RIGHT-WIDTH: 0px } .x-tab-panel-noborder .x-tab-panel-body-noborder { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: = 0px; BORDER-RIGHT-WIDTH: 0px } .x-tab-panel-noborder .x-tab-panel-header-noborder { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-RIGHT-WIDTH: 0px } .x-tab-panel-noborder .x-tab-panel-footer-noborder { BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; BORDER-RIGHT-WIDTH: = 0px } .x-tab-panel-bbar-noborder .x-toolbar { BORDER-TOP: #d0d0d0 1px solid; BORDER-LEFT-WIDTH: 0px; = BORDER-BOTTOM-WIDTH: 0px; BORDER-RIGHT-WIDTH: 0px } .x-tab-panel-tbar-noborder .x-toolbar { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM: #d0d0d0 = 1px solid; BORDER-RIGHT-WIDTH: 0px } .x-panel-header { FONT-SIZE: 90%; FONT-FAMILY: Arial, Verdana, Sans-Serif; = BACKGROUND-COLOR: #e3e3e3; xbackground: none } ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: text/css; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Content-Location: http://www.ncbi.nlm.nih.gov/portal/portal3rc.fcgi/36616/css/31348/12313.css .footer { CLEAR: both } .dynamic_footer { FONT-SIZE: 62.5% } #footer { LINE-HEIGHT: 1.8em; FONT-FAMILY: "Helvetica Neue", GillSans, helvetica, = "lucida sans", arial, sans-serif } #NCBIFooter_dynamic { LINE-HEIGHT: 1.8em; FONT-FAMILY: "Helvetica Neue", GillSans, helvetica, = "lucida sans", arial, sans-serif } #footer H3 { FONT-SIZE: 1.1em; COLOR: #505050 } .foot_list H3 { FONT-SIZE: 1.1em } #footer { FONT-SIZE: 1.1em } #NCBIFooter_dynamic { CLEAR: both; FONT-SIZE: 1.1em; Z-INDEX: 10; COLOR: #505050; POSITION: = relative; TOP: 2.5em; _top: -1.5em } .breadcrumbs { LEFT: 1.6em; POSITION: absolute; TOP: 1.1em } .help_desk { RIGHT: 1em; POSITION: absolute; TOP: 1.1em } #NCBIFooter_dynamic A { COLOR: #14376c; TEXT-DECORATION: none } #footer A { COLOR: #14376c; TEXT-DECORATION: none } #NCBIFooter_dynamic A:hover { TEXT-DECORATION: underline; BORDER-BOTTOM-STYLE: none } #footer A:hover { TEXT-DECORATION: underline; BORDER-BOTTOM-STYLE: none } .contact_info A:hover { TEXT-DECORATION: underline; BORDER-BOTTOM-STYLE: none } #footer-contents-right { FLOAT: right; TEXT-ALIGN: right; _margin-top: 1em } #footer-contents-right A { PADDING-LEFT: 2px; FLOAT: left; OVERFLOW: hidden; WIDTH: 50px; = TEXT-INDENT: 10em; PADDING-TOP: 14px; HEIGHT: 41px } #footer-contents-right A.nih_img_link { BACKGROUND: url(/coreweb/images/ncbi/footer/nih_logo_footer.gif) = no-repeat 0pt 100%; WIDTH: 48px } #footer-contents-right A.nlm_img_link { BACKGROUND: url(/coreweb/images/ncbi/footer/nlm_logo_footer.gif) = no-repeat 0pt 100%; WIDTH: 50px } #footer-contents-right A.dhhs_img_link { BACKGROUND: url(/coreweb/images/ncbi/footer/dhhs_logo_footer.gif) = no-repeat 0pt 100%; WIDTH: 49px } #footer-contents-right A.usagov_img_link { BACKGROUND: url(/coreweb/images/ncbi/footer/usagov_logo_footer.gif) = no-repeat 0pt 100%; WIDTH: 94px } #footer-contents-left { =09 } #footer-contents-left P.address { MARGIN: 0px; PADDING-TOP: 1px } #footer-contents-left P.updateinfo { MARGIN: 1px; PADDING-TOP: 12px; TEXT-ALIGN: right } #footer-contents-left A { FONT-WEIGHT: bold } #footer-contents-left P.address .adr { DISPLAY: block } #footer-contents-left P.address .url { FONT-WEIGHT: normal; MARGIN: 0px } #footer { CLEAR: both; Z-INDEX: 1; BACKGROUND: = url(/portal/portal3rc.fcgi/36616/img/27840) #e5e5e5 repeat-x left top; = ZOOM: 1; POSITION: relative; TOP: 2.5em; _margin-top: -4em } .crest { BACKGROUND: url(/portal/portal3rc.fcgi/36616/img/27842) no-repeat left = top; LEFT: 46.8%; WIDTH: 50px; POSITION: absolute; TOP: -2.3em; HEIGHT: = 50px; _background-image: none } #footer { OVERFLOW: visible; COLOR: #14376c; BACKGROUND-COLOR: #fff; TEXT-ALIGN: = center } .contact_info { OVERFLOW: visible; COLOR: #14376c; BACKGROUND-COLOR: #fff; TEXT-ALIGN: = center } .foot_list { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FLOAT: left; PADDING-BOTTOM: = 0px; MARGIN: 4em 0px 0px; WIDTH: 19%; PADDING-TOP: 0px; LIST-STYLE-TYPE: = none; TEXT-ALIGN: left } .foot_list LI H3 { MARGIN: 0px 0px 0.05em; TEXT-TRANSFORM: uppercase } .contact_info { CLEAR: both; PADDING-RIGHT: 0px; PADDING-LEFT: 1.6em; BACKGROUND: = url(/portal/portal3rc.fcgi/36616/img/26957) repeat-y left top; = PADDING-BOTTOM: 0.6em; PADDING-TOP: 0.3em; ZOOM: 1; POSITION: relative; = TOP: 0.6em; TEXT-ALIGN: left; _padding-bottom: 5em } .subfooter { MARGIN-LEFT: 1.6em } #footer-contents-left SPAN.url A { FONT-WEIGHT: normal } .offscreen_noflow { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FLOAT: left; PADDING-BOTTOM: = 0px; MARGIN: 0px; TEXT-INDENT: -9999em; PADDING-TOP: 0px; HEIGHT: 0px } #footer { MARGIN-BOTTOM: 6em } .universal_header .inline_list LI A { FONT-SIZE: 1.2em } .myncbi A { FONT-SIZE: 1.2em } .universal_header { FONT-FAMILY: "Helvetica Neue", GillSans, helvetica, "lucida sans", = arial, sans-serif; HEIGHT: 2.7em; BACKGROUND-COLOR: #369; _font-size: = 1em } UL.resources_list { MARGIN-LEFT: 1.3em } .myncbi A { COLOR: #fff; TEXT-DECORATION: none } .myncbi A:hover { TEXT-DECORATION: underline } #ncbihome:focus { BACKGROUND: none transparent scroll repeat 0% 0% } .myncbi { RIGHT: 1em; FLOAT: right; COLOR: #fff; POSITION: relative; TOP: 0.3em } .myncbi A { MARGIN-LEFT: 0.6em } #ncbihome { PADDING-RIGHT: 0.8em; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; COLOR: #fff; PADDING-TOP: 0.25em } BODY UL.jig-ncbimenu A:focus { =09 } UL.jig-ncbimenu A.topanchor { COLOR: #fff } UL.jig-ncbimenu A:hover { TEXT-DECORATION: none } .ui-ncbimenu-item-no-hlt { =09 } DIV.universal_header UL.jig-ncbimenu LI A { FONT-SIZE: 1.09em } .ui-ncbimenu-item { BORDER-BOTTOM: #e5e5e5 1px dotted; BACKGROUND-COLOR: #fcfcfc } .ui-ncbimenu LI.ui-ncbimenu-item-first = A.ui-ncbimenu-first-link-has-submenu { PADDING-RIGHT: 20px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0.2em; = PADDING-TOP: 0.5em } BODY UL.ui-ncbimenu-submenu { BORDER-RIGHT: #aaa 1px solid; BORDER-TOP: #ddd 1px solid; BORDER-LEFT: = #ddd 1px solid; BORDER-BOTTOM: #aaa 1px solid; box-shadow: .4em .4em = .5em #bbb; -webkit-box-shadow: .4em .4em .5em #bbb; -moz-box-shadow: = .4em .4em .5em #bbb } BODY .ui-ncbimenu-item-first-active { COLOR: #fff; BACKGROUND-COLOR: #4c96df } BODY UL LI A.ui-ncbimenu-item-active { COLOR: #fff; BACKGROUND-COLOR: #4c96df } ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: text/css; charset="iso-8859-1" Content-Transfer-Encoding: 7bit Content-Location: http://www.ncbi.nlm.nih.gov/portal/portal3rc.fcgi/36616/css/31982.css #NCBIFooter_dynamic { DISPLAY: none } ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: text/css; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Content-Location: http://www.ncbi.nlm.nih.gov/portal/portal3rc.fcgi/35478/css/15942/15826/12974/29755/26014/9685/698/18985/18997/2280/28059/15863/32030/15551/15444/3305/15291.css BODY { =09 } #pagewrap { MARGIN: auto; WIDTH: 960px; xborder: solid 1px red } #page { FONT-SIZE: 11pt; MARGIN: 1em } #footer { CLEAR: both; MIN-WIDTH: 800px; FONT-SIZE: 70%; PADDING-TOP: 1em } #NCBIFooter_dynamic { FONT-SIZE: 1.12em } #pmc-home-hdr { HEIGHT: 73px } #pmc-home-hdr #homelink { FLOAT: left } #pmc-home-hdr #homelink IMG { BORDER-TOP-STYLE: none; BORDER-RIGHT-STYLE: none; BORDER-LEFT-STYLE: = none; BORDER-BOTTOM-STYLE: none } #pmc-home-hdr H1 { MARGIN: 0px 0px 0px 144px; ZOOM: 1; FONT-FAMILY: Arial, Verdana, = Sans-Serif; POSITION: relative; TOP: -1px; BACKGROUND-COLOR: #3c78bc } #pmc-home-hdr UL { MARGIN: 0px 0px 0px 144px; ZOOM: 1; FONT-FAMILY: Arial, Verdana, = Sans-Serif; POSITION: relative; TOP: -1px; BACKGROUND-COLOR: #3c78bc } #pmc-home-hdr H1 { PADDING-RIGHT: 2em; BORDER-TOP: transparent 2px solid; FONT-SIZE: 2em; = COLOR: white; LINE-HEIGHT: 52px; TEXT-ALIGN: right } #pmc-home-hdr UL { BORDER-RIGHT: #3c78bc 1px solid; BORDER-BOTTOM: #3c78bc 3px solid; = HEIGHT: 18px; BACKGROUND-COLOR: #a0c0e0 } #pmc-home-hdr UL LI { PADDING-RIGHT: 40px; DISPLAY: inline; PADDING-LEFT: 40px; FONT-SIZE: = 1.3em; PADDING-BOTTOM: 0px; MARGIN: 0px; LINE-HEIGHT: 18px; PADDING-TOP: = 0px; LIST-STYLE-TYPE: none } #pmc-home-hdr UL LI A { PADDING-RIGHT: 10px; PADDING-LEFT: 10px; PADDING-BOTTOM: 2px; = PADDING-TOP: 2px; TEXT-DECORATION: none } #pmc-home-hdr UL LI A:hover { TEXT-DECORATION: underline } A:visited { COLOR: #7119b4 } #pmc-home-hdr UL LI.sel A { FONT-WEIGHT: bold; COLOR: white; BACKGROUND-COLOR: #3c78bc; = TEXT-DECORATION: none } #pmc-home-hdr UL LI.sel A:visited { FONT-WEIGHT: bold; COLOR: white; BACKGROUND-COLOR: #3c78bc; = TEXT-DECORATION: none } #pmc-home-hdr UL LI.sel A:hover { FONT-WEIGHT: bold; COLOR: white; BACKGROUND-COLOR: #3c78bc; = TEXT-DECORATION: none } .footer-section { MARGIN: 0px 1em 1em; TEXT-ALIGN: center } BODY #cols { BORDER-RIGHT: transparent 1px solid; BORDER-TOP: transparent 1px solid; = BORDER-LEFT: transparent 1px solid; BORDER-BOTTOM: transparent 1px solid } @media Print =20 { .footer { DISPLAY: none } TD.pmc-watermark { MIN-WIDTH: 0px; WIDTH: 0px } .issue-block { BORDER-COLLAPSE: collapse } .iss-cell { BORDER-RIGHT: black 1px solid; BORDER-TOP: black 1px solid; = BORDER-LEFT: black 1px solid; BORDER-BOTTOM: black 1px solid } .vol-cell { BORDER-RIGHT: black 1px solid; BORDER-TOP: black 1px solid; = BORDER-LEFT: black 1px solid; BORDER-BOTTOM: black 1px solid } } .nopagesectioncontent { DISPLAY: none } .port { FONT-SIZE: 1em } .port { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port DIV { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port DL { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port DT { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port DD { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port UL { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port OL { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port LI { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port H1 { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port H2 { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port H3 { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port H4 { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port H5 { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port H6 { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port PRE { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port FORM { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port FIELDSET { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port INPUT { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port P { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port BLOCKQUOTE { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port TH { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port TD { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; PADDING-TOP: 0px } .port IMG { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: = 0px; BORDER-RIGHT-WIDTH: 0px } .port OL { LIST-STYLE-TYPE: none } .port UL { LIST-STYLE-TYPE: none } .x-unselectable { -moz-user-select: none; -khtml-user-select: none } .x-unselectable * { -moz-user-select: none; -khtml-user-select: none } .x-panel { BORDER-RIGHT: #99bbe8 0px solid; BORDER-TOP: #99bbe8 0px solid; = BORDER-LEFT: #99bbe8 0px solid; BORDER-BOTTOM: #99bbe8 0px solid } .x-panel-header { BORDER-RIGHT: #99bbe8 1px solid; PADDING-RIGHT: 3px; BORDER-TOP: = #99bbe8 1px solid; PADDING-LEFT: 5px; BACKGROUND: = url(/core/extjs/ext-2.1/resources/images/default/panel/white-top-bottom.g= if) repeat-x 0px -1px; PADDING-BOTTOM: 4px; FONT: bold 11px/15px = tahoma,arial,verdana,sans-serif; OVERFLOW: hidden; BORDER-LEFT: #99bbe8 = 1px solid; COLOR: #15428b; PADDING-TOP: 5px; BORDER-BOTTOM: #99bbe8 1px = solid; ZOOM: 1 } .x-panel-body { BORDER-RIGHT: #99bbe8 1px solid; BORDER-TOP: #99bbe8 0px; BACKGROUND: = white; OVERFLOW: hidden; BORDER-LEFT: #99bbe8 1px solid; BORDER-BOTTOM: = #99bbe8 1px solid; POSITION: relative } .x-panel-bbar .x-toolbar { BORDER-RIGHT: #99bbe8 1px solid; PADDING-RIGHT: 2px; BORDER-TOP: = #99bbe8 0px; PADDING-LEFT: 2px; PADDING-BOTTOM: 2px; OVERFLOW: hidden; = BORDER-LEFT: #99bbe8 1px solid; PADDING-TOP: 2px; BORDER-BOTTOM: #99bbe8 = 1px solid } .x-panel-tbar .x-toolbar { BORDER-RIGHT: #99bbe8 1px solid; PADDING-RIGHT: 2px; BORDER-TOP: = #99bbe8 0px; PADDING-LEFT: 2px; PADDING-BOTTOM: 2px; OVERFLOW: hidden; = BORDER-LEFT: #99bbe8 1px solid; PADDING-TOP: 2px; BORDER-BOTTOM: #99bbe8 = 1px solid } .x-panel-tbar-noheader .x-toolbar { BORDER-TOP: #99bbe8 1px solid; BORDER-BOTTOM: 0px } .x-panel-mc .x-panel-tbar .x-toolbar { BORDER-TOP: #99bbe8 1px solid; BORDER-BOTTOM: 0px } .x-panel-body-noheader { BORDER-TOP: #99bbe8 1px solid } .x-panel-mc .x-panel-body { BORDER-TOP: #99bbe8 1px solid } .x-panel-header { OVERFLOW: hidden; ZOOM: 1 } .x-panel-tl .x-panel-header { BORDER-RIGHT: 0px; PADDING-RIGHT: 0px; BORDER-TOP: 0px; PADDING-LEFT: = 0px; BACKGROUND: none transparent scroll repeat 0% 0%; PADDING-BOTTOM: = 4px; FONT: bold 11px tahoma,arial,verdana,sans-serif; BORDER-LEFT: 0px; = COLOR: #15428b; PADDING-TOP: 5px; BORDER-BOTTOM: 0px } .x-panel-tl .x-panel-icon { BACKGROUND-POSITION: 0px 4px; PADDING-LEFT: 20px! important; = BACKGROUND-REPEAT: no-repeat; ZOOM: 1 } .x-window-tl .x-panel-icon { BACKGROUND-POSITION: 0px 4px; PADDING-LEFT: 20px! important; = BACKGROUND-REPEAT: no-repeat; ZOOM: 1 } .x-panel-inline-icon { BACKGROUND-POSITION: 0px 0px; MARGIN-TOP: -1px; MARGIN-BOTTOM: -1px; = VERTICAL-ALIGN: middle; WIDTH: 16px; MARGIN-RIGHT: 4px; = BACKGROUND-REPEAT: no-repeat; HEIGHT: 16px } .x-panel-tc { BACKGROUND: = url(/core/extjs/ext-2.1/resources/images/default/panel/top-bottom.gif) = repeat-x 0px 0px; OVERFLOW: hidden } .ext-strict .ext-ie7 .x-panel-tc { OVERFLOW: visible } .x-panel-tl { PADDING-LEFT: 6px; BACKGROUND: = url(/core/extjs/ext-2.1/resources/images/default/panel/corners-sprite.gif= ) no-repeat 0px 0px; BORDER-BOTTOM: #99bbe8 1px solid; ZOOM: 1 } .x-panel-tr { PADDING-RIGHT: 6px; BACKGROUND: = url(/core/extjs/ext-2.1/resources/images/default/panel/corners-sprite.gif= ) no-repeat right 0px; ZOOM: 1 } .x-panel-bc { BACKGROUND: = url(/core/extjs/ext-2.1/resources/images/default/panel/top-bottom.gif) = repeat-x 0px bottom; ZOOM: 1 } .x-panel-bc .x-panel-footer { ZOOM: 1 } .x-panel-bl { PADDING-LEFT: 6px; BACKGROUND: = url(/core/extjs/ext-2.1/resources/images/default/panel/corners-sprite.gif= ) no-repeat 0px bottom; ZOOM: 1 } .x-panel-br { PADDING-RIGHT: 6px; BACKGROUND: = url(/core/extjs/ext-2.1/resources/images/default/panel/corners-sprite.gif= ) no-repeat right bottom; ZOOM: 1 } .x-panel-mc { BORDER-RIGHT: 0px; PADDING-RIGHT: 0px; BORDER-TOP: 0px; PADDING-LEFT: = 0px; BACKGROUND: #dfe8f6; PADDING-BOTTOM: 0px; MARGIN: 0px; FONT: 11px = tahoma,arial,helvetica,sans-serif; BORDER-LEFT: 0px; PADDING-TOP: 6px; = BORDER-BOTTOM: 0px } .x-panel-mc .x-panel-body { BORDER-RIGHT: 0px; BORDER-TOP: 0px; BACKGROUND: none transparent scroll = repeat 0% 0%; BORDER-LEFT: 0px; BORDER-BOTTOM: 0px } .x-panel-ml { PADDING-LEFT: 6px; BACKGROUND: = url(/core/extjs/ext-2.1/resources/images/default/panel/left-right.gif) = #fff repeat-y 0px 0px; ZOOM: 1 } .x-panel-mr { PADDING-RIGHT: 6px; BACKGROUND: = url(/core/extjs/ext-2.1/resources/images/default/panel/left-right.gif) = repeat-y right 0px; ZOOM: 1 } .x-panel-bc .x-panel-footer { PADDING-BOTTOM: 6px } .x-panel-nofooter .x-panel-bc { FONT-SIZE: 0px; LINE-HEIGHT: 0; HEIGHT: 6px } .x-panel-nofooter .x-window-bc { FONT-SIZE: 0px; LINE-HEIGHT: 0; HEIGHT: 6px } .x-panel-bwrap { OVERFLOW: hidden; ZOOM: 1 } .x-panel-body { OVERFLOW: hidden; ZOOM: 1 } .x-panel-collapsed .x-resizable-handle { DISPLAY: none } .ext-gecko .x-panel-animated DIV { OVERFLOW: hidden! important } .x-plain-body { OVERFLOW: hidden } .x-plain-bbar .x-toolbar { PADDING-RIGHT: 2px; PADDING-LEFT: 2px; PADDING-BOTTOM: 2px; OVERFLOW: = hidden; PADDING-TOP: 2px } .x-plain-tbar .x-toolbar { PADDING-RIGHT: 2px; PADDING-LEFT: 2px; PADDING-BOTTOM: 2px; OVERFLOW: = hidden; PADDING-TOP: 2px } .x-plain-bwrap { OVERFLOW: hidden; ZOOM: 1 } .x-plain { OVERFLOW: hidden } .x-tool { BACKGROUND: = url(/core/extjs/ext-2.1/resources/images/default/panel/tool-sprites.gif) = no-repeat; FLOAT: right; MARGIN-LEFT: 2px; OVERFLOW: hidden; WIDTH: = 15px; CURSOR: pointer; HEIGHT: 15px } .x-tool-toggle { BACKGROUND-POSITION: 0px -60px } .x-tool-toggle-over { BACKGROUND-POSITION: -15px -60px } .x-panel-collapsed .x-tool-toggle { BACKGROUND-POSITION: 0px -75px } .x-panel-collapsed .x-tool-toggle-over { BACKGROUND-POSITION: -15px -75px } .x-tool-close { BACKGROUND-POSITION: 0px 0px } .x-tool-close-over { BACKGROUND-POSITION: -15px 0px } .x-tool-minimize { BACKGROUND-POSITION: 0px -15px } .x-tool-minimize-over { BACKGROUND-POSITION: -15px 50% } .x-tool-maximize { BACKGROUND-POSITION: 0px -30px } .x-tool-maximize-over { BACKGROUND-POSITION: -15px -30px } .x-tool-restore { BACKGROUND-POSITION: 0px -45px } .x-tool-restore-over { BACKGROUND-POSITION: -15px -45px } .x-tool-gear { BACKGROUND-POSITION: 0px -90px } .x-tool-gear-over { BACKGROUND-POSITION: -15px -90px } .x-tool-pin { BACKGROUND-POSITION: 0px -135px } .x-tool-pin-over { BACKGROUND-POSITION: -15px -135px } .x-tool-unpin { BACKGROUND-POSITION: 0px -150px } .x-tool-unpin-over { BACKGROUND-POSITION: -15px -150px } .x-tool-right { BACKGROUND-POSITION: 0px -165px } .x-tool-right-over { BACKGROUND-POSITION: -15px -165px } .x-tool-left { BACKGROUND-POSITION: 0px -180px } .x-tool-left-over { BACKGROUND-POSITION: -15px -180px } .x-tool-up { BACKGROUND-POSITION: 0px -210px } .x-tool-up-over { BACKGROUND-POSITION: -15px -210px } .x-tool-down { BACKGROUND-POSITION: 0px -195px } .x-tool-down-over { BACKGROUND-POSITION: -15px -195px } .x-tool-refresh { BACKGROUND-POSITION: 0px -225px } .x-tool-refresh-over { BACKGROUND-POSITION: -15px -225px } .x-tool-minus { BACKGROUND-POSITION: 0px -255px } .x-tool-minus-over { BACKGROUND-POSITION: -15px -255px } .x-tool-plus { BACKGROUND-POSITION: 0px -240px } .x-tool-plus-over { BACKGROUND-POSITION: -15px -240px } .x-tool-search { BACKGROUND-POSITION: 0px -270px } .x-tool-search-over { BACKGROUND-POSITION: -15px -270px } .x-tool-save { BACKGROUND-POSITION: 0px -285px } .x-tool-save-over { BACKGROUND-POSITION: -15px -285px } .x-tool-help { BACKGROUND-POSITION: 0px -300px } .x-tool-help-over { BACKGROUND-POSITION: -15px -300px } .x-tool-print { BACKGROUND-POSITION: 0px -315px } .x-tool-print-over { BACKGROUND-POSITION: -15px -315px } .x-panel-ghost { Z-INDEX: 12000; BACKGROUND: #cbddf3; FILTER: alpha(opacity=3D65); LEFT: = 0px; OVERFLOW: hidden; POSITION: absolute; TOP: 0px; opacity: .65; = -moz-opacity: .65 } .x-panel-ghost UL { BORDER-RIGHT: #99bbe8 1px solid; PADDING-RIGHT: 0px; BORDER-TOP: = #99bbe8 0px; DISPLAY: block; PADDING-LEFT: 0px; FONT-SIZE: 0px; = PADDING-BOTTOM: 0px; MARGIN: 0px; OVERFLOW: hidden; BORDER-LEFT: #99bbe8 = 1px solid; LINE-HEIGHT: 0; PADDING-TOP: 0px; BORDER-BOTTOM: #99bbe8 1px = solid } .x-panel-ghost * { CURSOR: move! important } .x-panel-dd-spacer { BORDER-RIGHT: #99bbe8 2px dashed; BORDER-TOP: #99bbe8 2px dashed; = BORDER-LEFT: #99bbe8 2px dashed; BORDER-BOTTOM: #99bbe8 2px dashed } .x-panel-btns-ct { PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 5px; = PADDING-TOP: 5px } .x-panel-btns-ct .x-btn { CLEAR: none; FLOAT: right } .x-panel-btns-ct .x-panel-btns TD { BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; = BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; = PADDING-TOP: 0px; BORDER-RIGHT-WIDTH: 0px } .x-panel-btns-ct .x-panel-btns-right TABLE { CLEAR: none; FLOAT: right } .x-panel-btns-ct .x-panel-btns-left TABLE { CLEAR: none; FLOAT: left } .x-panel-btns-ct .x-panel-btns-center { TEXT-ALIGN: center } .x-panel-btns-ct .x-panel-btns-center TABLE { MARGIN: 0px auto } .x-panel-btns-ct TABLE TD.x-panel-btn-td { PADDING-RIGHT: 3px; PADDING-LEFT: 3px; PADDING-BOTTOM: 3px; = PADDING-TOP: 3px } .x-panel-btns-ct .x-btn-focus .x-btn-left { BACKGROUND-POSITION: 0px -147px } .x-panel-btns-ct .x-btn-focus .x-btn-right { BACKGROUND-POSITION: 0px -168px } .x-panel-btns-ct .x-btn-focus .x-btn-center { BACKGROUND-POSITION: 0px -189px } .x-panel-btns-ct .x-btn-over .x-btn-left { BACKGROUND-POSITION: 0px -63px } .x-panel-btns-ct .x-btn-over .x-btn-right { BACKGROUND-POSITION: 0px -84px } .x-panel-btns-ct .x-btn-over .x-btn-center { BACKGROUND-POSITION: 0px -105px } .x-panel-btns-ct .x-btn-click .x-btn-center { BACKGROUND-POSITION: 0px -126px } .x-panel-btns-ct .x-btn-click .x-btn-right { BACKGROUND-POSITION: 0px -84px } .x-panel-btns-ct .x-btn-click .x-btn-left { BACKGROUND-POSITION: 0px -63px } .x-btn-menu-wrap { WIDTH: 0px! important } .x-menu { BACKGROUND: #f0f0f0 0px 0px } .x-menu-list-item IMG { DISPLAY: none } .x-menu-list-item A.x-menu-item { PADDING-LEFT: 8px } .port H1.x-panel-header-text { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; PADDING-BOTTOM: = 0px; MARGIN: 0px; PADDING-TOP: 0px } .port H2.x-panel-header-text { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; PADDING-BOTTOM: = 0px; MARGIN: 0px; PADDING-TOP: 0px } .port H3.x-panel-header-text { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; PADDING-BOTTOM: = 0px; MARGIN: 0px; PADDING-TOP: 0px } .port H4.x-panel-header-text { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; PADDING-BOTTOM: = 0px; MARGIN: 0px; PADDING-TOP: 0px } .port H5.x-panel-header-text { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; PADDING-BOTTOM: = 0px; MARGIN: 0px; PADDING-TOP: 0px } .port H6.x-panel-header-text { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; PADDING-BOTTOM: = 0px; MARGIN: 0px; PADDING-TOP: 0px } DIV.x-panel-body { PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 5px; = PADDING-TOP: 5px } .port .x-panel-header { PADDING-RIGHT: 3px; PADDING-LEFT: 5px; PADDING-BOTTOM: 4px; = PADDING-TOP: 5px } .x-panel { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-STYLE: solid; BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-STYLE: = solid; BORDER-LEFT-STYLE: solid; BORDER-RIGHT-COLOR: #d0d0d0; = BORDER-BOTTOM-STYLE: solid } .x-panel-header { BORDER-RIGHT: #d0d0d0 1px solid; BORDER-TOP: #d0d0d0 1px solid; = BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/panel/white-top-bottom.gif); = BORDER-LEFT: #d0d0d0 1px solid; COLOR: #333; BORDER-BOTTOM: #d0d0d0 1px = solid } .x-panel-body { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-bbar .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-tbar .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-tbar-noheader .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-mc .x-panel-tbar .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-body-noheader { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-mc .x-panel-body { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-tl .x-panel-header { COLOR: #333 } .x-panel-tc { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/panel/top-bottom.gif) } .x-panel-tl { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/panel/corners-sprite.gif); = BORDER-BOTTOM-COLOR: #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; = BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-tr { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/panel/corners-sprite.gif) } .x-panel-bc { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/panel/top-bottom.gif) } .x-panel-bl { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/panel/corners-sprite.gif) } .x-panel-br { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/panel/corners-sprite.gif) } .x-panel-mc { BACKGROUND: #f1f1f1 } .x-panel-mc .x-panel-body { BORDER-RIGHT: 0px; BORDER-TOP: 0px; BACKGROUND: none transparent scroll = repeat 0% 0%; BORDER-LEFT: 0px; BORDER-BOTTOM: 0px } .x-panel-ml { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/panel/left-right.gif) } .x-panel-mr { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/panel/left-right.gif) } .x-tool { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/panel/tool-sprites.gif) } .x-panel-ghost { BACKGROUND: #e0e0e0 } .x-panel-ghost UL { BORDER-LEFT-COLOR: #b0b0b0; BORDER-BOTTOM-COLOR: #b0b0b0; = BORDER-TOP-COLOR: #b0b0b0; BORDER-RIGHT-COLOR: #b0b0b0 } .x-grid-panel .x-panel-mc .x-panel-body { BORDER-RIGHT: #d0d0d0 1px solid; BORDER-TOP: #d0d0d0 1px solid; = BORDER-LEFT: #d0d0d0 1px solid; BORDER-BOTTOM: #d0d0d0 1px solid } .x-btn-left { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/button/btn-sprite.gif) } .x-btn-right { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/button/btn-sprite.gif) } .x-btn-center { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/button/btn-sprite.gif) } .x-border-layout-ct { BACKGROUND: #f0f0f0 } .x-accordion-hd { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/panel/light-hd.gif) } .x-layout-collapsed { BORDER-LEFT-COLOR: #e0e0e0; BORDER-BOTTOM-COLOR: #e0e0e0; = BORDER-TOP-COLOR: #e0e0e0; BACKGROUND-COLOR: #eee; BORDER-RIGHT-COLOR: = #e0e0e0 } .x-layout-collapsed-over { BACKGROUND-COLOR: #fbfbfb } .x-tip .x-tip-top { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-top-left { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-top-right { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-ft { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-ft-left { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-ft-right { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-bd-left { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/qtip/tip-sprite.gif) } .x-tip .x-tip-bd-right { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/qtip/tip-sprite.gif) } .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/bg.gif) #f0f4f5 repeat-x left = top; BORDER-BOTTOM-COLOR: #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; = BORDER-RIGHT-COLOR: #d0d0d0 } .x-toolbar BUTTON { COLOR: #444 } .x-toolbar .x-btn-menu-arrow-wrap .x-btn-center BUTTON { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/btn-arrow.gif) } .x-toolbar .x-btn-text-icon .x-btn-menu-arrow-wrap .x-btn-center BUTTON = { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/btn-arrow.gif) } .x-toolbar .x-btn-over .x-btn-left { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-over .x-btn-right { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-over .x-btn-center { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-over BUTTON { COLOR: #111 } .x-toolbar .x-btn-click .x-btn-left { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-pressed .x-btn-left { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-menu-active .x-btn-left { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-click .x-btn-right { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-pressed .x-btn-right { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-menu-active .x-btn-right { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-click .x-btn-center { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-pressed .x-btn-center { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .x-btn-menu-active .x-btn-center { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/toolbar/tb-btn-sprite.gif) } .x-toolbar .ytb-sep { BACKGROUND-IMAGE: = url(/core/extjs/ext-2.1/resources/images/default/grid/grid-split.gif) } .x-tab-panel-header { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND: #eaeaea; BORDER-BOTTOM-COLOR: = #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-panel-footer { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND: #eaeaea; BORDER-BOTTOM-COLOR: = #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-panel-header { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-panel-footer { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } UL.x-tab-strip-top { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND: = url(/core/ext.ncbi/1/img/oldentrez/tabs/tab-strip-bg.gif) #dbdbdb = repeat-x left top; BORDER-BOTTOM-COLOR: #d0d0d0; BORDER-TOP-COLOR: = #d0d0d0; PADDING-TOP: 2px; BORDER-RIGHT-COLOR: #d0d0d0 } UL.x-tab-strip-bottom { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/tabs/tab-strip-btm-bg.gif); = BORDER-BOTTOM-COLOR: #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; = BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-strip SPAN.x-tab-strip-text { COLOR: #333 } .x-tab-strip-over SPAN.x-tab-strip-text { COLOR: #111 } .x-tab-strip-active SPAN.x-tab-strip-text { COLOR: #333 } .x-tab-strip-disabled .x-tabs-text { COLOR: #aaaaaa } .x-tab-strip-top .x-tab-right { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/tabs/tabs-sprite.gif) } .x-tab-strip-top .x-tab-left { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/tabs/tabs-sprite.gif) } .x-tab-strip-top .x-tab-strip-inner { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/tabs/tabs-sprite.gif) } .x-tab-strip-bottom .x-tab-right { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/tabs/tab-btm-inactive-right-bg.gif) } .x-tab-strip-bottom .x-tab-left { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/tabs/tab-btm-inactive-left-bg.gif) } .x-tab-strip-bottom .x-tab-strip-active .x-tab-right { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/tabs/tab-btm-right-bg.gif) } .x-tab-strip-bottom .x-tab-strip-active .x-tab-left { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/tabs/tab-btm-left-bg.gif) } .x-tab-strip .x-tab-strip-closable A.x-tab-strip-close { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/tabs/tab-close.gif) } .x-tab-strip .x-tab-strip-closable A.x-tab-strip-close:hover { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/tabs/tab-close.gif) } .x-tab-panel-body { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND: #fff; BORDER-BOTTOM-COLOR: = #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-panel-bbar .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-panel-tbar .x-toolbar { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-panel-header-plain .x-tab-strip-spacer { BORDER-LEFT-COLOR: #d0d0d0; BACKGROUND: #eaeaea; BORDER-BOTTOM-COLOR: = #d0d0d0; BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-tab-scroller-left { BORDER-LEFT-COLOR: #aeaeae; BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/tabs/scroll-left.gif); = BORDER-BOTTOM-COLOR: #aeaeae; BORDER-TOP-COLOR: #aeaeae; = BORDER-RIGHT-COLOR: #aeaeae } .x-tab-scroller-right { BORDER-LEFT-COLOR: #aeaeae; BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/tabs/scroll-right.gif); = BORDER-BOTTOM-COLOR: #aeaeae; BORDER-TOP-COLOR: #aeaeae; = BORDER-RIGHT-COLOR: #aeaeae } .x-window-proxy { BORDER-LEFT-COLOR: #b0b0b0; BACKGROUND: #e0e0e0; BORDER-BOTTOM-COLOR: = #b0b0b0; BORDER-TOP-COLOR: #b0b0b0; BORDER-RIGHT-COLOR: #b0b0b0 } .x-window-tl .x-window-header { COLOR: #555 } .x-window-tc { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/window/top-bottom.png) } .x-window-tl { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/window/left-corners.png) } .x-window-tr { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/window/right-corners.png) } .x-window-bc { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/window/top-bottom.png) } .x-window-bl { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/window/left-corners.png) } .x-window-br { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/window/right-corners.png) } .x-window-mc { BORDER-RIGHT: #d0d0d0 1px solid; BORDER-TOP: #d0d0d0 1px solid; = BACKGROUND: #e8e8e8; BORDER-LEFT: #d0d0d0 1px solid; BORDER-BOTTOM: = #d0d0d0 1px solid } .x-window-ml { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/window/left-right.png) } .x-window-mr { BACKGROUND-IMAGE: = url(/core/ext.ncbi/1/img/oldentrez/window/left-right.png) } .x-panel-ghost .x-window-tl { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-collapsed .x-window-tl { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-window-plain .x-window-mc { BORDER-RIGHT: #eee 1px solid; BORDER-TOP: #d0d0d0 1px solid; = BACKGROUND: #e8e8e8; BORDER-LEFT: #d0d0d0 1px solid; BORDER-BOTTOM: #eee = 1px solid } .x-window-plain .x-window-body { BORDER-RIGHT: #d0d0d0 1px solid; BORDER-TOP: #eee 1px solid; = BACKGROUND: none transparent scroll repeat 0% 0%; BORDER-LEFT: #eee 1px = solid; BORDER-BOTTOM: #d0d0d0 1px solid } BODY.x-body-masked .x-window-mc { BACKGROUND-COLOR: #e4e4e4 } BODY.x-body-masked .x-window-plain .x-window-mc { BACKGROUND-COLOR: #e4e4e4 } .x-html-editor-wrap { BORDER-LEFT-COLOR: #d0d0d0; BORDER-BOTTOM-COLOR: #d0d0d0; = BORDER-TOP-COLOR: #d0d0d0; BORDER-RIGHT-COLOR: #d0d0d0 } .x-panel-noborder .x-panel-body-noborder { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: = 0px; BORDER-RIGHT-WIDTH: 0px } .x-panel-noborder .x-panel-header-noborder { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM: #d0d0d0 = 1px solid; BORDER-RIGHT-WIDTH: 0px } .x-panel-noborder .x-panel-tbar-noborder .x-toolbar { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM: #d0d0d0 = 1px solid; BORDER-RIGHT-WIDTH: 0px } .x-panel-noborder .x-panel-bbar-noborder .x-toolbar { BORDER-TOP: #d0d0d0 1px solid; BORDER-LEFT-WIDTH: 0px; = BORDER-BOTTOM-WIDTH: 0px; BORDER-RIGHT-WIDTH: 0px } .x-window-noborder .x-window-mc { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: = 0px; BORDER-RIGHT-WIDTH: 0px } .x-window-plain .x-window-body-noborder { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: = 0px; BORDER-RIGHT-WIDTH: 0px } .x-tab-panel-noborder .x-tab-panel-body-noborder { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: = 0px; BORDER-RIGHT-WIDTH: 0px } .x-tab-panel-noborder .x-tab-panel-header-noborder { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-RIGHT-WIDTH: 0px } .x-tab-panel-noborder .x-tab-panel-footer-noborder { BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; BORDER-RIGHT-WIDTH: = 0px } .x-tab-panel-bbar-noborder .x-toolbar { BORDER-TOP: #d0d0d0 1px solid; BORDER-LEFT-WIDTH: 0px; = BORDER-BOTTOM-WIDTH: 0px; BORDER-RIGHT-WIDTH: 0px } .x-tab-panel-tbar-noborder .x-toolbar { BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM: #d0d0d0 = 1px solid; BORDER-RIGHT-WIDTH: 0px } .x-panel-header { FONT-SIZE: 90%; FONT-FAMILY: Arial, Verdana, Sans-Serif; = BACKGROUND-COLOR: #e3e3e3; xbackground: none } DIV.section.port { MARGIN-TOP: 0.5em; PADDING-TOP: 0.5em; FONT-FAMILY: = Arial,Helvetica,Sans-Serif } DIV.x-panel-body DIV.section.port { MARGIN-TOP: 0px; PADDING-TOP: 0px } DIV.section.port DIV.window { PADDING-LEFT: 0.5em; MARGIN-BOTTOM: 0.5em } DIV.port LI.item EM.error.linklist { FONT-SIZE: 1.2em; COLOR: #cc0000; BACKGROUND-COLOR: #eaebc8 } DIV.norender.port { FONT-FAMILY: Arial,Lucida Sans,Trebuchet,Sans-Serif } DIV.brieflink { MARGIN-TOP: 0.5em; PADDING-TOP: 0.5em; FONT-FAMILY: Arial, Lucida Sans, = Trebuchet, Sans-Serif } DIV.brieflink H2 { FONT-WEIGHT: bold; FONT-SIZE: 0.8em; PADDING-BOTTOM: 0.3em; = MARGIN-LEFT: 0.2em; COLOR: #000000 } DIV.brieflink DIV { BORDER-TOP: #bdbdbd 1px solid } DIV.brieflink UL { FONT-SIZE: 0.8em; COLOR: #212121 } DIV.brieflink UL LI.item { BACKGROUND-POSITION: 0px 0.35em; PADDING-LEFT: 1.2em; MIN-HEIGHT: = 1.25em; BACKGROUND-IMAGE: url(/portal/portal3rc.fcgi/35478/img/29089); = MARGIN: 0.25em 0px 0px; OVERFLOW: hidden; MAX-HEIGHT: 2.5em; = LINE-HEIGHT: 1.25em; PADDING-TOP: 0.1em; BACKGROUND-REPEAT: no-repeat; = ZOOM: 1; POSITION: relative } DIV.brieflink UL LI.note.item { HEIGHT: 2.5em } DIV.brieflink UL LI.more { MARGIN-TOP: 0.5em; PADDING-TOP: 0.1em; WHITE-SPACE: nowrap; TEXT-ALIGN: = right; BORDER-BOTTOM-STYLE: none } DIV.brieflink UL LI.item A { FLOAT: left; OVERFLOW: hidden; COLOR: #212121; MAX-HEIGHT: 2.5em; = TEXT-DECORATION: none; BORDER-BOTTOM-STYLE: none } DIV.brieflink UL LI.more A { COLOR: #212121; TEXT-DECORATION: none; BORDER-BOTTOM-STYLE: none } DIV.brieflink UL LI A:hover { TEXT-DECORATION: underline; _border-bottom: none } DIV.brieflink LI.item P.desc { LEFT: 1000px; BOTTOM: 1000px; LINE-HEIGHT: 0; POSITION: relative; = HEIGHT: 0px } DIV.brieflink UL LI.item P.note { DISPLAY: inline; PADDING-LEFT: 0.2em; RIGHT: 0px; OVERFLOW: hidden; = COLOR: #666666; WHITE-SPACE: nowrap; POSITION: absolute; TOP: 1.3em; = BACKGROUND-COLOR: white } DIV.brieflink LI.footer { BORDER-TOP: #bdbdbd 1px solid; MARGIN-TOP: 0.4em; FONT-SIZE: 0.9em; = MARGIN-LEFT: 1.5em; COLOR: #666666; LINE-HEIGHT: 1.5em; TEXT-ALIGN: = right } .poptext { DISPLAY: none } .popper { DISPLAY: none; Z-INDEX: 1000; MARGIN: 0px; WIDTH: 300px; ZOOM: 1; = POSITION: absolute } .pop-getxy { DISPLAY: none; Z-INDEX: 1000; MARGIN: 0px; WIDTH: 300px; ZOOM: 1; = POSITION: absolute } .port { ZOOM: 1! important } .pop-getxy { VISIBILITY: hidden } .popped.popper { DISPLAY: block; BACKGROUND-COLOR: #fff } DIV.pop-left.popped.popper DIV.popperInnerDiv { MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 0px } DIV.pop-right.popped.popper DIV.popperInnerDiv { MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-RIGHT: 0px } DIV.pop-above.popped.popper DIV.popperInnerDiv { MARGIN-TOP: 0px; MARGIN-LEFT: 0px; MARGIN-RIGHT: 0px } DIV.pop-below.popped.popper DIV.popperInnerDiv { MARGIN-BOTTOM: 0px; MARGIN-LEFT: 0px; MARGIN-RIGHT: 0px } .popper { FONT-SIZE: 0.8em; WIDTH: 30em; COLOR: #222; FONT-FAMILY: Arial, Lucida = Sans, Trebuchet, Sans-Serif } .popped.popper { BACKGROUND: url(/portal/portal3rc.fcgi/35478/img/29062) no-repeat = center center; xbackground: transparent = url(http://iwebdev/staff/mjohnson/proj/components/popper/pop2.png) = no-repeat center center } .popped.popper DIV.popperInnerDiv { BORDER-RIGHT: #369 1px solid; PADDING-RIGHT: 0.5em; BORDER-TOP: #369 = 1px solid; PADDING-LEFT: 0.5em; PADDING-BOTTOM: 0.5em; MARGIN: 15px; = BORDER-LEFT: #369 1px solid; PADDING-TOP: 0.5em; BORDER-BOTTOM: #369 1px = solid; BACKGROUND-COLOR: #f0f8ff } DIV#popContent DIV.popperInnerDiv { PADDING-RIGHT: 0.5em; PADDING-LEFT: 0.5em; FONT-SIZE: 80%; Z-INDEX: 5; = PADDING-BOTTOM: 0.5em; COLOR: #444444; PADDING-TOP: 0.5em; FONT-FAMILY: = Verdana, Arial, sans-serif; BACKGROUND-COLOR: #f0f8ff; opacity: 1 } DIV.pop-left.popped.popper { BACKGROUND-POSITION: 100% -12px } DIV.pop-right.popped.popper { BACKGROUND-POSITION: 0px -12px } DIV.pop-above.popped.popper { BACKGROUND-POSITION: -12px 100% } DIV.pop-below.popped.popper { BACKGROUND-POSITION: -12px 0px } DIV.section DIV.window.brieflink { MARGIN-TOP: 0.75em; PADDING-TOP: 0px } DIV.window.brieflink UL LI.item { HEIGHT: auto } DIV#HTDisplay { FONT-FAMILY: Arial,sans-serif } DIV#HTDisplay A { COLOR: #232323; BORDER-TOP-STYLE: none; BORDER-RIGHT-STYLE: none; = BORDER-LEFT-STYLE: none; TEXT-DECORATION: underline; = BORDER-BOTTOM-STYLE: none } DIV#HTDisplay UL { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 80%; PADDING-BOTTOM: = 0px; MARGIN: 1.3em 0em 1em; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; = _padding-top: 1.3em } DIV#HTDisplay UL LI { PADDING-RIGHT: 0.2em; PADDING-LEFT: 1.8em; MARGIN: 0.8em 0.3em 0.8em = 0.7em; OVERFLOW: hidden; COLOR: #232323; MAX-HEIGHT: 2.6em; POSITION: = relative; HEIGHT: auto } DIV#HTDisplay UL LI.query { MIN-HEIGHT: 15px; BACKGROUND: = url(/portal/portal3rc.fcgi/35478/img/29088) no-repeat 0px 0px } DIV#HTDisplay UL LI.query DIV.textwrapper { MAX-WIDTH: 85% } DIV#HTDisplay UL LI.record { BACKGROUND: url(/portal/portal3rc.fcgi/35478/img/29132) no-repeat 0px = 20%; LINE-HEIGHT: 1.3 } DIV#HTDisplay UL LI.bottomline { PADDING-BOTTOM: 0.3em; BORDER-BOTTOM: #999999 1px solid } DIV#HTDisplay UL LI A.hidden { DISPLAY: none } DIV#HTDisplay UL LI.record A { TEXT-DECORATION: none } DIV#HTDisplay UL LI.record A:hover { TEXT-DECORATION: underline } DIV#HTDisplay UL .count { LEFT: 0.3em; POSITION: relative; TOP: 1px } DIV#HTDisplay DIV.action { OVERFLOW: hidden } DIV#HTDisplay DIV.action A { FONT-SIZE: 75%; FLOAT: right; MARGIN: 0em 0.5em 0.25em } DIV#HTDisplay P { CLEAR: both; FONT-SIZE: 85%; MARGIN: 1.2em 0em 0.6em 0.5em } DIV#HTDisplay UL LI .thumb { RIGHT: 0px; PADDING-TOP: 0.4em; POSITION: absolute; BACKGROUND-COLOR: = white; _padding-right: 0.4em } DIV#HTDisplay P { DISPLAY: none } DIV#HTDisplay .action A.HTOff { DISPLAY: none } DIV.HTOff#HTDisplay .action A.HTOn { DISPLAY: none } DIV.HTOff#HTDisplay P.HTOff { DISPLAY: block } DIV.HTOn#HTDisplay P.HTOn { DISPLAY: block } DIV.HTOff#HTDisplay .action A.HTOff { DISPLAY: block } DIV.HTOn#HTDisplay .action A.HTOn { DISPLAY: block } DIV#HTDisplay UL.hide { DISPLAY: none } IMG.htbpoparrow { Z-INDEX: 4; BACKGROUND: url(/corehtml/query/PubMed/right.jpg) no-repeat = right top; LEFT: 22px; FLOAT: right; ZOOM: 1; POSITION: relative; TOP: = -7px; _left: 25px } DIV#htbpopper { BORDER-RIGHT: #369 1px solid; PADDING-RIGHT: 0.5em; BORDER-TOP: #369 = 1px solid; DISPLAY: block; PADDING-LEFT: 0.5em; FONT-SIZE: 80%; Z-INDEX: = 5; PADDING-BOTTOM: 0.5em; BORDER-LEFT: #369 1px solid; WIDTH: 32em; = COLOR: #444; PADDING-TOP: 0.5em; BORDER-BOTTOM: #369 1px solid; ZOOM: 1; = FONT-FAMILY: Verdana; POSITION: absolute; BACKGROUND-COLOR: #f0f8ff; = opacity: 100 } DIV.popper P { MARGIN: 0px 0px 0.25em } P#htbpcit { DISPLAY: block; FONT-SIZE: 85% } P.pmid { DISPLAY: block; FONT-SIZE: 85% } P#htbpcit { FONT-STYLE: italic } .hidden#htbpopper { DISPLAY: none } DIV#HTDisplay UL LI SPAN.thumb { BACKGROUND-COLOR: #f8f8f8 } BODY #col1 { BORDER-RIGHT: #00c 1px solid; BORDER-TOP: #00c 1px solid; BORDER-LEFT: = #00c 1px solid; BORDER-BOTTOM: #00c 1px solid } BODY #col2 { BORDER-RIGHT: #00c 1px solid; BORDER-TOP: #00c 1px solid; BORDER-LEFT: = #00c 1px solid; BORDER-BOTTOM: #00c 1px solid } BODY #subheader { BORDER-RIGHT: #00c 1px solid; BORDER-TOP: #00c 1px solid; BORDER-LEFT: = #00c 1px solid; BORDER-BOTTOM: #00c 1px solid } BODY #subfooter { BORDER-RIGHT: #00c 1px solid; BORDER-TOP: #00c 1px solid; BORDER-LEFT: = #00c 1px solid; BORDER-BOTTOM: #00c 1px solid } BODY #subfooter { TEXT-ALIGN: center } #Table2 { WIDTH: 100%; BACKGROUND-COLOR: #ecf0f4 } TD.pmc-watermark { MIN-WIDTH: 20px; MIN-HEIGHT: auto } TD.format-menu { PADDING-RIGHT: 0px; PADDING-LEFT: 0.75em; FONT-SIZE: 80%; = PADDING-BOTTOM: 0px; PADDING-TOP: 0px } TD.format-menu UL { PADDING-RIGHT: 0px; DISPLAY: inline; PADDING-LEFT: 0.25em; = PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0px 0.2em; PADDING-TOP: 0px } TD.format-menu H2 { DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 1em; COLOR: #000 } TD.format-menu UL LI { DISPLAY: inline; MARGIN: 0px 0.1em 0px 0px } TD.format-menu UL LI A { COLOR: #000000 } TD.format-menu UL LI.selected { COLOR: #5e5e5e } TD.content-cell > DIV TD.content-cell > DIV > DIV { ZOOM: 1 } TD.sidebar-cell { MIN-WIDTH: 250px; MAX-WIDTH: 350px; WIDTH: 350px } TD.message-cell { MAX-WIDTH: 570px; WIDTH: 570px } BODY.pmc-body #Table3 DIV.navlink-box { FONT-WEIGHT: normal; WIDTH: auto; BORDER-BOTTOM: #5e5e5e 1px solid } DIV.cited-ref { MIN-WIDTH: 250px; MAX-WIDTH: 350px; MARGIN: 0.3em 0.75em; WIDTH: 350px; = POSITION: absolute } DIV.section-content > DIV.p { WIDTH: 550px; WORD-WRAP: break-word } IMG.equation { MAX-WIDTH: 502px; ; WIDTH: expression(this.clientWidth - 2 < 500? = "auto" : "502px") } DIV.section-content DIV.figure-table-caption-in-article DIV.p { WIDTH: auto } DIV.ArticleRefDocsums { =09 } DIV.pmlinks UL.links { PADDING-RIGHT: 0px; LIST-STYLE: none none outside; BORDER-TOP: #cccccc = 1px solid; DISPLAY: block; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; = MARGIN: 0px; PADDING-TOP: 0px; FONT-FAMILY: Arial,Helvetica,sans-serif } DIV.cited-ref UL { PADDING-RIGHT: 0px; LIST-STYLE: none none outside; BORDER-TOP: #cccccc = 1px solid; DISPLAY: block; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; = MARGIN: 0px; PADDING-TOP: 0px; FONT-FAMILY: Arial,Helvetica,sans-serif } DIV.pmlinks UL.links LI.ovfl { DISPLAY: block; FONT-SIZE: 80%; BACKGROUND: = url(/portal/portal3rc.fcgi/35478/img/29089) no-repeat left top; MARGIN: = 0.75em 0.2em 0px 0px; OVERFLOW: hidden; WIDTH: 100%; LINE-HEIGHT: 1.2em; = ZOOM: 1; POSITION: relative } DIV.cited-ref LI.ovfl { DISPLAY: block; FONT-SIZE: 80%; BACKGROUND: = url(/portal/portal3rc.fcgi/35478/img/29089) no-repeat left top; MARGIN: = 0.75em 0.2em 0px 0px; OVERFLOW: hidden; WIDTH: 100%; LINE-HEIGHT: 1.2em; = ZOOM: 1; POSITION: relative } DIV.pmlinks UL.links LI.ovfl A.pl { DISPLAY: block; PADDING-LEFT: 1.5em; OVERFLOW: hidden; COLOR: = rgb(35,35,35); HEIGHT: 2.4em; TEXT-DECORATION: none } DIV.cited-ref LI.ovfl A.pl { DISPLAY: block; PADDING-LEFT: 1.5em; OVERFLOW: hidden; COLOR: = rgb(35,35,35); HEIGHT: 2.4em; TEXT-DECORATION: none } DIV.pmlinks UL.links LI.ovfl A.pl:hover { TEXT-DECORATION: underline } DIV.cited-ref LI.ovfl A.pl:hover { TEXT-DECORATION: underline } DIV.pmlinks UL.links LI.ovfl SPAN.pub { PADDING-RIGHT: 0.5em; MARGIN-TOP: 0.2em; DISPLAY: block; PADDING-LEFT: = 0.5em; Z-INDEX: 4; RIGHT: 0px; PADDING-BOTTOM: 2px; OVERFLOW: hidden; = COLOR: #666; BOTTOM: -0.2em; PADDING-TOP: 0px; ZOOM: 1; FONT-FAMILY: = Verdana,Arial,Sans-Serif; WHITE-SPACE: nowrap; LETTER-SPACING: -1px; = POSITION: absolute; BACKGROUND-COLOR: #f8f8f8 } DIV.cited-ref LI.ovfl SPAN.pub { PADDING-RIGHT: 0.5em; MARGIN-TOP: 0.2em; DISPLAY: block; PADDING-LEFT: = 0.5em; Z-INDEX: 4; RIGHT: 0px; PADDING-BOTTOM: 2px; OVERFLOW: hidden; = COLOR: #666; BOTTOM: -0.2em; PADDING-TOP: 0px; ZOOM: 1; FONT-FAMILY: = Verdana,Arial,Sans-Serif; WHITE-SPACE: nowrap; LETTER-SPACING: -1px; = POSITION: absolute; BACKGROUND-COLOR: #f8f8f8 } DIV.pmlinks UL.links LI.ovfl SPAN.flag { PADDING-RIGHT: 0.3em; MARGIN-TOP: -0.1em; PADDING-LEFT: 0.2em; = FONT-WEIGHT: 500; PADDING-BOTTOM: 0px; VERTICAL-ALIGN: middle; COLOR: = white; MARGIN-RIGHT: 0.5em; PADDING-TOP: 0px; FONT-STYLE: italic; = BACKGROUND-COLOR: #a81b0e } DIV.cited-ref LI.ovfl SPAN.flag { PADDING-RIGHT: 0.3em; MARGIN-TOP: -0.1em; PADDING-LEFT: 0.2em; = FONT-WEIGHT: 500; PADDING-BOTTOM: 0px; VERTICAL-ALIGN: middle; COLOR: = white; MARGIN-RIGHT: 0.5em; PADDING-TOP: 0px; FONT-STYLE: italic; = BACKGROUND-COLOR: #a81b0e } P.desc { DISPLAY: none } DIV.brieflink DIV.PPMCPubmedRA UL LI.item P.note { BACKGROUND-COLOR: #f8f8f8 } DIV.cited-ref { LEFT: -1000px; TEXT-ALIGN: right } DIV.cited-ref UL { PADDING-TOP: 0.55em; TEXT-ALIGN: left } DIV.cited-ref A.all-articles { MARGIN-TOP: 0.5em; DISPLAY: block; FONT-SIZE: 80%; COLOR: = rgb(35,35,35); TEXT-DECORATION: none } DIV.cited-ref A.all-articles:hover { TEXT-DECORATION: underline } DIV.port { MIN-WIDTH: 250px; MAX-WIDTH: 350px; MARGIN-LEFT: 0.75em; WIDTH: 350px } DIV.x-panel-body { BACKGROUND-COLOR: transparent } DIV.sameauthor-seemore { FONT-SIZE: 75%; TEXT-ALIGN: right } DIV.x-panel-body SPAN.separator-bar { MARGIN: 0px 0.5em; COLOR: #ccc } SPAN.review { PADDING-RIGHT: 0.1em; PADDING-LEFT: 0.1em; FONT-SIZE: 85%; = PADDING-BOTTOM: 0.1em; COLOR: #fff; PADDING-TOP: 0.1em; FONT-STYLE: = italic; BACKGROUND-COLOR: #a81b0e } DIV.messagearea UL.messages LI { BACKGROUND-POSITION: 0.1em 0.2em; FONT-SIZE: 80% } @media Print =20 { HTML BODY.pmc-body { MIN-WIDTH: 0px } TD.sidebar-cell DIV.port { DISPLAY: none } #ArticleRefDocsums { DISPLAY: none } .format-menu { DISPLAY: none } .other-sections { DISPLAY: none } TD.content-cell { MIN-WIDTH: 0px; MAX-WIDTH: none; WIDTH: auto } DIV.section-content > DIV.p { MIN-WIDTH: 0px; MAX-WIDTH: none; WIDTH: auto } DIV.sec { MIN-WIDTH: 0px; MAX-WIDTH: none; WIDTH: auto } #Table3 TD.sidebar-cell { MIN-WIDTH: 0px; MAX-WIDTH: none; WIDTH: auto } TD.content-cell { PADDING-LEFT: 0px } .canvas-media-player-outer .splash-ph { DISPLAY: none } } .mb { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; LINE-HEIGHT: 1; PADDING-TOP: 0px; LIST-STYLE-TYPE: none } .mb UL { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: = 0px; LINE-HEIGHT: 1; PADDING-TOP: 0px; LIST-STYLE-TYPE: none } .mb A { DISPLAY: block; WIDTH: 10em; CURSOR: pointer; TEXT-DECORATION: = underline; outline: none } .mb LI { FLOAT: left; WIDTH: 10em } .mb A.first-link { COLOR: #336699; TEXT-DECORATION: none } UL.mb LI SPAN.delta { COLOR: #336699 } .mb LI UL.submenu { LEFT: -999em; WIDTH: 10em; POSITION: absolute } .mb LI UL UL { MARGIN: -1em 0px 0px 10em } UL.mb LI.submenu-item UL { BORDER-RIGHT: red 1px solid; BORDER-TOP: red 1px solid; LEFT: -999em; = BORDER-LEFT: red 1px solid; BORDER-BOTTOM: red 1px solid; POSITION: = absolute } UL.mb LI.active-item UL { LEFT: 3px } UL.mb LI UL.opened { BORDER-RIGHT: #ffffff 1px solid; PADDING-RIGHT: 2px; BORDER-TOP: = #ffffff 1px solid; MARGIN-TOP: 4px; PADDING-LEFT: 2px; LEFT: auto; = PADDING-BOTTOM: 2px; BORDER-LEFT: #ffffff 1px solid; PADDING-TOP: 2px; = BORDER-BOTTOM: #ffffff 1px solid; BACKGROUND-COLOR: #ffffff } UL.mb LI UL.opened LI { MARGIN-BOTTOM: 3px } UL.mb LI UL.opened LI.active-item { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BACKGROUND: #336699; = PADDING-BOTTOM: 0px; PADDING-TOP: 0px } UL.opened LI.active-item A { COLOR: #ffffff } UL.mb LI UL A { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 2px; MARGIN: 0px = 3px; COLOR: #222222; PADDING-TOP: 2px; TEXT-DECORATION: none } DIV.messagearea { CLEAR: both; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: = 0px; MARGIN: 0px; PADDING-TOP: 0px; BORDER-BOTTOM: #888 1px solid } .empty#messagearea { CLEAR: both; BORDER-TOP-STYLE: none; BORDER-RIGHT-STYLE: none; = BORDER-LEFT-STYLE: none; BORDER-BOTTOM-STYLE: none } UL.messages { PADDING-RIGHT: 0px; PADDING-LEFT: 0px; LIST-STYLE-IMAGE: none; = PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px; FONT-FAMILY: Arial; = LIST-STYLE-TYPE: none } UL.messages LI { PADDING-RIGHT: 0.25em; BACKGROUND-POSITION: 0.5em 0.3em; PADDING-LEFT: = 28px; FONT-SIZE: 1em; PADDING-BOTTOM: 0.25em; MARGIN: 0.22em 0px; = PADDING-TOP: 0.25em; BACKGROUND-REPEAT: no-repeat; BACKGROUND-COLOR: = transparent } UL.messages LI.success { BORDER-RIGHT: #8c8 1px solid; BORDER-TOP: #8c8 1px solid; = BACKGROUND-IMAGE: url(/portal/portal3rc.fcgi/35478/img/24965); = BORDER-LEFT: #8c8 1px solid; BORDER-BOTTOM: #8c8 1px solid; = BACKGROUND-COLOR: #dfd } UL.messages LI.error { BORDER-RIGHT: #c88 1px solid; BORDER-TOP: #c88 1px solid; = BACKGROUND-IMAGE: url(/portal/portal3rc.fcgi/35478/img/1724); = BORDER-LEFT: #c88 1px solid; BORDER-BOTTOM: #c88 1px solid; = BACKGROUND-COLOR: #fcc } UL.messages LI.warn { BORDER-RIGHT: #cc8 1px solid; BORDER-TOP: #cc8 1px solid; = BACKGROUND-IMAGE: url(/portal/portal3rc.fcgi/35478/img/25968); = BORDER-LEFT: #cc8 1px solid; BORDER-BOTTOM: #cc8 1px solid; = BACKGROUND-COLOR: #ffc } UL.messages LI.info { BACKGROUND-IMAGE: url(/portal/portal3rc.fcgi/35478/img/9186) } UL.messages LI.suggest { BACKGROUND-IMAGE: url(/portal/portal3rc.fcgi/35478/img/26044) } UL.messages LI.hi_warn { FONT-WEIGHT: bold; BACKGROUND-IMAGE: = url(/portal/portal3rc.fcgi/35478/img/25968); BORDER-TOP-STYLE: none; = BORDER-RIGHT-STYLE: none; BORDER-LEFT-STYLE: none; BACKGROUND-COLOR: = transparent; BORDER-BOTTOM-STYLE: none } DIV#messagearea UL.messages LI.hi_warn { MARGIN: 2.5em 0px } UL.messages LI.hi_warn EM.detail { PADDING-LEFT: 0.5em; FONT-WEIGHT: normal; FONT-STYLE: normal } TD.content-cell { MIN-WIDTH: 550px; WIDTH: 550px } #Table3 { TABLE-LAYOUT: fixed } .col-watermark { MIN-WIDTH: 20px; WIDTH: 20px } .col-content { MIN-WIDTH: 570px; WIDTH: 570px } .col-sidebar { MIN-WIDTH: 370px; WIDTH: 370px } ------=_NextPart_000_0000_01CB1950.A50CAAE0 Content-Type: application/octet-stream Content-Transfer-Encoding: quoted-printable Content-Location: http://www.ncbi.nlm.nih.gov/corehtml/pmc/js/jquery-1.3.2.min.js /*=0A= * jQuery JavaScript Library v1.3.2=0A= * http://jquery.com/=0A= *=0A= * Copyright (c) 2009 John Resig=0A= * Dual licensed under the MIT and GPL licenses.=0A= * http://docs.jquery.com/License=0A= *=0A= * Date: 2009-02-19 17:34:21 -0500 (Thu, 19 Feb 2009)=0A= * Revision: 6246=0A= */=0A= (function(){var = l=3Dthis,g,y=3Dl.jQuery,p=3Dl.$,o=3Dl.jQuery=3Dl.$=3Dfunction(E,F){return= new = o.fn.init(E,F)},D=3D/^[^<]*(<(.|\s)+>)[^>]*$|^#([\w-]+)$/,f=3D/^.[^:#\[\.= ,]*$/;o.fn=3Do.prototype=3D{init:function(E,H){E=3DE||document;if(E.nodeT= ype){this[0]=3DE;this.length=3D1;this.context=3DE;return this}if(typeof = E=3D=3D=3D"string"){var = G=3DD.exec(E);if(G&&(G[1]||!H)){if(G[1]){E=3Do.clean([G[1]],H)}else{var = I=3Ddocument.getElementById(G[3]);if(I&&I.id!=3DG[3]){return = o().find(E)}var F=3Do(I||[]);F.context=3Ddocument;F.selector=3DE;return = F}}else{return o(H).find(E)}}else{if(o.isFunction(E)){return = o(document).ready(E)}}if(E.selector&&E.context){this.selector=3DE.selecto= r;this.context=3DE.context}return = this.setArray(o.isArray(E)?E:o.makeArray(E))},selector:"",jquery:"1.3.2",= size:function(){return this.length},get:function(E){return = E=3D=3D=3Dg?Array.prototype.slice.call(this):this[E]},pushStack:function(= F,H,E){var = G=3Do(F);G.prevObject=3Dthis;G.context=3Dthis.context;if(H=3D=3D=3D"find"= ){G.selector=3Dthis.selector+(this.selector?" = ":"")+E}else{if(H){G.selector=3Dthis.selector+"."+H+"("+E+")"}}return = G},setArray:function(E){this.length=3D0;Array.prototype.push.apply(this,E= );return this},each:function(F,E){return = o.each(this,F,E)},index:function(E){return = o.inArray(E&&E.jquery?E[0]:E,this)},attr:function(F,H,G){var = E=3DF;if(typeof F=3D=3D=3D"string"){if(H=3D=3D=3Dg){return = this[0]&&o[G||"attr"](this[0],F)}else{E=3D{};E[F]=3DH}}return = this.each(function(I){for(F in = E){o.attr(G?this.style:this,F,o.prop(this,E[F],G,I,F))}})},css:function(E= ,F){if((E=3D=3D"width"||E=3D=3D"height")&&parseFloat(F)<0){F=3Dg}return = this.attr(E,F,"curCSS")},text:function(F){if(typeof = F!=3D=3D"object"&&F!=3Dnull){return = this.empty().append((this[0]&&this[0].ownerDocument||document).createText= Node(F))}var = E=3D"";o.each(F||this,function(){o.each(this.childNodes,function(){if(thi= s.nodeType!=3D8){E+=3Dthis.nodeType!=3D1?this.nodeValue:o.fn.text([this])= }})});return E},wrapAll:function(E){if(this[0]){var = F=3Do(E,this[0].ownerDocument).clone();if(this[0].parentNode){F.insertBef= ore(this[0])}F.map(function(){var = G=3Dthis;while(G.firstChild){G=3DG.firstChild}return = G}).append(this)}return this},wrapInner:function(E){return = this.each(function(){o(this).contents().wrapAll(E)})},wrap:function(E){re= turn this.each(function(){o(this).wrapAll(E)})},append:function(){return = this.domManip(arguments,true,function(E){if(this.nodeType=3D=3D1){this.ap= pendChild(E)}})},prepend:function(){return = this.domManip(arguments,true,function(E){if(this.nodeType=3D=3D1){this.in= sertBefore(E,this.firstChild)}})},before:function(){return = this.domManip(arguments,false,function(E){this.parentNode.insertBefore(E,= this)})},after:function(){return = this.domManip(arguments,false,function(E){this.parentNode.insertBefore(E,= this.nextSibling)})},end:function(){return = this.prevObject||o([])},push:[].push,sort:[].sort,splice:[].splice,find:f= unction(E){if(this.length=3D=3D=3D1){var = F=3Dthis.pushStack([],"find",E);F.length=3D0;o.find(E,this[0],F);return = F}else{return this.pushStack(o.unique(o.map(this,function(G){return = o.find(E,G)})),"find",E)}},clone:function(G){var = E=3Dthis.map(function(){if(!o.support.noCloneEvent&&!o.isXMLDoc(this)){va= r I=3Dthis.outerHTML;if(!I){var = J=3Dthis.ownerDocument.createElement("div");J.appendChild(this.cloneNode(= true));I=3DJ.innerHTML}return o.clean([I.replace(/ = jQuery\d+=3D"(?:\d+|null)"/g,"").replace(/^\s*/,"")])[0]}else{return = this.cloneNode(true)}});if(G=3D=3D=3Dtrue){var = H=3Dthis.find("*").andSelf(),F=3D0;E.find("*").andSelf().each(function(){= if(this.nodeName!=3D=3DH[F].nodeName){return}var = I=3Do.data(H[F],"events");for(var K in I){for(var J in = I[K]){o.event.add(this,K,I[K][J],I[K][J].data)}}F++})}return = E},filter:function(E){return = this.pushStack(o.isFunction(E)&&o.grep(this,function(G,F){return = E.call(G,F)})||o.multiFilter(E,o.grep(this,function(F){return = F.nodeType=3D=3D=3D1})),"filter",E)},closest:function(E){var = G=3Do.expr.match.POS.test(E)?o(E):null,F=3D0;return = this.map(function(){var = H=3Dthis;while(H&&H.ownerDocument){if(G?G.index(H)>-1:o(H).is(E)){o.data(= H,"closest",F);return = H}H=3DH.parentNode;F++}})},not:function(E){if(typeof = E=3D=3D=3D"string"){if(f.test(E)){return = this.pushStack(o.multiFilter(E,this,true),"not",E)}else{E=3Do.multiFilter= (E,this)}}var F=3DE.length&&E[E.length-1]!=3D=3Dg&&!E.nodeType;return = this.filter(function(){return = F?o.inArray(this,E)<0:this!=3DE})},add:function(E){return = this.pushStack(o.unique(o.merge(this.get(),typeof = E=3D=3D=3D"string"?o(E):o.makeArray(E))))},is:function(E){return = !!E&&o.multiFilter(E,this).length>0},hasClass:function(E){return = !!E&&this.is("."+E)},val:function(K){if(K=3D=3D=3Dg){var = E=3Dthis[0];if(E){if(o.nodeName(E,"option")){return(E.attributes.value||{= }).specified?E.value:E.text}if(o.nodeName(E,"select")){var = I=3DE.selectedIndex,L=3D[],M=3DE.options,H=3DE.type=3D=3D"select-one";if(= I<0){return null}for(var F=3DH?I:0,J=3DH?I+1:M.length;F=3D0= ||o.inArray(this.name,K)>=3D0)}else{if(o.nodeName(this,"select")){var = N=3Do.makeArray(K);o("option",this).each(function(){this.selected=3D(o.in= Array(this.value,N)>=3D0||o.inArray(this.text,N)>=3D0)});if(!N.length){th= is.selectedIndex=3D-1}}else{this.value=3DK}}})},html:function(E){return = E=3D=3D=3Dg?(this[0]?this[0].innerHTML.replace(/ = jQuery\d+=3D"(?:\d+|null)"/g,""):null):this.empty().append(E)},replaceWit= h:function(E){return this.after(E).remove()},eq:function(E){return = this.slice(E,+E+1)},slice:function(){return = this.pushStack(Array.prototype.slice.apply(this,arguments),"slice",Array.= prototype.slice.call(arguments).join(","))},map:function(E){return = this.pushStack(o.map(this,function(G,F){return = E.call(G,F,G)}))},andSelf:function(){return = this.add(this.prevObject)},domManip:function(J,M,L){if(this[0]){var = I=3D(this[0].ownerDocument||this[0]).createDocumentFragment(),F=3Do.clean= (J,(this[0].ownerDocument||this[0]),I),H=3DI.firstChild;if(H){for(var = G=3D0,E=3Dthis.length;G1||G>0?I.c= loneNode(true):I)}}if(F){o.each(F,z)}}return this;function K(N,O){return = M&&o.nodeName(N,"table")&&o.nodeName(O,"tr")?(N.getElementsByTagName("tbo= dy")[0]||N.appendChild(N.ownerDocument.createElement("tbody"))):N}}};o.fn= .init.prototype=3Do.fn;function = z(E,F){if(F.src){o.ajax({url:F.src,async:false,dataType:"script"})}else{o= .globalEval(F.text||F.textContent||F.innerHTML||"")}if(F.parentNode){F.pa= rentNode.removeChild(F)}}function e(){return +new = Date}o.extend=3Do.fn.extend=3Dfunction(){var = J=3Darguments[0]||{},H=3D1,I=3Darguments.length,E=3Dfalse,G;if(typeof = J=3D=3D=3D"boolean"){E=3DJ;J=3Darguments[1]||{};H=3D2}if(typeof = J!=3D=3D"object"&&!o.isFunction(J)){J=3D{}}if(I=3D=3DH){J=3Dthis;--H}for(= ;H-1}},swap:functi= on(H,G,I){var E=3D{};for(var F in = G){E[F]=3DH.style[F];H.style[F]=3DG[F]}I.call(H);for(var F in = G){H.style[F]=3DE[F]}},css:function(H,F,J,E){if(F=3D=3D"width"||F=3D=3D"h= eight"){var = L,G=3D{position:"absolute",visibility:"hidden",display:"block"},K=3DF=3D=3D= "width"?["Left","Right"]:["Top","Bottom"];function = I(){L=3DF=3D=3D"width"?H.offsetWidth:H.offsetHeight;if(E=3D=3D=3D"border"= ){return}o.each(K,function(){if(!E){L-=3DparseFloat(o.curCSS(H,"padding"+= this,true))||0}if(E=3D=3D=3D"margin"){L+=3DparseFloat(o.curCSS(H,"margin"= +this,true))||0}else{L-=3DparseFloat(o.curCSS(H,"border"+this+"Width",tru= e))||0}})}if(H.offsetWidth!=3D=3D0){I()}else{o.swap(H,G,I)}return = Math.max(0,Math.round(L))}return = o.curCSS(H,F,J)},curCSS:function(I,F,G){var = L,E=3DI.style;if(F=3D=3D"opacity"&&!o.support.opacity){L=3Do.attr(E,"opac= ity");return = L=3D=3D""?"1":L}if(F.match(/float/i)){F=3Dw}if(!G&&E&&E[F]){L=3DE[F]}else= {if(q.getComputedStyle){if(F.match(/float/i)){F=3D"float"}F=3DF.replace(/= ([A-Z])/g,"-$1").toLowerCase();var = M=3Dq.getComputedStyle(I,null);if(M){L=3DM.getPropertyValue(F)}if(F=3D=3D= "opacity"&&L=3D=3D""){L=3D"1"}}else{if(I.currentStyle){var = J=3DF.replace(/\-(\w)/g,function(N,O){return = O.toUpperCase()});L=3DI.currentStyle[F]||I.currentStyle[J];if(!/^\d+(px)?= $/i.test(L)&&/^\d/.test(L)){var = H=3DE.left,K=3DI.runtimeStyle.left;I.runtimeStyle.left=3DI.currentStyle.l= eft;E.left=3DL||0;L=3DE.pixelLeft+"px";E.left=3DH;I.runtimeStyle.left=3DK= }}}}return L},clean:function(F,K,I){K=3DK||document;if(typeof = K.createElement=3D=3D=3D"undefined"){K=3DK.ownerDocument||K[0]&&K[0].owne= rDocument||document}if(!I&&F.length=3D=3D=3D1&&typeof = F[0]=3D=3D=3D"string"){var = H=3D/^<(\w+)\s*\/?>$/.exec(F[0]);if(H){return[K.createElement(H[1])]}}var= = G=3D[],E=3D[],L=3DK.createElement("div");o.each(F,function(P,S){if(typeof= S=3D=3D=3D"number"){S+=3D""}if(!S){return}if(typeof = S=3D=3D=3D"string"){S=3DS.replace(/(<(\w+)[^>]*?)\/>/g,function(U,V,T){re= turn = T.match(/^(abbr|br|col|img|input|link|meta|param|hr|area|embed)$/i)?U:V+"= >"});var = O=3DS.replace(/^\s+/,"").substring(0,10).toLowerCase();var = Q=3D!O.indexOf("",""]||!O.indexOf(""= ,""]||O.match(/^<(thead|tbody|tfoot|colg|cap)/)&&[1,"",= "

"]||!O.indexOf("

Formats:

PubMed articles by these = authors

Recent Activity

Links

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information